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T1D volunteer 
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Diabetes is a common chronic disease that affects almost all countries in the world and 
has continued to increase at an alarming rate in the last decades. It kills a person every 
seven seconds. Recent thinking treats both types of diabetes as inflammatory diseases. 
The aim of the thesis was to obtain a better understanding of the relationship between 
exercise and the management of diabetes by conducting surveys and experimental 
work. It investigates the effects of exercise on the physiology and metabolic control in 
Type 1 (T1D) and Type 2 diabetes (T2D), using non-diabetic (ND) people as a control.  
The management and treatment of T1D and T2D volunteers were first assessed in 
surveys and the novelty was second to expose both to exercise. In the latter, 
volunteers were compared biochemically including for inflammatory responses to their 
illness and to practical exercise.  
Four studies were undertaken in this thesis involving a mixed approach: questionnaire 
based studies (first and second surveys) and experimental based studies (first and 
second exercise studies). The first survey study was about insulin users with opinions 
gathered from both T1D and T2D (T2I) respondents (n=707). In this survey diabetic 
people were asked about the condition and coping strategies for the difficulties using 
insulin in daily life. The first survey does touch on exercise but only as part of the larger 
picture. The second survey study (n=240) evolved from the first one and was again 
about opinions but in this case oral anti-hyperglycaemics were included in the 
management of T2D respondents (T2T). This survey focused more strongly on the role 
of exercise. The surveys were conducted by post, email and online while detailed 
statistical analysis followed.  
Two exercise studies with the same volunteers (n=25; ND=7, T1D=7, T2T=7, T2I=4) 
were then carried out based on some findings of the surveys. These studies explored 
the effects of a combination of aerobic (AE) and resistance exercise (RE) components 
for a six week period on diabetes. The methodology of the first exercise study 
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concentrated on the physiological variables, involving the use of exercise and 
measurement equipment to monitor for expired gases and anthropometric changes. 
Substrate oxidation, blood profiles for lipid, blood glucose (BG) and glycated 
haemoglobin (HbA1c) were also assessed. The second exercise study builds on this 
with specific inflammatory marker profiles such as tumour necrosis alpha (TNF-α), 
interleukin-6 (IL-6), leptin and resistin on ND, T1D and T2D volunteers over the same 
time period as in the first exercise study.  
The first survey study showed that many respondents (13-47%) lacked adequate 
professional information about the various separate aspects of their insulin-treated 
illness. For example, 38% of T1D and 28% of T2I reported that they did not have 
enough information regarding raised cholesterol levels. The results for diabetes 
complications revealed that T2I had greater complications compared to T1D (for 
example angina 18.5% for T2I compared to 4.6% for T1D), although the groups could 
not be matched for age, reasons for responding to the survey, duration of illness or 
severity of illness when starting insulin.  
The second survey revealed that insulin users often had an HbA1c that did not meet 
best practice expectations of 6.5% - 7.5% (48 -58 mmol/mol). It also showed that those 
who did exercise regularly were more likely to have acceptable HbA1c values (5-7% or 
31-53mmol/mol), than those who did not. This is especially the case for the type 2 
groups (eg for T2T 46% exercising compared to 31% non-exercising) who were less 
likely (19% respondents compared to 25%) to have HbA1c over 8% or 64 mmol/mol.  
It was of interest to know the risks, barriers and likely recommendations for the two 
groups. For example, fewer T2I people test BG frequently (12.5% compared to T1D 
62%, testing four or more times daily), even when they are insulin basal bolus users, 
which could foster hypoglycaemic events during exercise. The findings of the first and 
second surveys showed that managing diabetes in the 21st century remains difficult for 
many people, despite the availability of diagnostic, monitoring and medication 
improvements. This leads to anxiety and illness over the short and long term.  
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In the first exercise study, it was clear that for this combined exercise regimen, the 
chronic effects were notable. The most significant finding was that the effect of 6 
weeks was the drop in HbA1c in all groups ND from 5.4-5.2% or 36-33mmol/mol (p ˂ 
0.01), T1D 7.0 to 6.7% or 53-50mmol/mol (p ˂ 0.01), T2T 7.6 to 7.2% or 60-
55mmol/mol (p ˂ 0.05), T2I 7.3 to 6.8 or 56-51mmol/mol (p ˂ 0.05). This is equivalent 
to raising insulin or other medication and while clearly very beneficial, especially as 
occurring as a result of moderate exercise over only 6 weeks.  
Lipid factors showed improvements, not all significantly but these were likely to be 
influenced by support medication such as statins. However, the heart rate (HR) and 
blood pressure (BP) reduced at rest for all groups over the six weeks. The respiratory 
exchange ratio (RER), a measure of substrates oxidation showed that the carbohydrate 
metabolism was steady. The muscular strength and the subjective assessment 
improved after the exercise period.  
The second exercise study showed the interleukin 6 levels fell with the chronic effects 
of combined exercise ND (3.97-2.7pg/ml), T1D (2.15-1.02 pg/ml), T2T (3.67-2.72pg/ml) 
and T2I (3.66-1.17pg/ml) as did TNFα and other cytokine levels which may thus be 
cardioprotective. This suggests that exercise could be part of the anti-inflammatory 
treatment of T1D and T2D. 
To conclude, the findings of the two survey studies showed that the management of 
diabetes is difficult for many diabetics. Furthermore, the exercise studies 
demonstrated that a regular combined (RE and AE) exercise trial at moderate intensity 
for six week could be physiologically beneficial for diabetics. The underlying 
mechanism for this could be improvements in glycaemic control, lipid profile, 
cardiovascular fitness level and strength, as well as the inflammatory features of both 
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Chapter 1: Introduction and literature review 
1.1 Introduction 
The aim of this chapter is to provide a scientific literature review to the research 
studies within this work as well as to find out the theoretical basis for research studies 
on T1D and T2D. This chapter begins with an overview of diabetes description, 
prevalence, classification, glucose and insulin metabolism, insulin resistance, diabetes 
diagnosis and complications. Following this is a description of T1D and T2D 
management and treatments will be discussed. Physiological and metabolic response 
to exercise as well as the effects of aerobic and resistance exercise (AE and RE) on T1D 
and T2D will also be explored. Finally the aims and objectives of this thesis were 
highlighted.  
1.2 Description and prevalence of diabetes mellitus 
Diabetes is a global health problem and most common chronic disease that affects 
almost all countries in the world. It has become a widespread epidemic and continues 
to increase at alarming rate in the last decades (Guariguata, Whiting et al. 2014). 
Diabetes occurs when the pancreatic β-cells do not release sufficient amount of the 
hormone insulin or the body cell cannot utilise insulin effectively (T2D) or by a damage 
of the pancreatic β-cells by the immune system which lead to T1D. The International 
Diabetes Federation (IDF) estimated the total number of people with diabetes 
worldwide was 387 million in 2014 (Figure 1) rising to 592 million in the next 25 years 
(International Diabetes Federation, 2014, Guariguata, Whiting et al. 2014). T2D 
accounts for 85% to 95% of all diabetes in high-income countries and may account for 
an even higher percentage in low- and middle income countries. The prevalence of 
diabetes in adults (20-79 years old) in the UK is 5.4% and much higher with 20.52% in 
the Kingdom of Saudi Arabia (KSA). Recently publications about diabetes stated that in 
the UK (24.5 T1D cases per 1000) and in KSA (31 cases of T1D per 1000) has one of the 
highest world’s rate of T1D in children aged 14 and below (5th and 3rd highest, 
respectively in the world), (International Diabetes Federation, 2014). These findings for 
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both types of diabetes T1D and T2D show how this chronic disease is a global huge 
health challenge. It also, provides an idea about the potential size of the diabetes 
epidemic facing these countries as well as the whole world. The cost of Diabetes and 
its complications is very expensive. About 11% of the total healthcare budget 
worldwide was spent on diabetes (USD 612 billion) in 2014 and this may increase in 
the future (International Diabetes Federation, 2014). 
The majority (80%) of diabetes patient live in low- and middle- income countries 
(International Diabetes Federation, 2014). According to Diabetes UK records in 2012 
more than £10 billion was spent by the NHS on treating diabetes (Diabetes UK, 2012). 
This was 10% of the NHS budget in 2010-2011 with total NHS expenditure of 
approximately £103 billion. After calculation, it is a cost of about £208 million per 
week, £30 million per day, £1.2 million per hour, £20,000 per minute.  
 






1.3 Classification of diabetes 
1.3.1 Type 1 diabetes (T1D) 
T1D Previously named ‘insulin dependent diabetes mellitus’, because most of the 
pancreatic β-cells have destructed which results in absolute chronic deficiency of 
insulin secretion (Figure 2). Therefore, immediate and urgent administration of insulin 
therapy is required to prevent diabetic ketoacidosis (DKA) which can lead to coma and 
death. T1D can be defined as an autoimmune disease where the body’s own natural 
defences progressively attack and destroy the cells that responsible to release insulin 
which are islets of Langerhans β-cells in the pancreas. Multiple autoimmune attack 
triggers the pathophysiology of T1D (Regnéll, Lernmark 2013, Hermann, Krikovszky et 
al. 2005). About 80% of β-cells destruction occurs before T1D become clinically 
diagnosed. Destruction of the β-cells might be pathogenically relevant to circulating 
autoantibodies against islet of Langerhans cells which precede the clinical onset of 
disease (Kawasaki 2014, Regnéll, Lernmark 2013, Shriver 2011). Normally, T1D affects 
children and adolescent only, although it can happen at any age and might be 
genetically inherited. It is usually developed in children and teenagers and persists 
during whole life. T1D patients would need both insulin treatment and extensive life 
time balance between nutritional consumption and insulin dose (Krochik, Botto et al. 
2015) . 
1.3.2 Type 2 diabetes (T2D) 
T2D previously called ‘non-insulin dependent diabetes mellitus’ and can be defined as 
a chronic disease whereby the body is unable to effectively use glucose as a fuel due to 
relative insulin deficiency caused by insulin resistance and progressive beta cell failure. 
T2D is a heterogeneous disorder in which multiple pathophysiologic defects result in 
an imbalance between the rate of glucose production (which is increased) and its 
disposal (which is decreased) resulting in hyperglycaemia (Figure 2).  
Among the defects is insulin resistance, leading to decreased glucose uptake by 
peripheral tissues (predominantly the muscles) and an increase in hepatic glucose 
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production (gluconeogenesis) (Meah, Juneja 2015). Thus both impaired pancreatic β 
cell function and insulin resistance further deteriorate physiological consequences of 
T2D. Muscle and adipocytes show impaired insulin-stimulated glucose uptake with 
reduced inhibition of liver glucose production. This condition of tissue specific 
pathophysiology contributes to increase fasting BG and the lack of ability to effectively 
dispose glucose from the blood stream in the post-prandial state (Frayn 2003).  
T2D develops slowly (mostly in older, obese people), and it has a long preclinical phase 
and about of 30- 50% or 174.8 million of all diabetes cases in adults are estimated to 
be undiagnosed for many years (Stevens, Khunti et al. 2015, Guariguata, Whiting et al. 
2014). People who are overweight or obese are more likely to have insulin resistance, 
(where the body does not respond correctly to insulin) because fat interferes with the 
body's ability to use insulin. Most of T2D have a family history of the disease or 
disorders and conditions commonly related with diabetes such as high lipid profile, 
hypertension (high blood pressure), sedentary life style, smoking and obesity (Wang, 
Bordi et al. 2015, Frontoni, Solini et al. 2014, Chen, Pei et al. 2015).  
Acute and chronic states of hyperglycaemia, if left untreated, could lead to a myriad of 
debilitating long-term complications (Beagley, Guariguata et al. 2014). Heart attacks 
and strokes are 2- to 3- fold higher in people with diabetes, along with increased risks 
for microvascualr diseases such as retinopathy, nephropathy and neuropathy. Life 
expectancy can be shortened by as much as 10-15 years as a result of premature and 
accelerated atherosclerosis, and the attendant medical complications (Laditka, Laditka 
2014). 
1.3.3 Gestational diabetes (GD) and other types 
GD is defined as glucose intolerance with onset or first recognition during pregnancy in 
a previously undiagnosed female and takes place mainly because body β-cells is not 
able to provide sufficient insulin to interact with the additional requirements of 
pregnancy which leads to abnormal high BG levels. Its prevalence varies from 4.6% to 
25% depending on the diagnostic criteria used and the study population (Goldstein, 
Gibson-Helm et al. 2015). GD is normally transitory and vanishes after delivery the 
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baby. Women who are overweight or obese are at a higher risk of GD and 
approximately 7% are at risk to develop T2D later in their lives (Goldstein, Gibson-Helm 
et al. 2015). Children born to mothers with GD also have a higher risk of suffering from 
obesity and T2D in later life (International Diabetes Federation, 2014). There are other 
minority diabetic conditions such as latent autoimmune diabetes of adults (LADA) and 








1.4 Glucose and Insulin  
1.4.1 Glucose and insulin metabolism 
Glucose is the primary source of energy for the body tissue cells to perform the normal 
physiological body functions ATP. Glucose taken up by the β-cells, utilised in the body 
tissue through different biochemical mechanisms (broken down into intermediates 
that fuel oxidative metabolism inside the mitochondria) to produce the primary 
energy-carrying molecule adenosine triphosphate (ATP) which is the body ultimate 
source of energy (Groschner, Alam et al. 2014). Glucose is carried into most cells by 
specific proteins or glucose transporters (GLUT) that cover the cell membrane and 
permit the connecting and transferring of glucose across the hydrophobic lipid layer 
(Scheepers, Joost et al. 2004). In the periphery through a number of intracellular 
signalling pathways, some of which are complex, insulin promotes glucose uptake in 
muscle and fat cells and inhibits lipogenesis and lipolysis in adipocytes (Frayn 2003). 
Normally BG utilised by the body tissue and used for energy, otherwise it is converted 
to glycogen and stored by the liver if it is not required directly (Glycogenesis). It is very 
important to maintain BG levels within the normal range and avoid any increase in the 
BG level (hyperglycaemia) or the opposite action low BG level (hypoglycaemia) which 
progressively may results in diabetes complications. 
1.4.1.1  Regulation of blood glucose and insulin 
Glucose is the main energy source for the tissue cells. It also acts as a precursor to 
various metabolites in nearly all tissues. There are two hormones released by the 
pancreatic cells mainly regulate BG level in the blood circulation; insulin which reduces 
blood BG level and glucagon is the hormone responsible for decrease blood BG level. 
Plasma blood glucose levels are typically managed within a limited range of (3.5-5.5 
mmol/L) through the insulin-glucose-glucagon regulatory system. Therefore BG levels 
are controlled through process of the negative biochemical feedback system (‘closed-
loop’) which manages constantly and immediately can give a proper response to the 
BG levels. Normal glucose management is controlled by means of the antagonistic 
process of the two pancreatic hormones, insulin and glucagon. Under normal 
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physiological conditions, BG level continues to rise in response to macronutrients 
(carbohydrate, fat and protein) intake. β-cells will respond to the increase of BG 
concentration and release corresponding amounts of insulin to meet the metabolic 
demand. Insulin acts on different body tissue cells to accelerate facilitated diffusion of 
glucose into cells especially skeletal muscles and adipose tissues. Then boost up 
conversion of BG into glycogen (glycogenesis) and supresses hepatic glucose 
production (gluconeogenesis and glycogenolysis) (Fu, Gilbert et al. 2013). As a result of 
these various mechanisms, blood BG levels falls to a normal range (Figure 3).  
The cascade of insulin action in vivo includes many steps through a number of 
intracellular signalling pathways (Figure 4). This is including transendothelial transport 
of hormone, binding to the insulin receptors, and activation of tyrosine kinase, 
followed by movement of GLUT4 transporters from cytoplasm inside the cell into the 
plasma membrane, which allows BG enter the cells to utilised or stored (Yoon, Dang et 
al. 2014). 
Low BG level (hypoglycaemia) enhance pancreatic α-cells to secrete glucagon which 
acts on hepatocytes (liver cells) to facilitate breaking down glycogen molecules into 
glucose and to promote formation of glucose from lactic acid. Hepatocytes then 
release glucose into the circulation more rapidly and BG increases to the 
normoglyceamic state (Figure 3) (Fu, Gilbert et al. 2013, Saltiel, Kahn 2001). 
Adipose tissue cells are essential in metabolic regulation, releasing free fatty acid (FFA) 
that decrease BG uptake in muscle cells, insulin secretion from the β-cells, and 
increase gluconeogenesis from the hepatocytes (Boden 2003). Adipose tissue cells can 
also secrete 'adipokines' such as leptin, adiponectin and TNF, which regulate food 






Figure 3: Overview of glucose homoeostasis under normal physiological condition (Saltiel, 
Kahn 2001). 
 




1.4.2 Insulin  
Insulin is a peptide hormone that is secreted by the β-cells and permits cellular glucose 
uptake and regulates levels of glucose in the blood stream. Insulin involves in different 
biochemical mechanisms and performs its function by controlling the metabolism of 
lipids, carbohydrate and protein and encouraging cell division (Preza, Pinon et al. 2013, 
Strachan, Frier 2013). 
1.4.3 Type of insulin 
Patients with T1D cannot survive without administration of insulin as well as T2D to 
whom insulin is administered much later in their treatment. Table 1 describes key 
features from all the commercially available insulin most widely in use today. 
1.4.4   Pathology of glucose and insulin metabolism 
1.4.4.1  Insulin resistance 
Insulin resistant (IR) is a pathological condition and one of the main metabolic sign of 
T2D and it can be defined as reduced response to a physiological amount of insulin 
when the body cells receptors fail to respond to the regular amounts of circulating 
insulin. There are two possible reasons for IR condition, first one it might be defect in 
the receptors may prevent insulin from binding or there are no enough receptors for 
insulin to attach. Secondly, insulin may attach to the receptors, but the tissue cells do 
not recognise the signal to oxidise the BG (Liu, Park et al. 2015). 
IR is known as an impaired sensitivity to glucose removal by insulin-mediated signalling 
pathway resulting in systemic hyperglycaemia. It is commonly affect T2D, however, 
over the last ten years it has been shown that IR plays a key role in the development of 
T1D (Krochik, Botto et al. 2015). As insulin has pleiotropic functions, IR is closely linked 
with other metabolic symptoms such as hypertension and hyperlipidaemia, unhealthy 
life-style and endocrine abnormalities (Krochik, Botto et al. 2015, Goyal, Singh et al. 
2014). Obesity is the most common cause of IR in humans with or without 
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hyperglycaemia (Wang, Chang et al. 2013). An important potential mechanism of IR in 
obesity has been the observation that adipose tissue cells may produce and secrete 
hormones or cytokines that affect metabolism and insulin sensitivity, such as leptin 
which may play a role in the modulation of IR following weight loss (Wang, Chang et al. 
2013). In addition, prolong exposure of β-cells to insulin and glucose leads to 
desensitisation and reduced insulin sensitivity and progression to β-cells damage (Fu, 
Gilbert et al. 2013). 
1.5 Signs and symptoms of T1D and T2D 
The typical symptoms and signs of T1D are usually include polyuria (frequent urination, 
especially at night), extreme tiredness, polydipsia (excessive thirst), hyperglycaemia, 
blurred vision, and normally recent unexplained loss of weight along with at least two 
of the following characteristic features: rapid onset of symptoms over days or weeks, 
glucosuria or blood glucose markedly raised, ketones in the urine or blood, 
ketoacidosis or family history of T1D (International Diabetes Federation, 2014).  
The symptoms in T2D almost the same but milder than T1D and usually remain 
unrecognized at the beginning with often complications developing before diagnosis. 
Signs of IR or conditions associated with IR such as acanthosis nigricans (brown to 
black, poorly defined, hyperpigmentation marks of the skin), hypertension and 
dyslipidaemia. Excessive thirst, polyuria, polydipsia are characteristic symptoms for 
T2D (Hays, Galassetti et al. 2008, International Diabetes Federation, 2014). 
1.6 Diagnosis of T1D and T2D  
Based on the American Diabetes Association (ADA) and IDF guidelines there are four 
key tests used for the diagnosis of diabetes and they are as follows: first test is 
glycosylated haemoglobin test (HbA1c), with level of ≥6.5%. Second one is fasting 
plasma glucose (FPG) of 7 mmol/L (126mg/dL), patient should fast for at least 8 hours 
before this test. Third one is oral glucose tolerance test (OGTT) with BG value of ≥11.1 
mmol/L (200 mg/dL), after two hours of having a 75mg dose of glucose. Last test is 
random plasma glucose (RPG) of ≥ 11.1 mmol/L (200 mg/dL) in a patient with classic 
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symptoms of hyperglycaemia or hyperglycaemic crisis. To confirm the diagnosis in the 
absence of unequivocal hyperglycaemia, tests 1 – 3 should be performed again in 
another day (International Diabetes Federation, 2014, ADA 2014). People who have a 
fasting BG level between 6.1 and 6.9 mmol/L (100 and 124.2 mg/dL) are described as 
having an impaired fasting glucose (IFG) and may need an OGTT to confirm the 
diagnosis of diabetes or not. The ADA also recommended an HbA1c of 39−46 
mmol/mol (5.7-6.4%), FPG 5.6 mmol/L (100 mg/dL) to 6.9 mmol/L (125 mg/dL) IFG or 
2-h PG (plasma glucose) in the 75-g OGTT 7.8 mmol/L (140 mg/dL) to 11.0 mmol/L (199 
mg/dL) (IGT) indicates a high risk of diabetes (pre-diabetes). 
1.7 Treatments and management of diabetes 
1.7.1 Exercise, lifestyle and diet 
Sedentary lifestyle is one of the most important risk factors for T2D. Studies in 
prediabetic and diabetic subjects have demonstrated benefits of physical activity in the 
prevention and management of T2D. The mechanisms by which exercise produces 
positive results in patients with diabetes include improvement in insulin sensitivity and 
glucose disposal in the skeletal muscle, expression of nitric oxide synthase in the 
endothelial cells, improvement in obesity, and body fitness (Hall, McDonald et al. 2013, 
Maahs, Taplin et al. 2009, Snowling, Hopkins 2006).  
Exercise interventions that produce fat losses should produce improvements in 
glyceamic control or insulin sensitivity, especially if the fat loss is from visceral 
deposits. Even if fat loss is not present, reductions in HbA1c may be observed as a 
result of the cumulative chronic effects of the individual exercise programme (Church, 
Blair et al. 2010).  
In the UK there have been two education programmes which are nationally developed 
in order to support people with diabetes to gain the skills and right attitude to manage 
their disorder. Certainly one is made for T1D, a programme known as the Dose 
Adjustment for Normal Eating (DAFNE) had been developed to help people to regulate 
their insulin injection therapy to match their lifestyles (Leelarathna, Ward et al. 2011). 
DAFNE programme is a method of controlling T1D and provides people with the 
12 
 
knowledge that is necessary to calculate the carbohydrate in every food and then to 
inject the corrected dose of insulin. Some studies show significant reductions in total, 
quick acting and basal insulin doses in patients undergoing DAFNE training 
(Leelarathna, Ward et al. 2011) The other one is designed for T2D patients and is 
known as The Diabetes Education and Self-Management for On-going and Newly 
Diagnosed (DESMOND) and not essentially focused on insulin. DESMOND is a NHS 
education training course to provide T2D patient with the essential knowledge about 
diabetes and how to manage it to achieve their targets and to be aware of the health 
risks and consequence complications. DESMOND and other education programmes 
such as a low-intensive lifestyle education programme (DiAlert) lead to improvements 
in the metabolic control and body composition in T2D (Heideman, de Wit et al. 2012, 
Srinivasan, Davies 2014). 
An epidemiologic analysis conducted by the United Kingdom Prospective Diabetes 
Study (UKPDS) Group estimated that for every 1% decrease in mean HbA1c, a marker 
of long-term glycaemic control, the incidence of clinical complications decreased 
significantly over the entire range of HbA1c levels represented in the study (<6% - 
>10%), the risk for microvascular complications was reduced by 37% for each 1% 
reduction in HbA1c, the risk for any clinical event or death associated with diabetes 
was reduced by 21%, and the risk for myocardial infarction was reduced by 14% for all 
relative hazards (Stratton, Adler et al. 2000). 
To achieve normoglycaemic state, T1D needs intensive diabetes management and the 
care of T1D patient either child or adult should be under specialists supervision team 
qualified in the care of diabetes such as dietician, diabetes nurse and diabetologist 
(Care 2011). T1D children are different from T1D adults in many respects such as ability 
to provide self-care, insulin sensitivity, and unique neurological weakness to 





1.7.2 Oral medication 
The first therapeutic approach and management of T2D usually start with changes 
lifestyle by increasing physical activity and exercise as well as eating healthy diet with 
low saturated fat and cholesterol, and reduce calorie intake as recommended by 
health service carers to manage BG level close to the normal ranges. However, as data 
from the UKPDS demonstrate, only a small minority of patients are able to reach or 
maintain the currently accepted glycaemic targets without pharmacologic intervention 
(Stratton, Adler et al. 2000). 
If diet and exercise alone are not sufficient to improve or maintain glucose control 
within 3 months, the next step is to add an oral hypoglycaemic agent. Several classes 
of oral hypoglycaemic agents are approved by the United States Food and Drug 
Administration as treatment for T2D. Sulfonylureas (Glimepiride® and Gilclazide ®) 
bind to K+ channels on the β-cells membrane, leading to increased insulin release in 
elevated BG. Biguanides (Metformin®) inhibit hepatic gluconeogenesis while increasing 
hepatic and muscular sensitivity to insulin and act primarily on liver. The sulfonylureas 
and metformin® are most effective for decreasing HbA1c (decrease 1.3%-2.0%). 
Rosiglitazone® or Pioglitazone® (thiazolidinediones) act on muscle and fat tissue and 
decrease HbA1c by 1.0% -1.3%. Acarbose® or Miglitol® (Alpha-glucosidase inhibitors) 
interfere with carbohydrate digestion, delaying and reducing gastrointestinal 
absorption of dietary glucose (Srinivasan, Davies 2014).  
1.7.3 Insulin 
T1D patients need a lifelong administration of exogenous insulin because their 
pancreatic β-cells had destroyed which lead an absolute deficiency of insulin. Typical 
treatment for T1D is extensive insulin therapy. In contrast to people with T1D, the 
majority of those with T2D usually do not have need of daily doses of insulin to survive. 
Many of T2D able to manage their condition by a healthy diet and increased physical 
activity or oral agents as mentioned earlier.  
For those who are unable to regulate their BG levels and the oral hypoglycaemic is not 




Table 1: Insulin types, onset of action and peak. 
* The above information from http://www.diabetes.co.uk/insulin.
Insulin type Name of insulin Manufacturer Source Vial, cartridge or 
prefilled pen 
Onset of action* Peak* 
Rapid-acting 
analogue 
Humalog Lilly analogue cartridge, vial & prefilled 
pen 
< 15 min 15-60 min 
Novorapid (Novolog Novo Nordisk analogue vial < 15 min 15-60 min 
Long-acting 
analogue 
Glargine (Lantus) Aventis analogue cartridge, vial & prefilled 
pen 
< 60 min No peak as such 
Detemir (Levemir) Novo Nordisk analogue cartridge < 60 min No peak as such 
Short-acting Actrapid Novo Nordisk human cartridge, vial & prefilled 
pen 
< 30 min 1 – 3 hours 
Humulin S Lilly human vial & cartridge < 30 min 1 – 3 hours 
Hypurin  CP Pharmaceuticals Beef/pork vial & cartridge < 60 min 2 – 5 hours 
Insuman Rapid Aventis Pharma human cartridge, vial & prefilled 
pen 
< 30 min 1 – 3 hours 
Medium &  
long-acting 
Humulin I Lilly human cartridge, vial & prefilled 
pen 
< 120 min 2-12 hours 
Insulatard Novo Nordisk human/pork cartridge, vial & prefilled 
pen 
< 120 min 6-12 hours 
Hypurin Bovine 
Isophane 
CP Pharmaceuticals human/beef/pork vial & cartridge < 120 min 6-12 hours 
Hypurin CP Pharmaceuticals Beef/pork Vial & cartridge < 120 min 6-12 hours 
Insuman Basal Aventis Pharma human Vial, cartridge & 
prefilled pen 




Basal bolus methodology consists of a basal dose which is a calculated background of 
long acting insulin together with a short acting bolus or boost of insulin which is 
administered at mealtimes. This variable dosing allows the patient a much more 
normal diet. More importantly this must be done in conjunction with frequent BG 
testing to prevent excursions from normoglycaemia. It is often the case that most 
diabetes patients find regular injections and finger prick testing uncomfortable and 
invasive and this could be alleviated to some degree by the use of continuous glucose 
monitors for BG testing and insulin pumps for infusion (DCCT, EDIC 2014).  
1.7.4 Insulin Pump 
There is a cannula which usually inserted abdomen subcutaneous, continuous 
subcutaneous insulin infusion (CSII). The main advantage of insulin pump therapy over 
multiple daily insulin injections (MDI) is its ability to significantly reducing the risk of 
hyperglycaemia and hypoglycaemia. It has been observed that insulin pump users have 
fewer events of post-exercise hyperglycaemia as compared with MDI users (Yardley, 
Iscoe et al. 2013). Furthermore, T1D sufferers who use insulin pump, children and 
adults, reported lowering of HbA1c (Battelino, Phillip et al. 2011). 
1.7.5 Artificial Pancreas 
This is an insulin dispensing device that responds to the body to deliver variable doses 
as an intelligent response to the blood glucose. Instead of two to four injections into 
the skin at intervals throughout the day, this is a continuous supply, but one that 
adapts to the changing blood levels and should give better outcomes as a result. The 
intention is that it will be totally implantable and nothing would therefore be visible 
from the outside. It is not ready yet for human trials but already known to work to 




1.8 Complications of T1D and T2D Diabetes 
About five millions of diabetes patients have died in 2014 because of diabetes 
complications which mean that every 7 seconds one person dies from diabetes and its 
complications (International Diabetes Federation, 2014, Guariguata, Whiting et al. 
2014). 
T1D requires both insulin therapy and careful lifelong control of the balance between 
dietary intake and insulin dose. Without insulin replacement, people developing T1D 
risk surviving and with which they can participate normally in the usual daily activities, 
but still are at risk of associated complications. T1D and T2D individuals are at risk of 
the following complications: metabolic complications such as hyperglycaemic 
ketoacidosis, hypoglycaemia, and dyslipidaemia. Hypoglycaemia is a condition when is 
the BG level fall to ˂ 3.5 mmol/L due to the effect of different reasons such as fasting, 
exercise and over insulin dose (Forbes, Cooper 2013). 
Macrovascular complications (chronic complications) such as cardiovascular vascular 
diseases (CVD), coronary artery disease (CAD). Microvascular complications such as 
retinopathy (eye impairment), nephropathy (kidney impairment), sensory, motor, and 
autonomic neuropathy (nerve impairment). Moreover, psychological complications 
such as depression and anxiety might present in T1D and T2D. In addition, other 
complications associated with non-adherence to recommended management in 
children and young adults due to family conflict or risky behaviour. Pregnant women 
have increased risks of complications, such as: hypertension and pre-eclampsia, foetal 
and neonatal complications such as congenital malformations (a physical defect 





1.9 Impact of Exercise on healthy and diabetes people 
1.9.1 Diabetes, lipid profile and risk factors 
Diabetes is associated with a high risk of CVD, CHD and other heart disease mortality 
(Chen, Pei et al. 2015, Li, Xiao et al. 2014, Jaiswal, Schinske et al. 2014). It has been 
known for decades that exercise and physical activity are one of the main cornerstones 
along with medication and diet to treat and manage diabetes and high lipid profiles 
(Yavari, Najafipoor et al. 2012, Sigal, Kenny et al. 2006). Dietary intervention, and 
changes in sedentary lifestyle by increasing physical activity contribute to the 
prevention and management of T2D and lead to significant benefit in risk factors that 
are known to be associated with development of CVD in patients with T2D such as 
HbA1c, Body Mass Index (BMI), Systolic Blood Pressure (SBP), Diastolic Blood Pressure 
(DBP) and lipid profile: Total Cholesterol (TC), Low Density Lipoprotein (LDL), High 
Density Lipoprotein (HDL) and Triglyceride (TG) (Chen, Pei et al. 2015, Li, Xiao et al. 
2014). BMI measurement of less than 18.5 suggests underweight and between 18.5 to 
24.9 is healthy weight. However from 25 to 29.9 indicates that the individual is 
overweight and 30 or more is obese. High BMI is an indicator of obesity and it is 
associated with T2D (Li, Xiao et al. 2014). 
Presence of lipid disorders can be found in both T1D and T2D and it is associated with 
the development of T2D (Billimek, Malik et al. 2015, Jaiswal, Schinske et al. 2014, 
Verges 2009, Hjerrild, Gravholt 2006). Therefore, it is crucial to investigate lipid 
abnormalities and to control lipids profile in people with T1D and T2D to reduce the 
risk of CVD and other diabetes complications such as Hyperglycaemia, micro- and 
macrovascular complications (Jaiswal, Schinske et al. 2014, Maahs, Ogden et al. 2010). 
An improvement in glycaemia is suggested as an initial treatment for dyslipidaemia 
when caring for patients with T1D and T2D. Nevertheless, lipid-lowering medicine can 
also be administered if lipid goals are not achieved (Jaiswal, Schinske et al. 2014, 
Brunzell, Davidson et al. 2008, Buse, Ginsberg et al. 2007). 
Elevated HbA1c level has been considered as a risk factor for CHD and CVD in patients 
with diabetes (Haring, Baumeister et al. 2014, Selvin, Coresh et al. 2005, Selvin, 
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Marinopoulos et al. 2004). Furthermore, it is also has been observed that there is a 
direct correlation between raised HbA1c concentration and the severity of CAD and 
CVD in people with diabetes (Hong, Li et al. 2014, Jaiswal, Schinske et al. 2014).  
A significant correlation between HbA1c and lipid profile in T1D and T2D has been 
reported by several researchers (Jaiswal, Schinske et al. 2014, Yan, Liu et al. 2012, 
Faulkner, Chao et al. 2006). Raised lipid levels decrease insulin-stimulated glucose 
disposal in the skeletal muscle, probably because of fatty acid–mediated inhibition of 
insulin signalling (Szendroedi, Frossard et al. 2012). Reduced insulin sensitivity is linked 
with abnormal lipid profile in people who have T1D either as adults or in their youth 
(Maahs, Nadeau et al. 2011)  as well as in T2D (Jaiswal, Schinske et al. 2014). High TG 
and lipid profile levels are correlated with CVD in T1D and T2D (Maahs, Eckel 2015, 
Mäkinen, Soininen et al. 2013, Maahs, Ogden et al. 2010). 
1.9.2 Aerobic and resistance exercise  
Aerobic exercise (AE) is any exercise that depends on oxygen for energy such as 
walking, running and swimming, and increases heart rate (HR) up for a prolonged 
period of time and large muscle groups are included. Resistance exercise (RE) is 
anaerobic exercise, such as weight lifting, strength exercise using machines or even 
using body weight. Normally, RE performed in short bouts with rest periods between 
each set and is anaerobic, meaning that oxygen is not used for providing energy, 
however, the source energy from ATP, creatine phosphate and muscle glycogen 
(Lucotti, Monti et al. 2011). Both of these approaches lead to health benefits for ND 
and people with diabetes (T1D and T2D). AE, RE or combined exercise programme is 
recommended in the management of T1D and T2D, and has physiological benefits 
including improved physical work capacity, body composition, blood pressure, blood 
lipid profile (Chen, Pei et al. 2015) and HbA1c (Yardley, Kenny et al. 2013). It is 
associated with less risk of diabetes complications and mortality in individuals with 




1.9.3 Substrates oxidation measurements and the principles of Indirect 
Calorimetry 
Indirect calorimetry is a method to non-invasively measure metabolic rate and allows 
calculation of substrate utilisation under different conditions (Frayn 1983). The basic 
principles of this technique are based on the measurement of the oxygen consumption 
and carbon dioxide production at the level of the lungs, nitrogen excretion and the 
knowledge of the stoichiometry of carbohydrate, protein and fat oxidation. 
Respiratory exchange ratio (RER) is the ratio of the volume of carbon dioxide (VCO2) 
released to the volume of oxygen (VO2) taken up into the lungs at the same time. 
Respiratory exchange ratio normal ranges are between 0.7 and 1.0 and this factor is 
used as an indicator of substrate oxidation, where 1.0 indicates total carbohydrate 
oxidation, while 0.7 refers to total fat oxidation (Ferrannini 1988). Frayn (1983) chose 
glucose and palmitoyl-stearoyl-oleoyle-glycerol (PSOG) to represent carbohydrate and 
fat oxidation, respectively. The stoichiometry of glucose and PSOG is as follows: 
Glucose (C6H12O6) + 6 O2 → 6 H2O + 6 CO2    
PSOG (C55H104O6) + 78 O2 → 52 H2O + 55 CO2    
From the above equations, oxidation of 1 mol of glucose, requires an uptake of 6 mol 
of oxygen and a release of 6 mol of carbon dioxide, thus, RER will be 6/6 =1.0. Also, the 
oxidation of 1 mol of PSOG requires an uptake of 78 mol of oxygen and a release of 55 
mol of carbon dioxide, thus, RER will be 0.70. 
There are different techniques used in indirect calorimetry to measure fuel oxidation, 
the Douglas bag method and breath-by-breath system (Jeukendrup, Wallis 2005). In 
this method the volunteer is required to wear a nose clip and breathe through a mouth 
piece into tube connected to a chamber and gas analyser. Expired air can be analysed 
to calculate the fraction of oxygen and carbon dioxide by passing the expired air into a 
gas analyser. The indirect calorimetry methods are considered as an attractive way to 
conduct research due to the non-invasive nature and the quick response time (Jequier, 
Acheson et al. 1987).  
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In order for RER to be used to estimate substrate oxidation during exercise, the subject 
must have reached the steady state, which means that physiological function remains 
relatively stable (Jequier, Acheson et al. 1987). This is important because it is only 
during steady state exercise that the ratio of VCO2 to VO2 reflects the metabolic gas 
exchange in the body tissues (Jeukendrup & Wallis, 2005).  
Basically, during low to moderate exercise intensities this does not present a problem, 
because the lactate concentration in the circulation during low to moderate intensity 
exercise may be matched or slightly higher than the baseline value, but it is still in 
steady rate (Jeukendrup & Wallis, 2005). Therefore, lactate production in the muscles 
is mostly in equilibrium with lactate elimination, due to oxidation and conversion to 
glucose in the liver (Jeukendrup & Wallis, 2005). 
However, during high intensity exercise, where lactate acid production can be greater 
than oxidation, lactate will accumulate in the muscle (Jeukendrup & Wallis, 2005), 
resulting in hydrogen ions release and increased in plasma. These ions are may 
buffered by bicarbonate [HCO3
-], and finally extra non-metabolic CO2 will be excreted 
on the breath (Frayn, 1983). Thus, during heavy exercise when lactate excretion is 
high, estimation of substrate utilisation by indirect calorimetry technique may be 
flawed (Frayn, 1983).  
1.9.4 Normal glycaemic response to exercise 
The glycaemic response to exercise is dependent on the intensity and duration of 
exercise. BG concentration does not change very much in the short-term when 
participating in moderate exercise, however when high intensity exercise is performed 
plasma BG concentrations will initially rise and then fall as exercise continues will the 
symptoms of hypoglycaemia being rare. An increase in hepatic glucose output 
maintains BG homeostasis by balancing increases in BG uptake by working muscles. 
The balance must be maintained between reducing insulin concentrations and/or 
increasing glucagon concentrations which become necessary for plasma BG 
homeostasis. When changes in insulin and glucagon are prevented BG concentrations 
21 
 
fall. Any deviation from euglycaemia can result in a mismatch between hepatic glucose 
production and peripheral glucose use (Frayn 2003). 
The role of the liver for maintaining glucose homeostasis is pivotal as it is able to store 
large amounts of glycogen as well release glucose by glycogenolysis. Additionally, 
lactate, glycerol and amino acids can be converted to glucose by gluconeogenesis 
within the liver. During exercise the rate of muscle glucose uptake is linked to hepatic 
glucose produced and with prolonged exercise an increasing contribution is derived 
from gluconeogenesis. When participating in high intensity exercise hepatic glucose 
production increases and is often higher than the glucose used, this can be attributed 
to a rise in catecholamines rather than to changes in insulin and glucagon levels. This 
marked increase in catecholamines results in increased muscle glycogenolysis and 
increased glucose-6-phosphate (McArdle, Katch et al. 2006). 
1.9.5 Effect of different intensities and duration of exercise on ND, T1D and 
T2D 
According to two widely-cited studies by (Romijn, Coyle et al. 1993, Romijn, Coyle et al. 
2000) fat oxidation increases with increasing exercise duration. Romijn et al (1993) 
studied exercise intensity and substrate utilisation during prolonged exercise using 
indirect calorimetry and isotopes (tracer techniques). They examined trained subjects, 
five males in the first study and eight females in the second. Subjects exercised at 25%, 
65%, and 85% of maximum volume oxygen consumption (
2OV
 max). They found that 
the rate of fat oxidation increased from low-intensity exercise (25% of 
2OV
 max) to 
moderate-intensity (65% of 
2OV
 max), and then reduced at high-intensity (85% of 
2OV
 max). Fat oxidation rates increased from rest to low- to moderate-intensity 
exercise and plasma fatty acid was the main substrate utilised for energy. However, 
when the exercise intensity exceeded 75-85% of 
2OV
 max, carbohydrate oxidation 
became the major source of energy provision and fat oxidation was suppressed; this 
suppression is probably the result of the stimulation of glycolysis and glycogenolysis 
during high-intensity exercise (Jeukendrup 2003).  
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1.9.6 Effect of resistance and aerobic exercise on T1D and T2D 
A significant reduction of 0.3 to 0.5% HbA1c levels achieved by combination exercise 
programme (AE + RE) might be expected to produce a 5% to 7% reduction in CVD risk 
and a 12% reduction in risk of microvascular complications (Church 2011). The 
improvements of glycaemic control without weight gain has been associated with 
lipids control and this include TG, TC and LDL (Purnell, Hokanson et al. 1998). AE, RE or 
combined exercise programme is recommended in the management of T1D and T2D, 
and has physiological benefits including improved physical work capacity, body 
composition, blood pressure, blood lipid profile (Chen, Pei et al. 2015) and HbA1c 
(Yardley, Kenny et al. 2013). It is associated with less risk of diabetes complications and 
mortality in individuals with diabetes (Hordern, Dunstan et al. 2012).  
Small-scale studies have revealed that RE decreased HbA1c in patients with T1D 
(Yardley, Kenny et al. 2013) and T2D, it has been reported that HbA1c was significantly 
improved after 4 months of AE or RE (Bacchi, Negri et al. 2012). Furthermore, other 
study reported a statistically significant impact of exercise (AE, RE and combined 
training) on the management of glucose HbA1c (Shriver 2011). 
1.9.7 Immune-inflammatory markers  
Interleukin-6 (IL-6) plays a role in obesity and insulin resistance and is widely expressed 
in adipose tissue as well as obesity in humans. IL-6 interrupts insulin signalling 
mediating insulin resistance which facilitates obesity (Senn, Klover et al. 2003). It has 
been reported that IL-6 deficient mice show an onset in obesity on maturity, hepatic 
inflammation and insulin resistance which can be reversed on IL-6 administration 
(Matthews, Allen et al. 2010, Wallenius, Wallenius et al. 2002). This administration of 
IL-6 enhances energy expenditure and decreases obesity by influencing obesity and 
insulin sensitivity through a central nervous system mechanism.  
Tumor necrosis factor-α TNFα a pro-inflammatory cytokine has increased in obese 
humans and rodents suggesting that it contributes to insulin resistance. TNF-α levels in 
the circulation correlate positively with insulin resistance, and neutralisation of TNF-α 
improves the insulin sensitivity in rodents, although clinical effects of TNF-α 
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neutralisation in humans are debatable (Hotamisligil 2007, Hotamisligil, Shargill et al. 
1993). 
 
Leptin is a hormone that has been recognised as a mediator of long-term regulation of 
energy balance it acts by suppressing food intake and thereby inducing weight loss. 
Consumption of fat and fructose do not initiate insulin secretion, results in lower 
circulating leptin levels, a consequence which may lead to overeating and weight gain 
in individuals or populations consuming diets high in energy derived from these 
macronutrients. Leptin levels in circulation have been shown to increase in obese 
rodents and humans suggesting that obese subjects display leptin resistance. This 
resistance is mediated by impaired leptin transport in blood brain barrier (Kievit, 
Howard et al. 2006) and activates monocytes and macrophages to produce pro-
inflammatory IL-6, TNF-α. Leptin production is usually regulated by insulin-induced 
changes of adipocyte metabolism.  
 
Resistin is a hormone identified as one of the markers of atherosclerosis and is one of 
the important predicting factors of CVD (Kadoglou, Perrea et al. 2007) as a promoter of 
insulin resistance (Steppan, Bailey et al. 2001). The increase in the level of resistin 
mostly happens in inflammatory conditions and it is shown that resistin stimulates the 
synthesis and the release of pre-inflammatory cytokines such as TNFα (Silswal, Singh et 
al. 2005). However resistin’s function in humans unclear, as levels in blood circulation 
do not correlate with obesity and insulin resistance. The major sources of resistin in 
humans are monocytes and macrophages and inflammatory cytokines such as IL-1β, IL-
6, TNF-α, and LPS induce the resistin are widely expressed in these macrophages 
(Silswal, Singh et al. 2005).  
 
In obese rodents and humans the liver and muscle have been shown to produce mild 
inflammatory responses without significant numerical changes in immune cells. 
Adipose tissue depots become vulnerable to mediate significant immune cells 
infiltration and inflammation contributing to insulin resistance and systemic 
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inflammation (Odegaard, Chawla 2013). Adipose tissue provides the majority of excess 
nutrient storage for TG as well as producing adipokines (Waki, Tontonoz 2007). Leptin 
and adiponectin are generated from adipose tissue to regulate feeding behaviour and 
pro- and anti-inflammatory adipokines to modulate inflammatory responses.  
 
Adipocytes are the most abundant cell population of adipose tissue and act as an 
energy storage secreting hormones and many bioactive substances (adipocytokines) 
such as IL-6, TNFα , resistin and leptin that are required for normal body function and 
are found at altered levels in metabolic disease (Poulos, Hausman et al. 2010, Galic, 
Oakhill et al. 2010). Thus an increase in nutritional intake results in adipocytes 
hypertrophy and hyperplasia which provoke cellular stress which in turn initiates 
oxidative stress and inflammatory responses in adipose tissue. These inflammatory 
responses in adipose tissues become self-generating and lead to an increase in pro-
inflammatory cytokines such as TNFα, IL-6, IL-1β, at a systemic level and are the causes 
of insulin resistance. Along with inflammatory adipokine production in adipose tissues, 
obesity-related hyperlipidemia, hyperglycaemia, hypoxia and oxidative stress which 
induces insulin resistance in peripheral tissues resulting in activation of inflammatory 
signalling cascades in adipose tissues (Labouesse, Gertz et al. 2014). 
1.9.8 Exercise (AE and RE) and immune-inflammatory markers 
AE and RE (acute and chronic) have different impacts on inflammatory adipocytokines 
(Cullen, Thomas et al. 2015, Moran, Barwell et al. 2011, Goldhammer, Tanchilevitch et 
al. 2005). It is well-known that a single bout of strenuous or moderate exercise acutely 
increases systemic IL-6 levels, as well as concentrations of other cytokines such as 
TNFα (Christiansen, Bruun J. et al. 2013, Pedersen, Steensberg et al. 2001). In acute 
exercise, IL-6 is released by muscles and the level of IL-6 may increase significantly 
(Christiansen, Bruun J. et al. 2013, Petersen, Pedersen 2005). Chronic exercise for 
different duration and intensities has reduced the basal level of TNFα, IL-6, resistin and 
leptin (Reihmane, Dela 2014, Rashidlamir, Saadatnia 2012, Moran, Barwell et al. 2011).  
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It has been determined that regular physical activity and exercise decrease the levels 
of inflammatory markers and decrease the risk of CHD (Beavers, Hsu et al. 2010). The 
results of different researches investigated the effects of regular exercise in diabetes 
TD1, T2D as well as ND have reported significantly decreases in the levels of TNF-α, IL-
6, IL-1β and C-reactive protein (CRP) (Rosa, Heydari et al. 2011, Christiansen, Paulsen 
et al. 2010, Nicklas, Hsu et al. 2008, Kadoglou, Perrea et al. 2007, Kohut, McCann et al. 
2006). There is a relationship between higher levels of physical activity/physical fitness 
and lower levels of these inflammatory markers (Akbarpour 2013). It has been 
established that IL-6 can be released locally from contracting skeletal muscle tissue 
and that the net release from the muscle can account for the exercise-induced rise in 
arterial concentration of IL-6 (Cullen, Thomas et al. 2015).  
Moderate exercise can stimulate the immune system; however, high or extreme 
exercise might suppress it (Liesen, Baum 1997, Fitzgerald 1988). Evidence suggests that 
exercise intensity and duration as well as the form of contraction (e.g. eccentric or 
concentric) and muscle damage all influence IL-6 response to acute exercise 
(Reihmane, Dela 2014). Furthermore, previous study has demonstrated that resistin 
and IL-6 concentrations have reduced significantly after 12 weeks of AE in T2T 
(Kadoglou, Perrea et al. 2007).  
In addition, a research study has investigated the effects of 12-week of RE, AE, or 
combination exercise programme at moderate intensity showed a reduction in TNFα 
and IL-6 in healthy volunteers with obesity or overweight. They found that TNF-α levels 
were significantly decreased at week 12 compared to baseline by 20.8 % in AE group, 
26.9 % in RE group, and 32.6 % in the combination group. Thus, combination exercise 
may help to reduce the risk of common chronic diseases such as diabetes, CHD and 
CVD (Ho, Dhaliwal et al. 2013). Furthermore, another study on patients with CAD, 
reported that a 12 weeks of AE at 70–80% of individual maximal HR has reduced 
significantly baseline levels of inflammatory cytokines such as CRP, and IL-6 from 2.50
±1.50 to 1.44±0.57 pg/ml (Goldhammer, Tanchilevitch et al. 2005). Moreover, an 
investigation into the effect of 12 weeks of AE on inflammatory markers of CHD in 
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obese men found decreases in the levels of CRP, IL-6, leptin and BF% and an increase in 
the level of adiponectin in the experimental group relative to the control group. In 
addition, the level of TNFα in the experimental group decreased by 2.86% and 23.76% 
after 6 and 12-week AE, respectively, although this change was not statistically 
significant (Akbarpour 2013). 
Exercise has been shown to lower levels of inflammatory markers. However, results 
are inconsistent, indicating different modes, durations and intensities of exercise may 
have different effects on inflammatory cytokines. Exercise may lower the risk for CHD, 
CVD and diabetes by mitigating inflammation (Reihmane, Dela 2014, Christiansen, 




1.10 Aims and Objectives 
 
Chapter 3 (first survey): 
 Determine both positive and negative experiences of T1D and T2D patients 
currently using insulin by injection.  
 To compare T1D and T2D insulin users regarding the diagnosis, management, 
treatments and complications. 
Chapter 4 (second survey): 
 To assess views and attitudes of people with diabetes to diet and exercise and 
compare between T1D and T2D. 
 To compare the type and intensity of exercise that T1D and T2D normally 
perform.  
 To consider factors such as diet, insulin dose and BG management in non-
exercise and exercise days for T1D and T2D. 
 To assess barriers and coping strategies when exercising safely for diabetes 
patients.  
 This survey’s results may support and feedback to the practical part of the 
study. 
Chapter 5 and 6 (first and second exercise studies): 
 To compare and contribute research toward the effects of exercises in T1D and 
T2D with ND using same exercise intervention.  
 To study the effect of exercise on HbA1c, BG, lipid profile (TC, LDL, HDL and TG), 
insulin, other physiological and immunological parameters (TNF-α, IL-6, leptin 
and resistin) on ND, T1D and T2D volunteers. 
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 To investigate the effects of acute and chronic combined exercise programme 
(AE and RE).  
 To improve insulin dosing and exercise regimes to prevent hypoglycaemic and 








Chapter 2: Materials and methods 
2.1 Overview  
This chapter describes the methods used for the analysis of the first survey (T1D and 
T2I users diabetes management survey) and the second survey with (T1D and T2D Diet 
and Exercise survey), as well as the practical studies involved in this thesis. It describes 
the methods employed in enrolling participants for the surveys, volunteers for the 
exercise trials and the measurement of the anthropometric, metabolic and 
physiological variables required in the study protocol.  
A combined (RE and AE) exercise session involved the following: stretching and warm 
up on the ergometer bike followed by RE working upper and lower muscle groups. 
After rest, cycling as AE was conducted, the session ended with cooling down and 
stretching. Exercise trials included two combined exercise sessions a week for a six- 
week period (twelve sessions). 
BG levels were monitored before, during and after each exercise session. Lipid profile 
(TC, HDL, LDL and TG), metabolic and many of physiological parameters as well as 
immune-inflammatory markers ( IL- 6, TNFα, leptin and resistin) have been measured 
at different time points throughout the exercise trials. All studies were reviewed and 
approved by the Faculty of Health and Life Sciences Ethics Committee at De Montfort 
University, Leicester, UK. 
2.2 T1D and T2D Surveys: 
 First survey: T1D and T2I users diabetes management survey 2.2.1
The first survey produced by the research group questioned T1D and T2I users (707 
participants) about their attitudes and experiences with their approach to glucose 
management, their appreciation of its importance and their understanding of the 
practical difficulties of achieving desired glycaemic control. Responses were sought 
about their diagnosis, their medical check-ups as well other areas of their diabetes 
management such as diet, hypo- and hyperglycaemia awareness and other medical 
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conditions. This survey had 77 open and closed ended questions. Data from questions 
which were open were analysed but not included in this thesis as they ask for specific 
information relating to the views and attitudes of T1D and T2I injectors towards an 
implantable artificial pancreas. The first survey provided a good approach on how to 
design and analyse patient surveys in order to develop a second survey about diabetes, 
which focused more on how people who have T1D and T2D respond and deal with diet 
and exercise. 
 Second survey: T1D and T2D diet and exercise survey 2.2.2
A second survey discussed T1D and T2D experiences with various aspects of their 
diabetes and their attitudes toward exercise and diet (240 participants). This survey 
had 78 open and closed ended questions and included four sections: background 
information, diabetes diagnosis and management, hypoglycaemia and hyperglycaemia 
as well as exercise and diet (Appendix 1).  
 Surveys validity  2.2.3
In order to validate the surveys in this thesis, face validity was used. Initial drafts of the 
surveys were forwarded to a team of experts and scientists such as a Diabeteologist, 
Pharmacologist, Physiologist as well as some diabetes volunteers who read and 
critiqued the questions and replied with feedback to the researcher.  
 Surveys distribution 2.2.4
The surveys were produced in English and launched on Survey Monkey® website and 
distributed to T1D and T2D diabetes patients through various channels such as local 
newspapers (Leicester Mercury) and diabetes websites as well as through social 
network sites such as Twitter® and Facebook®. The surveys were distributed by the 
research group at the Diabetes Clinic (Leicester Royal Infirmary), Balance magazine, 
newspaper, Diabetes UK and several diabetes forums. Moreover, diabetes exhibitions 
and some community events in England, such as Diabetes UK and NHS exhibitions and 
conferences, were used to distribute these surveys. In addition, an internal e-mail and 
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advert were sent to all De Montfort University (DMU) staff and students as well as a 
panel and webpage were created on the DMU student portal. 
 Analysis of surveys responses 2.2.5
The responses from Survey Monkey® were downloaded in Microsoft Excel 2010® and 
then coded and modified before inputting into Statistical Package for the Social 
Sciences (SPSS) (version 22 “IBM”, Chicago, IL, US). All the responses from different 
questions in SPSS were then labelled and coded, for example all the questions with yes 
and no answers were coded as number 1 for (Yes) response and number 2 for (No) 
response. All postal responses were entered manually using the same coding directly 
into SPSS®. All data was analysed using SPSS and Microsoft Excel 2010®. All data were 
filtered and missing data were excluded from the analyses and only valid percentages 
were considered. Some of the open-ended questions were filtered and then grouped 
in the appropriate responses if possible. Descriptive statistics, frequencies and 
percentages were calculated to examine the different questions and variables in the 
survey. Responses and variables were compared using chi-square test. For normally 
distributed data paired t-test was used while for non-normal distributed data the 
Wilcoxon test was used to determine significance. Cross tabulations were used to 
investigate the relationship between T1D, T2T and T2I. Data values are reported as 
mean ± SD unless otherwise stated. The level of statistical significance was set at P < 
0.05. 
2.3 Exercise studies design and participants 
 Diabetes and Exercise Physiology lab (DEPL) 2.3.1
The Diabetes and Exercise Physiology Lab (DEPL) was established at the 
commencement of the exercise trials. The research team found a suitable laboratory 







Figure 5: Diabetes and exercise physiology lab (DEPL). 
 
At this early stage of the project, necessary advice was taken from the Sport Exercise 
Department at Loughborough University. The research group demonstrated the 
proposed exercise trial and sought technical guidance from Exercise Physiologists, 
Diabetologist, Physiologists, Pharmacologists and a Sports Medicine Consultant in the 
planning and regular review stages. 
 Phlebotomy, first aid and defibrillation training 2.3.2
In order to commence the exercise trials with the volunteers, the researcher had to be 
well trained and aware of all risks that might occur during the trials such as 
hypoglycaemia. Therefore, the researcher attended and passed a Phlebotomy course 
with full training at the Clinical Department, Royal Infirmary Hospital in Leicester.  
Furthermore, The Advanced First Aid at Work course provided by the East Midlands 
Ambulance Service NHS, Leicester and a defibrillation course provided by HeartSine 




 Equipment and procedures  2.3.3
Equipment and procedures used for exercise trials are as follows: 
 Multi-use gym machine 2.3.4
Volunteers were instructed on how to use a multi-use gym machine (Body Craft Jones 
Maxrack 3D Machine) for all the RE (Figure 6.) 
 
Figure 6: Multi-use gym machine. 
 
 Ergometer bike 2.3.5
Recumbent ergometer bike (Lode, Corival Recumbent, US) was used for warm-up and 
for the AE component exercise sessions. Workload and resistance were monitored via 





Figure 7: Recumbent ergometer bike. 
 
 Power lab system ADInstruments machine (ADI) 2.3.6
ADI Analysis System (PL3516/P ADInstruments, 16 channels, Australia) is a power lab 
system (Figure 8). This system included : gas analyser (Carbon dioxide CO2 and Oxygen 
O2), gas mixing chamber with a 4.7 L capacity for collecting, mixing and sampling 
expired respiratory gases, long smooth tubing for connection to the gas mixing 
chamber and face mask. ADI generates an immediate visual representation of 
performance associated with various metabolic variables for example oxygen 
consumption (VO2), carbon dioxide production (VCO2), respiratory exchange ratio 
(RER), heart rate (HR), bike revolutions per minute (RPM) and breath flow and 
temperature of respired air. The ADI software enabled the measurement of RER at rest 





Figure 8: ADI power lab system. 
 
 Calibrating, filtering and sterilising the ADInstruments analyser 2.3.7
The calibration of machines is very important in obtaining accurate and consistent 
results; therefore, the ADI power lab system used and described in section 2.3.6 was 
calibrated before use with reference gases from BOC Ltd, Surrey, UK. A rubber tube 
connected the reference gas bag with the gas analyser, and a calibration gas 
containing 16% oxygen, 4% carbon dioxide was passed through the gas analyser. This 
calibration was repeated every few hours to minimise the errors. To prevent moisture 
damage to the sensors and to remove any possible damaging particulates, an in-line 
filter (0.45μ hydrophobic membrane) was changed every 2–3 weeks. 
A face mask, nose clips (Speedo® Universal, UK) and drying tube were cleaned and 
sterilised before and after each exercise session. This was done by unclipping these 
components from the ADI hardware and immersing them in sterilising fluid (Chlor-




 Heart rate (HR) 2.3.8
 
The volunteer’s HR was monitored at rest and continuously during the combined 
exercise trial by short-range telemetry (Polar S610i, Polar Electro, Finland) using a 
chest heart rate monitor and watch (Polar, FT1-TRA/BLK, Finland). 
 Rate of perceived exertion (RPE) 2.3.9
Rate of perceived of exertion values were obtained from the subjects using the Borg 
scale (1973) during the resistance and aerobic exercise. The Borg scale ranged from 6 
as ‘minimum,’ and 7 as ‘very, very light’ to 19 as ‘very, very hard’ and 20 as ’maximum’ 
(Borg, 1973). This scale was shown to the volunteer, so he was be able to point at how 
hard or easy the exercise he performed was. 
 Finger pricking procedure (FPP) 2.3.10
FPP was used to obtain blood samples, which was as follows: A finger was sterilised 
with alcohol swab (Reliance Medical, UK) and allowed to dry for 10-15 seconds. A spot 
on a finger was chosen and pricked with a lancet device (Microlet 2, Bayer Contour, 
US) to obtain the required quantity of capillary blood for the test. 
 Glycated haemoglobin (HbA1C) analyser 2.3.11
HbA1c was measured by Quo-Test A1c reagent kit (Figure 9), which had been already 
tested for reasonable precision and accuracy. Using FPP, a blood sample of 4µl was 
loaded into Quo-Test cartridge. The cartridge was placed into the analyser and the 
result was displayed on the digital display and a printout of the result was taken within 
five minutes. 
 Blood glucose monitor 2.3.12
Blood glucose was measured specifically 4 times for each volunteer: at rest before 
exercise, after RE exercise, after 10 min of aerobic exercise and at the end of each trial. 
BG was measured using a blood glucose kit (Contour, BAYER, Switzerland) (Figure 9). A 
blood drop of ~1µl was obtained using FPP, and then placed within the dedicated well 
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in the test strip which absorbed enough blood to perform the test, a result was 
achieved within seconds. 
 Blood pressure monitor  2.3.13
BP was taken at different time points during exercise trials using an upper arm blood 
pressure monitor (Omron M10-IT, Omron Healthcare Co., Ltd, Japan), (Figure 9) . BP 
was taken with the volunteer sitting in a chair; the BP cuff was placed on the upper 
arm ensuring that the cuff was at the same level as the heart. The volunteer were 
asked to sit upright and not to move and talk while their BP was measured. 
 Measurement of lipids profile 2.3.14
TC, HDL, LDL, and TG were measured by a CardioChek® analyser (PA Bundle, Health 
Check Systems, Germany), (Figure 9). 15 µL of whole blood was obtained using FPP. A 
plastic blood pipette was used to collect exact amount of blood required for the test 
and it was placed on a test strip (PA Lipid Panel, Health Check Systems, Germany) 
which was present in the CardioChek analyser. 
 




 Collection, separation and analysis of venous blood samples 2.3.15
Volunteers were asked to sit on a comfortable chair in order to collect venous blood 
samples. An alcohol swab and a disposable latex-free tourniquet (Fisher Thermo 
Scientific- Cat no. 22-040-225) were used to avoid any infection or contamination. 
Venous blood samples from the Antecubital Fossa were collected using a S-Monovette 
(Monovette, SARSTEDT) blood collection system needle and 10 ml tube (BD, Plymouth, 
UK) containing EDTA (ethylenediaminetetraacetic acid) anticoagulant.  
In order to separate blood plasma, labelled samples were centrifuged at 3000 rpm for 
15 min at 4°C using a centrifuge (Fisher Thermo Scientific, UK). Plasma was then 
dispensed into labelled 1.5 ml Eppendorf tubes (Eppendorf, Germany) and stored in a -
80°C freezer until analysis which was within 6 weeks. 
In order to assess the immunological response to an acute exercise as described later 
in section 2.5.2 on the first exercise session three venous blood samples using the 
above procedure were collected. These were taken before any exercise was 
performed, after the RE component of the combined exercise programme and finally 
after the AE component (cycling).  
The chronic response to exercise over the 12 sessions was assessed by collecting 
venous blood samples in the following sessions: 1st, 2nd, 4th, 6th, 8th, 10th and 12th. 
 ELISA kit and plate reader 2.3.16
Insulin and C-peptide were determined using a commercially-available enzyme-linked 
immunosorbent assay (ELISA) with <0.01 cross reactivity with pro-insulin (Mercodia 
AB, Uppsala, Sweden). Microplate Reader with Manta Software, (Labtech LT-4000, 
Ireland) and a plate shaker (IKA® MTS 2/4 digital, Germany) was used to read and 
analyse the tests. Mercodia Insulin and C-peptide ELISA is a solid phase two-site 
enzyme immunoassay. It is based on a direct Sandwich technique in which two 
monoclonal antibodies are directed against separate antigenic determinants on the 
insulin or C-peptide molecule. The insulin assay procedure was as follows: 
39 
 
All reagents and samples were brought to room temperature before use and a 
calibrator curve was made for each assay run. Enzyme conjugate solution, wash buffer 
solution, sufficient microplate wells to accommodate calibrators and samples in 
duplicate were prepared. The experiment started with pipetting 25 μL of each 
Calibrator and sample into appropriate wells. After that, 100 μL of enzyme conjugate 
solution was added to each well and Incubated on a plate shaker (700-900 rpm) for 1 
hour at room temperature (18–25°C). Then microplate wells reaction volume was 
discarded by inverting the microplate over a sink. 350 µL wash buffer solution was 
added to each well then discarded by inverting the microplate over a sink. The 
microplate then was tapped firmly several times against absorbent paper to remove 
excess liquid. This washing step was repeated 5 times. 
After washing, 200 μL of Substrate 3,3’,5,5’-tetramethylbenzidine (TMB) was added to 
each well then incubated for 15 minutes at room temperature (18–25°C). After the 
incubation 50 μL Stop Solution was added to each well. The plate was then placed on a 
shaker for approximately 5 seconds to ensure mixing. As a final step the plate was read 
at an optical density of 450 nm and insulin concentration calculated. 
C-peptide kit procedure was same as the insulin except the following: after pipetting 
25 μL each of calibrators and the samples, a 50 μL of Assay Buffer was added to each 
well and it had another washing step after the second incubation step which was for 1 
hour. The enzyme conjugate was adding after the first wash step and Substrate TMB 





Figure 10: ELISA technique. 
 
 Blood gas and electrolytes analyser 2.3.17
A Radiometer (ABL800 FLEX analyser, Denmark) was used to measure pH, blood gases 
(pCO2 and pO2) and electrolytes such as sodium (Na
+), potassium (K+), calcium (Ca2+), 
and chloride (Cl−) (Figure 11). For measurement of blood gases, arterial blood was 
required which was taken from the ear lobe of the volunteer into a plastic capillary 
tube (85 μL, safeClinitubes, Denmark) with anticoagulant (sodium heparin) and placed 




Figure 11: Radiometer, blood gas and electrolytes analyser. 
 
 Multiplexing ELISA 2.3.18
The Evidence Investigator (Randox, UK) which is a Multiplexing ELISA technology was 
used to measure immune- inflammatory markers such as Interleukin-6 (IL- 6), Tumour 
Necrosis Factor α (TNFα), resistin and leptin (Figure 12).  
 
 




 Body composition and anthropometric measurements 2.3.19
In the first session before exercise commenced, base line anthropometric 
measurements and other different physiological variables were recorded in the DEPL. 
Volunteer body mass was measured in (kg) to the nearest 0.10 kg using a digital 
weighing machine (SECA) while subjects were wearing light clothing. The volunteer 
stood without wearing shoes on a wall-mounted stadiometer to measure height to the 
nearest 0.1 cm. According to volunteer age, height and gender, body fat (%BF), and 
body water (%BW) percentages were analysed by a bioelectrical technique using SECA 
scale as follows: the volunteer stepped on to the scale which sends a small, harmless 
electrical current through the volunteer’s body to measure %BF and %BW. Hip and 
waist were measured in centimetres by measuring tape. The waist-to-hip ratio (WHR) 
was determined by measuring the waist circumference at the narrowest region 
between the costal margin and iliac crest and then dividing this measurement by the 
hip circumference measured at its greatest gluteal protuberance. BMI was calculated 
as weight (kg)/height (m)2. 
 Fridge, water cooler and temperature monitor 2.3.20
A suitable fridge and water cooler were used to provide cold water and Lucozade 
glucose drinks to the volunteer if needed. Lab temperature was adjusted at 20°C and 
monitored by a weather station (Oregon Scientific, Hong Kong) and the room’s climate 
control system. 
2.4 Selection criteria for volunteers  
The target population for this study were T1D, T2T, T2I and ND males volunteers aged 
between 18–55 years who were not physically active or taking part in any regular 
exercise programmes and met the inclusion criteria (Section 2.4.1). A total of sixty 




Twenty-eight volunteers were deemed unsuitable for inclusion because they did not 
meet the inclusion criteria due to different reasons such as medical problems, age, 
were female or they were participating in regular exercise. Seven subjects were 
excluded due to failure to return for follow-up sessions. 
The final study population consisted of 25 male volunteers divided in to following 
groups: ND control =7, T1D = 7, T2T = 7 and T2I = 4. 
 Exclusion criteria 2.4.1
Exclusion criteria for excluding the subjects were as follows: 
had any of the following: heart disease, liver disease, kidney disease, high blood 
pressure, rheumatic, heart murmur, HIV positive or aids, any allergy, hepatitis, asthma, 
tuberculosis (TB), stroke, epilepsy, any injury in head, hand or other injury and tumour 
(cancer) history. 
 were currently using glucocorticoids or beta blockers. 
 had an active infection. 
 anticipated a significant change in exercise regimen after admission.  
 had another medical condition or were using medication that in the judgment 
of the researcher could affect completion of the exercise trial. 
 had blood pressure greater than 160/95 mm Hg. 
 had participated in regular exercise two or more times weekly for 20 minutes 
or longer per session or any resistance training during the previous 6 months . 
 showed restriction in physical activity because of disease. 
 had recent blood loss or hemolytic anaemia. 
 were terminally or mentally ill. 




 Volunteers’ recruitment 2.4.2
A variety of media were utilised to publicise the study. Initial recruitment was 
generated from an advertisement in DMU, further exposure occurred through an 
article in the Leicester Mercury® which coincided with a press release from Western 
Park Gazette®. Recruitment posters were displayed around the main campus, and 
associated campuses across Leicester as well as outside other places of worship such 
as Mosques, Churches and Gurdwaras. A display panel on the DMU electronic student 
portal was used to further promote recruitment.  
A number of General Practitioners (GP) who provide primary care for patients with 
T1D and T2D diabetes through the Leicester Diabetes Service agreed to display 
recruitment posters in their surgery waiting rooms. Potential volunteers could access 
information about the study through a dedicated webpage sited on the University 
website. In addition to this, volunteers were able to provide basic contact details and 
note their interest by emails to the principal investigators. Information on the study 
was disseminated by word-of-mouth, by both the research group and volunteers 
themselves, and was responsible for a small proportion of the total number of subjects 
recruited. 
Participants included in the study met the following criteria: they were aged at 
admission time between 18 and 55 years old either healthy or diagnosed with T1D or 
T2D. Their HbA1c was ≤10.0% (86 mmol/mol) and they were not participating in any 
form of training, vigorous physical activity or formal exercise for 2 weeks before the 
commencing the study. They had normal thyroid function with no medication, anti-
inflammatory agents, steroids, antioxidants or vitamin supplements before, during, or 
after study entry. No recent history of infectious, inflammatory or immune diseases. 
Volunteers were recruited locally from Leicester area. Interested volunteers were 
initially contacted by telephone and email to provide informations and to arrange a 




 Ethical approval and risk assessment 2.4.3
Ethical approval of the exercise trials plan and procedures was granted by DMU Ethics 
Committee (Appendix 2). Some of the key documents and forms produced and 
submitted to the Ethics Committee to obtain the ethical approval are discussed below. 
 Volunteer information sheet (VIS) 2.4.4
The VIS (Appendix 3) explained the purpose and aims of the study for the interested 
volunteers. It contains information about what would happens to the volunteer if they 
decide to take part, an explanation of the experimental trials, expenses and payments, 
possible benefits or risks of participating in the exercise interventions, confidentiality, 
withdrawal time and who had reviewed the study. 
 Standard operating procedure (SOP) 2.4.5
The SOP (Appendix 4) provides details about preliminary and main experimental 
procedures and any tests used in the exercise programmes. 
 Risk assessment form  2.4.6
This document is an assessment of any possible hazards which might affect the 
volunteers and researchers during all the exercise trials. 
 Consent form  2.4.7
This form (Appendix 5) sought permission from the volunteers to take part in the study 
and to confirm that the volunteer had read the VIS and understood all the details 
about the exercise trials.  The document made volunteers aware that they were free to 
withdraw at any time. 
 Volunteers health screen  2.4.8
This document (Appendix 6) focused on information regarding the volunteers health 
and medical history. The health screen form was used to make sure that volunteers 
participating in the exercise trials were in good health and had no significant medical 
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problems or complications in the past or at present. All volunteers were asked to check 
with their GP before getting involved in this study to make sure that it was ideal for 
them to take part. Every volunteer had been given an information sheet describing all 
the trials and tests involved in the study to give it to their GP, and a GP approval letter 
was also sought, though was not compulsory. 
 Volunteer record sheet  2.4.9
After the subject agreed to participate in the exercise trials and had signed the consent 
form, a record sheet (Appendix 7) was given to be completed by the volunteer. This 
record sheet includes: volunteer name, contact details, type of diabetes or non-
diabetes, GP contact details, history of acute diabetic complications including number 
of hypoglycaemia and hyperglycaemia episodes and other medical conditions.  
 Confidentiality 2.4.10
In order to protect confidentiality, each participant’s identity was coded and stored by 
identification number. Access to this data and all other corresponding information was 
restricted and stored securely. Upon completion of enrolment into the study, signed 
informed consents and individual data were collected, coded, sorted by identification 
number, and kept in a locked file cabinet at the DEPL in the School of Pharmacy. 
2.5 Preliminary testing 
 Screen DEPL visit 2.5.1
Before enrolling in the study, all interested volunteers attended a screening visit to 
discuss and complete questionnaires regarding their health, family history and current 
physical activity levels. They were provided with VIS, given an oral presentation which 
explained the study and were then encouraged to give feedback and ask questions. 
Subjects were asked to fill out a questionnaire for a physical activity (Appendix 8) and 
health history screen (Appendix 6). The health history screen was designed to 
determine whether the subjects were taking any medicine or had any previous 
sickness or injuries that might affect their exercise performance.  
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Informed consent was obtained in duplicate. One copy was given to the volunteer for 
reference; one copy was retained as part of an individualised case record for the 
volunteer. Any subject met the inclusion criteria and agreed to participate in the study; 
a second appointment was booked for him in the DEPL for the familiarisation of RE and 
AE exercise.  
2.5.1.1 Familiarisation of resistance and aerobic exercise 
All participants were asked for a second visit to familiarise themselves with the 
laboratory and exercise equipment, testing procedures and exercise protocol. In this 
visit, a demonstration on how to lift the weights safely with the multigym machine was 
demonstrated as well as how to use and cycle on the recumbent bike. In addition, each 
subject was asked to do one set of 10 repetitions for each resistance exercise to ensure 
that the subject become familiar with RE.  
2.5.1.2 Determination of one repetition maximum (1RM) for RE  
One repetition maximum (1RM) is the highest amount of weight that can be lifted in a 
single repetition for resistance training and is used to determine intensity levels. As 
this may not be a safe protocol, especially for people with diabetes if tried at once, 
strategies have been designed to obtain an approximate value based on a weight and 
the number of repetitions the subject can perform to exhaustion for that exercise. 
There are particular methods of calculation 1RM. In this work the 1RM value was 
determined according to the (Brzycki 2000) formula (1RM=100×repweight/ (102.78 - 
(2.78×reps)) where repweight is the workload value of repetitions performed and reps 
is the number of repetitions performed. Prior to performing a 1RM, a warm-up was a 
compulsory step. The machine and the weights were optimised for each subject 
according to the target weight which was 50-60% of 1RM. 
2.5.1.3 Determination of intensity level for AE  
Volunteers were required to perform each exercise at 50- 60% of their estimated heart 
rate reserve (HRR). In order to record heart rate at rest the subjects were given heart 
rate monitors to take two readings when they are at complete rest (sitting or lying 
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down) in the late evening and two readings first thing in the morning when they wake 
up. After reviewing of literature, the Karvonen formula method (Equation.1) was used 
to determine HR reserve (Goldberg, Elliot et al. 1988; Shnayderman and Katz-Leurer 
2013) as follows: 
Karvonen formula: [(220-age)-(resting HR) × intensity] + resting HR 
For Example: if a volunteer aged 30 and the mean of his heart rate at rest is 65 bpm, 
his maximum heart rate would be 220 - 30 = 190 bpm. Heart rate reserve = maximum 
HR- HR at rest (bpm), 190 – 65 = 125 bpm. Based on Karvonen formula calculations 
methods, the target HR for the cycling in the exercise trials would be: (125 × 0.5 + 65 = 
127.5 bpm) 
 Main exercise trials 2.5.2
A combined exercise session involved stretches and warm up on the cycle ergometer 
for 10 min followed by 35 min of RE at 50-60% of 1RM then 5min of rest and after that 
20 min of AE (cycling) at 50-60% of HRR and finished by 10 min cooling down. 
Volunteers arrived at DEPL, asked to rest for 10 min before any measurements were 
taken. After resting, the HR chest monitor was attached to volunteer’s chest to record 
HR readings during the session. A venous blood sample (as described in section 2.3.15) 
and the first readings of BG and BP were taken before volunteers stretched lower and 
upper muscle groups left and right for a total of 5 min. Stretching included loosening 
front and back upper arms, chest, shoulders, middle back, lower arms, wrists, hands, 
fingers, back, tops of shoulders, neck, triceps, hamstrings, as well as hip flexor 
stretches and chest stretches for the pectoral muscles. 
After stretching, volunteers warmed up 10 min on the recumbent bike. Warm-up is an 
essential part of exercise sessions and designed to prepare the body for exercise, 
increase body temperature and reduce the potential for post-exercise injury or pain, 
especially muscle stiffness. Immediately, after warming up volunteers started the RE 
which last for 35 mins on the multi-gym machine. The RE performed included five 
different exercises working upper and lower muscle groups: squat, incline bench press, 
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lateral pull-down, bicep curls, and triceps (Figure 13). Volunteers performed three sets 
of ten repetitions of each type of exercise with one minute of rest before the start of 
the next exercise. After each set, RPE and the HR data were recorded. 
After RE, the volunteer had a 5 min rest, a second venous blood sample was collected, 
BG and BP were taken, and then both the subject and the bike were attached to ADI 
power lab analysis System. 
Physiological signals were converted from analog to digital during aerobic exercise by a 
PowerLab data acquisition unit LabChart (LabChart v6.1.3, ADInstruments, springs, 
Colorado) modules provided acquisition and analysis features specific to specialised 
applications. 
Volunteers were attached to the ADI via a breathing mask (breath-by-breath) system, 
Polar chest heart-rate monitor and Polar Receiver Interface Cable. Volunteers were 
asked to cycle for 20 min of moderate intensity at 50 to 60% of (HRmax) on a 
recumbent ergometer (Figure 14). After 10 min and at the end of the cycling, BG was 
monitored and volunteers were asked to rate their RPE (Figure 15). 
Finally, all volunteers were asked to cool down by stretching the lower and upper 
muscle groups as described previously in this section. After that, a third blood sample 
was collected and final readings of BP and BG were taken. In the event of low BG after 
final exercise, volunteer was asked to stay in the exercise lab and not to leave for final 
observation for 45min to 2 hours. 
During each exercise session, the measurements sheet (Appendix 9) was filled out. This 
sheet was designed to make sure every step was in the correct order and to follow up 
volunteer performance as well as to record all the different physiological variables 
measured during the exercise session. This exercise programme involved 2 sessions (48 









Figure 14: A volunteer cycling on the recumbent ergometer bike. 
 




2.5.2.1 Lipids, blood gases and electrolytes sampling timepoints 
Lipids (HDL, LDL, TC, TG), blood gases (PCO2, PO2), electrolytes (Na
+, K+, Ca2+, Cl− ) were 
measured three times: before the exercise programme at the first session, after 
session 6 and at the end after session 12.  
2.5.2.2 Timepoints of anthropometric measurements  
Weight, %BF, %BW and BMI data were measured at three time points: before the 
exercise programme at the first session, after session 6 and at the end after session 12. 
Waist and hip measurements were taken at two time points, before exercise at the 
first session and at the end after session 12. 
2.5.2.3 BG and HbA1c sampling timepoints  
BG was measured specifically 4 times for each volunteer in each exercise session: at 
rest before exercise, after RE exercise, after 10 min of cycling and at the end of each 
session. HbA1c level was measured at session 1 and after session 12. 
2.5.2.4 Insulin and immune- inflammatory markers sampling timepoints 
Using ELISA, plasma samples were analysed for, Insulin, C-peptide, and Inflammatory 
markers (IL- 6, TNFα, resistin and leptin,) after the following sessions: 1st, 2nd, 4th, 6th, 
8th, 10th and 12th. 
2.5.2.5 Assessment of caloric intake 
It was important that all volunteers weighed and recorded everything that they ate 
and drank for the day prior to each experimental exercise session. Food inventory 
sheets were provided to volunteers (Appendix 10 ). Volunteers were asked to try to 
keep the same food regimen for the 24 hours before each exercise session and to 
refrain from alcohol and smoking 24 hours before an exercise session. 
2.5.2.6 Statistical Analysis 
All data were analysed using (SPSS) and Microsoft Excel 2010®. Throughout the trials, 
differences in blood physiological parameters concentrations, BMI , weight, %BW, 
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%BF, electrolytes and  immune-inflammatory markers were compared using a one-way 
(trial vs. time) analysis of variance (ANOVA) with repeated measures, followed by 
Tukey’s post hoc test; for comparison of the mean of waist, hip and HbA1c values of 
different parameters, a paired t-test was used. Data values are reported as mean ± SD 





Chapter 3: Management of diabetes, hypoglycaemia and 
hyperglycaemia by T1D and T2I  
 
3.1  Introduction 
About 387 million people have various common forms of diabetes, including lifestyle 
associated T2D (90% of the total) (International Diabetes Federation, 2014, Malkova, 
Evans et al. 2000), with T1D, gestational (Manetta, Brun et al. 2002) and other minority 
diabetic conditions such as latent autoimmune diabetes of adults (LADA) and maturity 
onset diabetes of the young (MODY) account for the rest. It is expected that this number 
may rise by about 50% in the next 15 years, with about 10% of the world’s population 
experiencing one form or the other of diabetes (Manji, Shikora et al. 1990). 
In T1D, the most effective treatment for controlling changing BG levels remains the 
introduction of insulin, with the inclusion of statins and anti-hypertensives which aid in 
protecting against biochemical abnormalities occurring in the cardiovascular system. In 
T2D sulphonylureas (for example Gliclazide®) and other oral anti diabetic agents such as 
Metformin® are often combined with dietary control as a preventive therapy for 
metabolic derangement. The introduction of insulin is often started at a later stage of T2D 
treatment (often after a heart attack has occurred) and most medical professionals 
believe that its usage should occur much sooner (Marra, Scalfi et al. 1998). 
 
The loss of protein function that occurs in tissue (Marwick, Hordern et al. 2009) as a result 
of changes in body chemistry from diabetes usually occur from high BG concentrations 
where glycation to amine groups in proteins results in structural protein and enzyme 
changes both temporarily and permanently (Marzolini, Oh et al. 2008, McArdle, Katch et 
al. 2006). Other biochemical dysfunctions and compensatory anomalies occur in concert. 
These result in metabolic imbalances in lipids and carbohydrates that support the 
development of complications which can begin to develop in both types of diabetes when 
not controlled effectively (Melanson, Sharp et al. 2002). The main complications which 
are expensive to treat are renal, infection-related and wound-healing difficulties, 
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ophthalmic, dental, neurological and cardiovascular. 
For T1D and T2I diabetes patients the most effective treatment for maintaining 
satisfactory HbA1c levels comes from regimens such as basal bolus which are 
intensively controlled with regular BG testing in combination with insulin doses . 
 
Basal bolus methodology consists of a basal dose which is a calculated background of 
long acting insulin together with a short acting bolus or boost of insulin which is 
administered at mealtimes. This variable dosing allows the patient a much more 
normal diet. More importantly this must be done in conjunction with frequent BG 
testing to prevent excursions from normoglycaemia. It is often the case that most 
diabetes patients find regular injections and finger prick testing uncomfortable and 
invasive and this could be alleviated to some degree by the use of continuous glucose 
monitors for BG testing and insulin pumps for infusion. The use of insulin pumps is 
more common in the USA for this reason, and the UK and other countries often lack 
behind in investment in core areas of treatment such out-patient and community 
support staff, such as diabetes specialist nurses (DSNs).  
The financial burden in the UK amounts to £1 million per hour (Melanson, Sharp et al. 
2002, Meltzer, Leiter et al. 1998) which could be reduced by an improvement in the 
uptake of intensive control. Evidence across the world for children and adults shows 
that they fail to achieve optimum HbA1c (Merry, McConell 2009). A fall in HbA1c from 
7.9 to 7.0 (63 to 53mmol/mol) lowers microvascular risk by 25% which is critical 
because poorly controlled T1D can reduce lifespan by 20 years (Merry, McConell 
2009). 
 
In this work data presented from responses to a questionnaire distributed to T1D and 
T2I insulin users relating to their diagnosis, management, treatment and complications 




3.2  Survey design, distribution and response collection  
A survey of patients with T1D and T2I diabetes who were insulin users was carried out. 
The questionnaires were produced in English and distributed to T1D and T2I insulin 
users through various channels. Advertisements were placed in various local and 
national media (such as newspapers) within the UK, and in publications from various 
diabetes charities such as Diabetes UK. An interactive web-based version of the survey 
(Survey Monkey®) was also available via a dedicated website for participants who 
wanted to submit responses via the internet. The UK Diabetes Network and other 
diabetes websites also distributed copies to members on their databases. Finally we 
used social networking sites such Twitter® and Facebook® to publicise the survey 
(Refer to section 2.2). 
 
A total of 707 participants answered 77 questions relating to their approach to glucose 
management, their appreciation of its importance and their understanding of the 
practical difficulties of achieving desired control. Responses were sought about their 
attitudes since diagnosis, their medical check-ups as well other areas of their 
management such as diet, hypo- and hyperglycaemia and other medical conditions.  
3.3  Analysis of responses 
All data were analysed using (SPSS) and Microsoft Excel 2010®. Refer to section 2.2.5. 
3.4 Results 
3.4.1 Background information, diagnosis and check-ups 
From the 707 completed surveys, 95% of responses were from the UK where the 
survey was widely distributed and advertised with 91.1% of responses from British 
respondents of white ethnicity. The remaining responses were gathered from the USA. 
All respondents were insulin users with 71% having T1D diabetes and 29% having T2I 
diabetes. 42.2% of T1D respondents were male compared with 56.9% of T2I. 
Respondents were asked how old they were when they left full-time education with 
19.7% T1D and 44.3% T2I being 16 years or younger. However, 67.1% of T1D were 
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most likely in or had a higher education (e.g. university), compared to 46% of T2I.  
 
The most difficult aspect of the diabetes management for respondents was found to 
be exercising (36.6% for T2I and 34% for T1D). Other difficulties were identified as diet, 
testing BG and injecting insulin. About 19.4% of T1D and T2I did not report anything 
difficult about their diabetes. 58.5% of the respondents thought that their diabetes 
was very well controlled. 
 
Respondents were asked where they went for their diabetes check-up, the majority 
(93%) were seen at their doctor’s surgery or in a hospital clinic. Respondents were also 
asked to describe the amount of written and verbal information they received when 
they were first diagnosed with diabetes. For verbal, 3% of T1D and 7.3% of T2I did not 
receive any information, 27.1% of T1D, 31.7% of T2I received too little information and 
44.6% of T1D, 52.2% of T2I received the right amount of information. However, for 
written help, 8.8% of T1D and 14.6% of T2I did not receive any (such as leaflets or 
information booklets), 25.3% of T1D, 22.4% of T2I too little information and the right 
amount of information was received by 32.5% of T1D, 40.5% of T2I. Of these, 2.8% of 
T1D and 2.0% of T2I had not had a diabetes check-up in the last 12 months, 30.9% of 
T1D, 24% of T2I had one, 40% of T1D, 49.5% of T2I had two and 26.2% of T1D, 24.5% of 
T2I had had three or more check-ups. 
3.4.2 Management and diet 
In the last 12 months, 69% of T1D and T2I had an opportunity most of the time to 
discuss their ideas about the best way to manage their diabetes with their medical 
advisors. However, a high proportion, 38.8% of T1D and 37.9% of T2I had no chance or 
rarely discussed possible different medications. In addition to this, 41.5% of T1D and 
35.1% of T2I had rarely or never had personal advice about the kinds of food to eat 
and 43.5% of T1D, 37% of T2I received similarly little personal advice about their levels 





More than half of the respondents (50.7% T1D and 56.7% T2I) reported that they 
always or mostly had a plan to manage their diabetes over the next 12 months with 
their medical advisors. The majority of all respondents (95%) had had a HbA1c test, 
blood pressure measurement and their weight checked by a doctor or nurse in the 
previous 12 months as part of their treatment. Also in the past 12 months over 72.3% 
of T1D and T2I respondents had their cholesterol, eyes and bare feet examined. 36.3% 
of T1D and 26.3% of T2I had also talked to a dietician in the previous 12 months about 
their dietary management. When T1D and T2I respondents were asked if they had 
stayed in hospital overnight as a patient in the last 12 months, 19% of T1D and T2I 
reported that they had. Of those respondents 65.2% of T1D and 56.4% of T2I had 
stayed for 1 – 3 nights, with 43.7% of T1D and 17.9 of T2I reporting that the reason 





Table 2: Types of insulin  used by T1D and T2I respondents. 
 
Type of insulin T1D T2I 
Actrapid® 1.4% 0.5% 
Humalog® 4.8% 4.8% 
Humulin l® 2.8% 2.9% 
Humulin M® 0.4% 2.9% 
Humulin S® 0.6% 0.5% 
Hypurin® 0.6% 1.5% 
Insulotard® 4.8% 5.4% 
Mixtard® 1% 3.4% 
Novorapid® 7.1% 4.8% 
Novomix® 3.6% 13.6% 
Other 3.4% 22.4% 
Combination of insulins selected 
Lantus®/Levemir® + Novorapid® 54.5% 24.0% 
Lantus®/Levemir® + Humalog® 17.7% 9.3% 
Lantus®/Levemir® + Actrapid® 3% 0.5% 
Lantus®/Levemir® + Humulin I® 0.6% 0.5% 
Lantus®/Levemir® + Mixtard® 1% 0% 
Lantus®/Levemir® + Insulotard® 0.6% 0.5% 
Lantus®/Levemir® + Novomix® 0% 0.5% 
Lantus®/Levemir® +Other 0.2% 0.5% 
Lantus®/Levemir® + Humulin S® 0.6% 0.5% 
 
Table 2 shows the types of insulin used by T1D and T2I respondents. It should be noted 
that respondents were asked to tick all insulins they used and all respondents that 
injected Lantus® or Levemir® also used a short acting insulin such as Novorapid® 
(54.5% for T1D and 24% for T2I), Humalog® (17.7% for T1D and 9.3% for T2I) and 
Actrapid® (3% for T1D and 0.5% for T2I). 13.6% of T2I respondents also used Novomix® 
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and 22.9% used other insulins not listed in the survey responses and shown in Table 2. 
Most of T1D 77.6% and more than half of T2I 53.6% started using insulin longer than 5 
years ago. 
 
86.4% of T1D and 39.5% of T2I gave themselves 4 or more daily injections. 42.1% T2I 
gave themselves 2 injections compared with only 8.4% of T1D. 21.2% of T1D and 36.7% 
of T2I have been using the same number of injections since they started taking insulin 
and 45.1% of T1D compared with 21.3% of T2I have using the same regimen for 5 years 
or longer. 72.3% of T1D and 82% of T2I described the total amount of insulin they used 
for the previous 24 hours as more than 30 units. 
The majority of T1D (65%) and 22.6% of T2I tested their blood glucose 4 or more times 
a day. About half of T2I (49.2%) tested it once to three times a day compared to 27.6% 
of T1D. Respondents in this survey used the results of their BG tests to check or alter 
the amount of insulin they take (87.5% of T1D and 57.1% of T2I). A further 72.7% of 
T1D, 48.8% of T2I used BG tests to warn them about impending hypoglycaemic 
episodes. More than 79% of T1D and T2I respondents knew their HbA1c result and 






Table 3: How much information do you feel you have been given about the following aspects 
of your diabetes care? 
 
 Too much 
information 




T1D T2I T1D T2I T1D T2I 
How to manage your diabetes when you 
are ill, e.g. having flu. 
0.0% 0.0%   71.1% 51.7% 24.3% 42.0% 
Getting to and keeping to a certain weight 0.8% 1% 53.6% 59.5% 39% 32.7% 
What to expect if your blood glucose drops 
too low or becomes high. 
2.2% 0.5% 84.9% 74.6% 8.2% 19.5% 
The reasons for taking prescribed 
medicines to manage your diabetes. 
2.0% 1% 80.9% 76.6% 9.6% 15.1% 
The long term health effects of your 
diabetes. 
7.8% 3.9% 69.9% 69.8% 17.5% 21% 
The importance of raised cholesterol levels 
for people with diabetes 
1.4% 0.5% 55.4% 66.3% 38.2% 27.8% 
The importance of high blood pressure in 
people with diabetes 
0.8% 1.5% 59.4% 67.8% 34.5% 24.9% 
The importance of regular eye checks for 
people with diabetes 
2.6% 1.5% 87.8% 88.3% 5.2% 5.4%  
The importance of checking and looking 
after your feet 
1.6% 2% 77.7% 80% 16.3% 13.7% 
 How drinking alcohol can affect your 
diabetes 
1.8% 2.9% 66.7% 66.8% 25.3% 21.5% 
How smoking can affect people with 
diabetes 
2.4% 2.4% 72.3% 70.7% 17.5% 17.1% 
The effects of stress on your diabetes 0.8% 0.0% 39.2% 40.5% 54.4% 53.2% 





Table 3 outlines the amount of information respondents were given relating to the 
management of their diabetes.  
In terms of a healthy lifestyle and calorie balance, 71% of T1D and 58.1% of T2I found 
eating the right foods to help them manage their diabetes was easy, however, 29% of 
T1D and 41.9% of T2I found it difficult. More than 81% of T1D and T2I had been given 
dietary advice to help control their diabetes with 30.3% of T1D and 30.1% of T2I 
describing their daily calories consumed as between 1500 – 2000. 36.8% of T1D and 
28.4% of T2I did not know their daily calorific consumption. 79.8% of T1D and only 
32.2% of T2I respondents have been given information to help them to count 
carbohydrates. 68% of T1D compared with only 19.3% of T2I counted carbohydrates 
regularly in order to help them to control their diabetes. In addition, more than half of 
T1D (50.8%) and only minority (7.5%) of T2I used DAFNE to calculate or count 
carbohydrates. 
 
When questioned about exercise habits, 44.2% with T1D and 37.1% of those with T2I 
did between 1 and 3 hours of exercise per week, 32.1% of T1D and 24.4% of T2I 
participated in more than 3 hours of exercise. However, 11.1% of T1D and 17.8% of T2I 
did not do any exercise. Only 30.1% of T1D and 17.6% of T2I found BG results helpful in 
deciding how much physical activity they should do. 
 
With regards to respondents general health, 65.6% of T1D and 58.2% of T2I described 
their health since discovering they had diabetes as good, but 16.5% of T1D and 31.1% 
of T2I said their health remained poor since diagnosis of their diabetes. More than half 
of the respondents described diabetes as affecting their day-to-day activities and only 
5.6% of T1D and 8.2% of T2I found it did not affect their activities at all. 
3.4.3 Hypoglycaemia 
The vast majority of respondents had experienced hypoglycaemia at some time since 
diagnosis (98.9% T1D and 86.1% T2I), however, the majority of these respondents did 
not experience black out, convulsions/fit and coma when this occurred. Nevertheless, 
they experienced the following symptoms: paleness (45% of T1D and 22.4% of T2I), 
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trembling (64.7% of T1D and 56.1% of T2I) , sweating (76.9% of T1D and 62% of T2I), 
feeling of weakness (76.3% of T1D and 65.4% of T2I), rapid heartbeat (37.6% of T1D 
and 22.4% of T2I), hunger (49.2% of T1D and 25.9% of T2I), agitation/irritability (69.5% 
of T1D and  34.6% of T2I), poor concentration (68.9% of T1D and 46.3% of T2I), blurred 
vision (43% of T1D and 23.4% of T2I) and loss of coherence (45.2% of T1D and  21.5% 
of T2I). In general, the survey found that people with T1D diabetes have experienced 
these symptoms more than T2I. 
 
About 67% of T1D and T2I felt hypoglycaemic symptoms when their BG level was 
between 3 and 4 mmol/L. However, 6.3% of T1D and 19.9% of T2I felt similar 
symptoms between 4 and 5 mmol/L while 26.4% of T1D and 13.7% of T2I only felt 
symptoms below 3 mmol/L. 21.6% of T1D and 11% of T2I stated that hypoglycaemia 
affected their day-to-day activities quite a lot or great deal. However, 77.5% of T1D 
and 89% of T2I described little or no effect. Most of the respondents in this survey 
(93.2% of T1D and 76.1% of T2I) responded to a low BG by taking a sugary food or 
drink immediately. 
About 14.3% of T1D and 8.4% of T2I had decided whether or not to drive, either on 
occasion or permanently due to problems with low BG. 29.6% of T1D and 20.1% of T2I 
had had “severe” hypoglycaemic episodes during the past 12 months with 52.4% of 
T1D and 61.8% of T2I having severe symptoms once or twice. 25.2% of T1D and 17.6% 
of T2I had it three to five times and 22.4% of T1D and 20.6% of T2I had it six times or 
more. During a12 month period, 16.3% of T1D and 6.5% of T2I had passed out or had a 
seizure because of low blood sugar and required help from others. Most of them 
(73.3% of T1D and 81.8% of T2I) had this once or two times, 12% of T1D and 9.1% of 
T2I had it three to five times and 14.7% of T1D and 9.1% of T2I had it six times or more. 
When respondents were asked when their last “severe” low blood sugar episode 
happened, 55.3% of T1D and 43.2% of T2I reported that it happened longer than 6 
months ago and 24.8% of T1D and 33.3% of T2I said that they had it within the last 
month. 4.5% of T1D and 4.6% of T2I reported they had to go to hospital because of 




When respondents were asked if their BG had ever been above 20mmol/L, 84.2% of 
T1D and 57.5% of T2I replied positively. About 63.2% of T1D and 46.7% of T2I said they 
could sense when their BG was above 13mmol/L without testing. Interestingly, 
however, 31% of T1D and 33.8% of T2I had found their BG 13mmol/L or above once or 
twice a week. 59.2% of T1D and 33.1% of T2I had more than twice a week. Only a third, 
(33.1%) of T2I and 9.8% of T1D had never reported a BG as high as 13mmol/L or above, 
but despite the tendency to hyperglycaemia, 93.2% of T1D and 97.1% of T2I had never 
been in a coma because of high BG. When respondents were asked what triggered 
their high blood sugar (13mmol/L or above), 36.5% of T1D and 16.6% of T2I said it was 
due to a missed insulin injection. 27.1% of T1D and 25.9% of T2I mentioned the trigger 
was an illness or due to physiological stress such as infection.  
 
3.4.5 Other medical conditions and complications 
28.3% of those with T1D and 26.7% of T2I were hospitalised several times. Table 4 
shows a summary of responses from both T1D and T2I respondents relating to other 
medical conditions diagnosed or symptoms tested for. 57.6% of T2I and 32.7%T1D had 
been told that they had high blood pressure (BP) and 34.6% of T2I and 17.3% of T1D 
monitored their BP at home. When asked about BP medication, 60% of T2I and a 
quarter of T1D said that they took it. When respondents were questioned about other 
complications, 10.2% and 18.5% of T2I had had a heart attack or chest pain/pressure 
(angina), respectively, only 2% and 4.6% of T1D had these complications. Stroke was 




Table 4: Medical conditions or symptoms experienced by respondents. 
 
 T1D T2I 
Have you ever seen a specialist eye doctor (ophthalmologist)? 64.5% 61% 
Has your eyesight suffered as a consequence of your diabetes? 36.3% 37.6% 
Have you been diagnosed with retinopathy (decrease in visual 
acuity)? 
20.7% 22.0% 
Have you been diagnosed with diabetic macular oedema (blurred 
vision)? 
3.2% 4.9% 
Have you ever been told that you have protein in your urine? 30.3% 36.6% 
Do you have your blood creatinine checked? 48.8% 45.9% 
Do you have diabetic kidney disease? 3.8% 4.9% 
Do you require dialysis? 1.0% 1.0% 
Have you had a kidney transplant? 1.0% 0% 
Is your usual blood pressure normal? 74.3% 50.2% 
Have you ever been told you have high blood pressure 32.7% 57.6% 
Do you monitor your own blood pressure (BP) at home? 17.3% 34.6% 
Do you take medication for high blood pressure? 24.1% 60.0% 
Are you on lipid lowering medication (for high cholesterol or 
triglycerides)? 
32.1% 58.5% 
Have you ever had a heart attack? 2.0% 10.2% 
Do you ever have chest pain or pressure (angina)? 4.6% 18.5% 
Have you ever had a cardiac catheterisation? 2.6% 6.8% 
Have you ever had heart bypass surgery (coronary artery bypass)? 1.2% 7.3% 
Have you ever had a balloon angioplasty or a coronary stent placed? 1.6% 5.9% 
Have you ever had, or suspected that you had a stroke? 3.4% 12.2% 
Other symptoms experienced 
Numbness or tingling of extremities 31.7% 55.6% 
Burning or pain in feet  14.9% 35.1% 
Decreased sensation to a body part  10.8% 27.3% 
Foot deformity  1.4% 7.8% 
Loss of sensation to a body part or area  7.0% 20.0% 
Diagnosed with diabetic neuropathy  8.0% 22.9% 






In the UK the prevalence of T2D in comparison to T1D is approximately 9 to 1 
respectively (Melanson, Sharp et al. 2002). The causes of T2D are often attributed to 
patients being overweight or obese and the first line of treatment are usually oral 
medications (Sulfonylureas® and Metformin®) and lifestyle changes such as more 
frequent exercise and improvements in dietary control. Once these changes have been 
implemented and the patient still maintains abnormal BG and HbA1c readings 
suggesting that they no longer maintain normoglycaemia as a result of factors such 
loss of insulin receptor sensitivity and beta cell deterioration, insulin is introduced. 
Symptoms of T2D diabetes usually present in people who are over 25 years of age 
although the highest prevalence are in patients over 60 years of age (Meyer, Gassler et 
al. 2007). This study provides a comparison by means of a questionnaire between 
insulin users with T1D and T2D diabetes to assess how they have essentially managed 
and treated their diabetes. 
 
Most of the responses gathered in this survey were from patients with T1D diabetes 
which usually presents in people under the age of 40 with the majority of cases occur 
in juveniles. As these patients are generally younger than most T2I patients and they 
have to inject insulin daily in order to survive, they may respond more enthusiastically 
to questionnaires. There was a greater proportion of T1D than T2I respondents having 
received a higher education and this may underpin a keenness for learning more about 
their condition and engaging in research initiatives. It may be important when 
recruiting for surveys to think about the font size and other aspects of visual clarity, so 
that those with poor or ageing eyesight are not excluded. 
 
In 2007 the largest survey ever conducted by the Healthcare Commission’s National 
Patient Experience Survey Programme (Meyer, Gassler et al. 2007), which included 152 
Primary Care Trusts (PCT) across England collected responses from 68501 
questionnaires (a response rate of 55%), where 87% of the respondents were T2D and 
13% T1D. Of those respondents 96% T1D and 17% T2D (25% of the total 68501 
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respondents) were insulin users in the same way as those participating in this survey. 
They found that 73% of all respondents received the right amount of verbal 
information, compared with 57% of all respondents when it came to written 
information at the time of diagnosis. They also found that those patients diagnosed 
with diabetes in the last five years were more likely to receive the right amount of 
written and verbal information. Although the Healthcare Commission’s findings 
(Meyer, Gassler et al. 2007) were from all respondents in the survey (so include T2T as 
well as others) their results suggest that there is a lack of information provided across 
the whole spectrum of people diagnosed with diabetes in terms of information to 
allow self-management effectively. The results in this work show that the provision for 
verbal information at the time of diagnosis was similar or better than for written 
information to the Healthcare Commission’s (Meyer, Gassler et al. 2007), 70% of T1D 
and 61% T2I received at least the right amount of verbal information and 65.9% T1D 
and 61% received at least the right amount of written information at diagnosis. These 
results show that well targeted information in both forms seems a prerequisite for 
managing patients on insulin. 
 
Respondents were asked where they went for their diabetes check-up, 22.6% of T1D 
and 52.1% T2I were seen in their doctor’s surgery, 70.2% of T1D and 41.7% were seen 
at a hospital clinic. The Healthcare Commission survey (Meyer, Gassler et al. 2007) 
found that 85% of T2I diabetes patients had their check-up at their doctors surgery, 
with only 13% attending a hospital clinic, whereas those with T1D diabetes had a 
check-up in a hospital clinic (63%) and 32% at their GP’s surgery. These findings would 
incorporate T2T diabetes patients who were controlling their diabetes by tablet so 
were not so perhaps did not need more specialised diabetes clinics. However, the T2I 
patients in this survey were insulin users similar to those that are T1D yet 52.1% (T2I) 
versus 22.6% T1D were still seen by their GP suggesting that despite injecting insulin 





The results from this survey correlate well with those found in the Healthcare 
Commission’s report (Meyer, Gassler et al. 2007) which showed that in the 12 months 
prior to answering their questionnaire 98% of the respondents had had their blood 
pressure measured, 91% HbA1c and weight, 89% cholesterol, 87% a urine test for 
protein, 83% their bare feet examined and finally only 23% reported seeing a dietician 
within the last 12 months. In the UK these tests form the basis of the National Institute 
for Health and Clinical Excellence (NICE) guidelines for the nine care processes which 
diabetes patients should undergo, yet the National Diabetes Audit results for 2009/10 
(Morais, Campbell et al. 2011) showed that throughout the UK, two-thirds of adults 
with T1D diabetes, and half of people with T2I diabetes fail to get these annual tests 
and investigations that are recommended in the national standards (Morais, Campbell 
et al. 2011).  
This survey found that for people with T2I diabetes the most difficult aspect of their 
diabetes management was found to be exercise. This was reflected in responses where 
44.2% T1D and 37.1% T2I participated between one and three hours of exercise per 
week and 11.1% of T1D and 17.8% T2I respondents did not perform any exercise. T2I 
diabetes is often associated with lifestyle and in most cases can be related to lack of 
exercise and obesity. It was noticeable that the number of responses didn’t participate 
in any exercise was greater from people with T2I diabetes. This may have been 
influenced by the age of the T2I respondents who present diabetes symptoms in later 
life and they may also have other medical conditions which prevent participation in 
exercise. 
 
Diet was also identified by respondents as a source of difficulty for their diabetes with 
29% of T1D finding difficult to find the right foods to manage their diabetes compared 
with 41.9% T2I. This is despite 51% T1D using an educational DAFNE programme and 
over 81% of all respondents receiving some dietary advice since diagnosis from their 
medical advisors. (Monteiro, Mondini et al. 1995) found that patients with T1D using 
MDI therapy often underestimated their carbohydrate intake by 20% and this was 
usually a result of anticipated exercise or fear of hypoglycaemia as a result of their 
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injected insulin. Paradoxically, T1D patients who don’t have access to well-structured 
education may be systematically over-insulinised. Both these findings add to the 
growing body of evidence for the benefits of the DAFNE programme (Miyashita, Burns 
et al. 2008, Montain, Hopper et al. 1991). A judicious and targeted insulin therapy 
following DAFNE training in T1D has been found to allow patients to achieve better 
glycaemic targets with less insulin. Despite this only 7.2% of T2I respondents were 
using DAFNE and 50.8% of these T2I respondents counted their carbohydrates, 
suggesting that structured education programmes such as DAFNE for T2I insulin users 
were much less frequently used.  
 
The frequency of BG testing was higher in T1D insulin users with 65% T1D testing 4 or 
more times which correlates with 86.4% of T1D injecting insulin 4 or more times 
suggesting that respondents may have been injecting prior to calorie intake with a 
short-acting insulin such as Novorapid® or Humalog®. Table 2 showed that most T1D 
and T2I respondents were using Lantus®/Levemir® and in order to see if these 
respondents were on a basal bolus insulin regimen a cross tabulation of the data was 
performed with the short-acting insulin Novorapid®, Humalog® and Actrapid®. The 
data in Table 2 revealed all the insulin respondents were using so more than one 
option may have been ticked and for T1D respondents there were responses received 
which included more than two insulins but these were less than 1% of total T1D 
responses and have therefore not been separated out in Table 2.  
 
The data in Table 2 suggests that most T1D respondents (75%) were using the long 
acting insulin (Lantus® or Levemir®) in combination with short-acting insulin such as 
Novorapid®, Humalog® and Actrapid® and as such were using a basal bolus system. 
This was not the case for T2I respondents (34%) were using the same basal bolus 
system and 35% using Novomix® and other insulins not listed in the survey. In order to 
use a basal bolus insulin regimen the patient would have to test their BG prior to 
calorie intake and bolus accordingly which provides a more intensive BG control and 
would prevent hypo- and hyperglycaemia. (Millar, Stephens 1993) found that T2I 
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patients using a basal bolus system have found that the number of injections per day 
and more frequent hypoglycaemic episodes difficult and report that after 24 weeks T2I 
patients switching from basal-bolus insulin regimens to biphasic insulin aspart 30 
(Novomix®), glycaemic control and health related quality of life were significantly 
improved, and hypoglycaemia was significantly reduced. This may account for the 
higher number of T2I respondents using Novomix® in this survey. 
 
Differences in the testing of BG were found for T2I insulin users in this work compared 
to those of the Healthcare Commission (Meyer, Gassler et al. 2007) where 31% with 
T1D diabetes tested 4 or more with only 3% of T2I. Similarly, only 4% with T1D never 
monitored their BG compared with 29% T2I. This could be attributed to the greater 
number of participants taking part in the Healthcare Commission survey which was 
able to capture data over a broader range of patients with diabetes who may have 
been treating there diabetes with oral medications. 
 
Both T1D and T2I patients had experienced hypoglycaemia indicating that their current 
treatment by insulin injection allowed them drift lower than normoglycaemia. 
Although most of these respondents did not exhibit serious symptoms such as black 
out or coma they did experience more typical conditions such as trembling and 
weakness. Agitation and poor concentration were felt by more T1D respondents. Most 
T1D and T2I respondents felt these symptoms when their BG was between 3-4mmol/L. 
Defining BG values for hypoglycaemia remains difficult with surgeons and forensic 
pathologists defining spontaneous pathological hypoglycaemia requiring investigation 
and treatment at BG < 2.2 mmol/L, to avoid defining healthy people as hypoglycaemic 
(Nielsen, Hafdahl et al. 2006). At the other extreme, ADA defined BG concentrations of 
< 3.9 mmol/L as hypoglycaemia, based on the reduction in endogenous insulin and 
increase in pancreatic glucagon which can be demonstrated at this level. However, 
defining hypoglycaemia < 3.9 mmol/L could lead to overestimation of clinically 




The European Medicines Agency (EMEA), (Nicklas, Rogus et al. 1997) recommends a 
value of < 3.0 mmol/L when assessing hypoglycaemic risk of different treatment 
regimens. Impaired cognitive function is seen at plasma BG concentrations of 
< 3.0 mmol/L and avoidance of plasma BG concentrations of < 3.0 mmol/L has been 
able to restore hypoglycaemia awareness to people with T1D diabetes and defective 
counter regulation. As insulin-deficient patients with diabetes lose their ability to 
modulate either insulin or glucagon in response to hypoglycaemia and depend instead 
on autonomic activation, subjective awareness and adrenaline to defend against 
severe hypoglycaemia. Risk factors for individual episodes of hypoglycaemia in patients 
with T2I diabetes include behavioural, physiological and therapeutic factors, the most 
common behavioural factor being identified as missed or irregular meals. Other 
lifestyle factors include alcohol, exercise and incorrect use of glucose-lowering 
medication (dose/timing). 
 
Hyperglycaemia causes vascular risks such as hypertension and cerobropetal arteries 
increasing the chance of strokes taking place is twice as much in patients with diabetes 
(Ormsbee, Choi et al. 2009). The present survey shows that 63.2% of T1D respondents 
thought that they could sense when their BG was above 13mmol/L yet that 
dyslipidaemia as well as atherosclerotic changes in the heart and over 90% of T1D 
respondents had these above normal BG reading once or more a week. Similarly for 
T2I respondents 46.7% could sense an above normal BG with 68% have these high BG 
episodes more than once a week. 33% of T1D respondents had suffered from (DKA) 
and most of these had been hospitalised as a result indicating that the treatment and 
management of respondents was clearly not adequate to maintain BG control, similar 
trends were observed for T2I respondents. It is likely that the DKA episodes reported 
by T1D respondents will have included those that were reported at the time of 
diagnosis. 
 
The Diabetes Control and Complications Trial (DCCT) showed that 1422 patients with 
T1D diabetes who were treated with intensive control of BG concentrations for 6.5 
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years had a 57% reduced risk of cardiovascular events over a means follow up period 
of 17 years compared with individuals on conventional treatment (Oguri, Adachi et al. 
2009). These trials suggest that the balance of recurrent hypoglycaemia against the 
advantages of a low HbA1c value should consider factors such as the patient’s age, 
duration of diabetes and comorbidities. The results from this survey which focus on 
the common needs of insulin users show that careful follow-up after diagnosis, 
frequent testing and education about calorie turnover from intake and exercise are 
required for both T1D patients but more so for T2I patients whose needs become 
similar to those of T1D patients once they begin to inject insulin.  
Although these T2I insulin patients are often older than T1D insulin users who are 
often children at time of diagnosis the same resources should be made available in 
terms of management and treatment of their diabetes. The HbA1c value forms an 
important part of a diabetes patient’s management and subsequent treatment and as 
insulin is a potent drug the possibility of hypoglycaemia is always present. Treatments 
should therefore include judicious and frequent testing with a basal bolus insulin 
regimen. For T2I patients who struggle with BG management and frequent 
hyperglycaemia the introduction of insulin injections should also be much earlier 
before cumulative effects of complications make the patient too ill to really benefit. 
3.6 Conclusion 
Aside from the serious personal consequences, the cost of diabetes and its 
complications has been variously quoted as 5-10% of the UK NHS budget (Melanson, 
Sharp et al. 2002), depending on the costing criteria and a recent report quotes this as 
equating to about £1m/h. The results from this study show that current treatment and 
management of diabetes care still poses difficulty for most patients and that for T1D 





Chapter 4: Experiences and attitudes of people with T1D and 
T2D to Exercise 
 
4.1 Introduction 
Diabetes is a major public health concern associated with increased morbidity, 
mortality and cost for health services. The growing incidence of diabetes has been 
estimated to increase by 42% by 2030 (Duarte, de Almeida et al. 2012). Balancing 
calorie intake with insulin demands is difficult and patients often suffer excursions 
from normal BG levels, for example hypoglycaemic events when calorie output has not 
been properly accounted for. High BG levels result from diabetic defects in the system 
such as insulin secretion/action, or both, and lead to serious complications. Exercise 
along with diet therapy, and medications (oral hyperglycaemic and insulin, refer to 
Section 1.7) constitute the basic treatment for diabetes mellitus and are the 
cornerstones for glycaemic control (Lynch, Liebman et al. 2014, Kamiya, Ohsawa et al. 
1995). 
Exercise, however, is recommended as an effective lifestyle management technique 
for the prevention of T2D and for the management of both T1D and T2D. It has 
physiological benefits including improved physical work capacity, body composition, 
blood pressure (Sukala, Page et al. 2012) blood lipid profile (Kwon, Min et al. 2010) 
insulin sensitivity and BG management. It is associated with reducing risk of long term 
complications and mortality in individuals with diabetes (Hordern, Dunstan et al. 
2012). 
This chapter aims to assess the views and attitudes of people with diabetes to diet and 
exercise. Also to compare T1D, T2T as well as T2I regarding the type and intensity of 
exercise they normally perform. It also aims to consider factors such as insulin dose 
and BG management on normal and exercise days, to appreciate barriers and coping 
strategies for exercising safely when they have diabetes as well as to assess T1D, T2T 
and T2I understanding regarding self-care recommendations related to exercise. 
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Some of the key findings from this survey were combined with exercise trials 
conducted and presented in this thesis which will be discussed in Chapter 5 and 6. This 
may lead to recommendations to improve the lifestyle of people with diabetes in the 
future. The information could also help research toward a suitable exercise regime for 
people with diabetes. 
4.2 Survey design, distribution and response collection 
From the experience gained with questionnaire design and analysis from the first 
survey in Chapter 3, a second survey was produced about exercise and diet for people 
with diabetes (T1D, T2T and T2I). This survey had 78 open and closed ended questions 
and discussed T1D and T2D experiences with various aspects of their diabetes and 
their attitudes with diet and exercise. It comprised four sections:  
1. Background information: this section helped to collect respondent basic details 
such as, gender, age, height, weight, level of education and ethnic group. 
2. Diabetes diagnosis and management: this part was about diagnosis, type of 
diabetes, family history, insulin, HbA1c, check-ups and complications. 
3. Hypoglycaemia and hyperglycaemia: this section covered hypoglycaemia 
episodes and symptoms as well as hyperglycaemia episodes.  
4. Exercise and diet. This was the main section in this survey and outlined T1D, 
T2T and T2I opinions with various aspects of their perceptions with exercise 
and diet. It covered items such as diet approach, daily calories, dietary advice 
and programmes such as DAFNE. Furthermore, it explored the attitudes of T1D, 
T2T and T2I towards exercise and many aspects of diabetes management and 
specific care (before, during or after the exercise) such as BG values, testing BG, 
taking carbohydrate, insulin doses. The aim of this section was to assess T1D, 
T2T and T2I patients understanding regarding self-management 
recommendations related to exercise from their GP and/or their healthcare 
professionals. Questions sought information about the type of exercise and 
intensity, frequency and duration of performed exercise, and about symptoms 
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possibly related to hypoglycaemia during or after exercise. For those 
respondents reporting they did not exercise regularly, the barriers preventing 
them from taking part in more exercise were asked as well as the factors 
influence their decision to participate in exercise (Appendix 1). 
The questionnaires were produced in English and distributed to the participants 
through various channels such as local newspapers and websites as well as social 
networking sites as described in section 2.2.4.   
4.3 Statistical analyses (analysis of responses) 
All data were analysed using (SPSS) and Microsoft Excel 2010®. Refer to section 2.2.5 
4.4 Results and discussion 
The following sections describe and discuss the data collected from the survey: 
4.4.1 Background information and diagnosis 
A total of 240 respondents completed the questionnaire, 62.1% with T1D, and 37.9% 
with T2D (25.4% T2T and 12.5% T2I). Eighty-one percent of responses were from the 
UK where the survey was widely distributed and advertised with 82.5% of responses 
from respondents of white ethnicity. The remaining responses were gathered from the 
USA and Australia. Approximately 44% of T1D respondents were male compared with 
47.5% of T2T and 60% of T2I.  
Those with T1D tended to be diagnosed at an earlier age than those with T2D and 
those classed as having T2D were generally older. All T2I patients were over the age of 
40 with 30% between 61 and 80 years and were diagnosed between 51 and 60 years of 
age. Most of the T2T were aged between 41 and 60 years and 75% of them were 
diagnosed at age between 31 and 50 years while more than half 55.4% of T1D aged 
between 11 and 30 years and three quarter of those were diagnosed at age between 1 
and 20 years.  
When asked about their education level, 75% of T2T and T2I, and 70% T1 were in or 
have had a higher education or educational training. None of T2I and 6.7% of T2T was 
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still in full time education compared to 20.9% of T1D. As T1D is often described as 
juvenile diabetes these results suggest that some of the respondents fall into this 
category. Figure 16 shows that more than half 51% of T1D had healthy weight with 
normal BMI range between 18.5 and 24.9 kg/m2 compared to only 16.4% of T2T and 
20% of T2I. The highest percentage of obese respondents with BMI over 30 kg/m2 was 
among T2T with 59%. However, this compared with only 12.8% of T1D and 43.3% of 
T2I. In addition, 28.9% of T1D, 24.6% of T2T and 36.7% of T2I were overweight with 
BMI between 25-29.9. None of T2T and T2I was underweight with BMI under 18.5 
kg/m2, whereas 7.4% of T1D were underweight. The level of obesity and BMI ranges 
important risk factors and indicators of overall health and play a role in irregular 
glucose metabolism (Bombelli, Facchetti et al. 2011) which leads to insulin resistance 
and T2D (Li, Xiao et al. 2014) . 
A cross tabulation of data for respondent age and BMI found that 12.9% of T2T over 40 
years of age were of healthy weight compared with 20% of T2T who were overweight 
and 43% who were classified obese. For T2I who over 40 of age, 20% had a healthy 
BMI , 36% were overweight and 40% classified as obese. These results show that the 
majority of T2D who are treated by tablets and insulin injections struggle with their 
weight in later life. These findings as to be expected as T2D is a lifestyle disease with 
high energy intake and lack of physical activity. This supports previous researches 
which confirmed that being overweight and obese have close association with T2D 
(Wang, Li et al. 2014, Henry, Chilton et al. 2013, Lau, Teoh 2013). This is supported by 
Charpentier study on French patients with T2D, which revealed that 39% of the 
patients were obese (BMI ˃ 30 kg/m2 ), (Charpentier, Genès et al. 2003). 
Three- quarters (75%) of all respondents, reported having been diagnosed by (GP) and 
hospital clinics, while the rest 25% were diagnosed in A&E (Accident and Emergency), 
by themselves or by friend and family who picked some sign of the disease and led the 
patient to a medical professional. Half of T2I, 54.4% of T1D and 36.1% of T2T had a 
family history of diabetes. Respondents were asked what was their HbA1c when they 
were diagnosed with diabetes, 60.8% of T1D, 23.3% of T2I and 27.1% of T2T did not 
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know, whereas, 17.6% of T1D, 33.3% of T2I and 22% of T2T reported that it was over 
10% (86 mmol/mol). For T1D respondents this may have been because they were 
diagnosed in their childhood and recollection of this value was difficult or even 
reported to their parents. 
The most challenging element of the diabetes management for participants was found 
to be performing exercise (41.6% for T1D, 50% for T2I and 47.7% of T2T). Other 
difficulties were identified as diet and testing BG. These findings are consistent with a 
previous study by the author and the research group found that the most difficult 
aspect of the diabetes management for respondents was found to be exercising (36.6% 




Figure 16: BMI values for T1D, T2I and T2T. 
 
4.4.2 Check-up, management and complications 
Respondents were asked how often their HbA1c was measured, 41% of T1D and T2T, 
and 50% of T2I reported that they had had it measured every three months. More than 
half (51.4%) of T1D had been HbA1c tested every six months compared to 37.3% of 


























(NICE) recommendation for the frequency of measurements for HbA1c which is 2 - 6 
monthly depending on the level of control and /or treatment changes. It is very 
important in order to maintain acceptable BG level to have HbA1c measurements, 
because low frequency measurements of HbA1c results in poor glycaemic control in 
T2D (Alioune Camara 2014). Table 5 reflects the most recent medical check-up for 
respondents, with 61.4% of T1D, and more than half 56% of T2T and T2I having an 
HbA1c between 5-8%, 21.7% of T1D, 16.6% of T2I and 15.3% of T2T between 8 - 10% 
and 5% of T1D and T2T had an HbA1c over 10% compared to 13.3% of T2I. When asked 
what respondents thought their HbA1c should be, the majority of all the respondents 
91.1% of T1D, 83.3% of T2T and 67.2% of T2I thought a desirable HbA1c value would 
be between 5-7%. All respondents thought their HbA1c should not exceed 8%, 
suggesting that most of them know the acceptable HbA1c value. However less than 
half of all the groups did not achieve this and had high HbA1c values. Moreover, 15.5% 
of T2T and 10% of T2I thought that HbA1c value of less than 5% was desirable, 
indicating that they with the minority who said did not know what it should be are not 
fully understand this value.  
Evidence from across the world for children and adults shows that they find it difficult 
to achieve optimum HbA1c. A fall in HbA1c from 7.9 to 7.0 lowers microvascular risk by 
25% which is critical because poorly controlled diabetes can reduce lifespan and is a 
major cause of mortality (Monami, Vitale et al. 2013). One study found that low and 
high mean HbA1c values were associated with increased all-cause mortality and 
cardiac events. A high HbA1c value is linked with micro and macrovasculaur 
complications in later life. However, intensive insulin therapy should also be 
considered especially among the elderly as a desired low HbA1c value can also lead to 
CVD. Results showed a general association with the lowest hazard ratio found to be at 




Table 5: Recent HbA1c and perceived targets for T1D, T2I and T2T. 
 
HbA1c average  Don’t 
know 
< 5% 5-6% 6.1-7% 7.1-8% 8.1-9% 9.1-10% ˃ 10%  
T1D 
Recent HbA1c 10.8% 1.4% 10.1% 23.6% 27.7% 14.9% 6.8% 4.7% 
Would like to 
be 




13.3% 0.0% 23.3% 20.0% 13.3% 13.3% 3.3% 13.3% 
Would like to 
be 




18.6% 5.1% 23.7% 18.6% 13.6% 5.1% 10.2% 5.1% 
Would like to 
be 
17.2% 15.5% 51.7% 15.5% 0.0% 0.0% 0.0% 0.0% 
 
Table 6 shows the types of insulin used by T1D and T2I respondents. It should be noted 
that respondents were asked to tick all insulins they used and all respondents that 
injected Lantus® (47.7% of T1D and 73.3% of T2I) or Levemir®(35.6% of T1D and 26.7% 
of T2I) also used a short acting insulin such as Novorapid® (57.7% for T1D and 73.3%  
for T2I), Humalog® (33.6% for T1D and 26.7% for T2I) and Actrapid® (4% for T1D and 
0.5% for T2I). These findings show that 100% of the T2I are using Lantus® and Levemir® 
(73.3% + 26.7%) and must be using a basal bolus system. The best treatment for 
maintaining acceptable HbA1c values for T1D and T2I diabetes comes from frequent 
testing and insulin doses known as ‘intensive control’ (DCCT, EDIC 2014). However, 
some T2D have been prescribed Glargine® (Lantus®) in combination with oral 
hypoglycaemic such as Metformin® often quite early on their insulin therapy.  
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The evidence has been available for more than twenty years but the uptake is far from 
universal. The methodology is usually a combination of calculated background long 
acting (basal) and meal associated insulin boost (short-acting bolus) doses and 
characterised by the variation of dosing to allow a more normal diet than previously. 
Most of T1D and T2I, 62.2% and 70%, respectively, inject themselves 4 or more insulin 
injections in a normal day.  
When they were asked how long they have been injecting this number of injections 
each day, 28% of the respondents reported that this regimen had been used ever since 
they started taking insulin, and 40.3% of T1D and 34.5% of T2I started using insulin 
longer than 5 years ago. 59% of T1D and 83.3% of T2I described the total amount of 
insulin they used every day and for the previous 24 hours as more than 40 units. Of 
these, 2.9% of T1D and 33.3% of T2I use over 100 units of insulin every day. A 
crosstabulation of the data shows that 46% of T2I injected more than 80 units per day 
and were on the overweight or obese in BMI suggesting that these respondents must 
suffering a loss of the insulin sensitivity. 
The majority of T1D (62%), and 12.5% of T2I tested their blood glucose 4 or more times 
a day. Most of T2I (68.8%) tested it only two to four times a day compared to 28.4% of 
T1D who did likewise, 9.8% of T1D and 18.8% of T2I tested it once daily. As would 
expected, more than half 55.9% of T2T tested their BG once a day compared to 38.2% 
tested it two to four times and only 5.9% more than 4 times. T2I users who test their 
BG once a day must be estimating their calorie intake on several occasions on a daily 
basis which would suggest that their BG management is not as good as it should be. 
This would have an impact on their HbA1c values and suggests that they may feel 








Table 6: Types of insulin used by T1D and T2I respondents. 
 
Type of insulin T1D T2I 
Actrapid® 4% 0% 
Humalog®(Lispro) 33.6% 26.7% 
Humulin l® 1.3% 0% 
Humulin M3® 2% 0% 
Humulin S® 1.3% 0% 
Insulatard® 1.3% 3.3% 
Novorapid® or Novolog®(Aspart) 57.7% 73.3% 
Levemir® 35.6% 26.7% 
Lantus® 47.7% 73.3% 
 
The majority of all respondents (>89%) had had their blood pressure and weight 
checked by a doctor or nurse in the previous 12 months as part of their treatment. 
Also in the past 12 months over 70% of T1D, T2I and T2T respondents had had their 
cholesterol, eyes and bare feet examined (Table 7). This is important because these 




Table 7: Check-ups in the last 12 months. 
 
In the last 12 months T1D T2I T2T 
Your blood pressure taken by a doctor/nurse 94.5% 100% 98.3% 
A cholesterol test by a doctor/nurse 75.9% 96.4% 91.7% 
An eye test where a photograph of the back of your eyes 
were taken 
83.4% 92.9% 73.3% 
Your bare feet were examined 75.5% 90% 70.1% 
You have had your weight checked by a doctor/nurse 93.1% 89.3% 91.7% 
 
4.4.3 Medical condition and complications 
Table 8 shows a summary of responses from all respondents relating to other 
diagnosed medical conditions and complications. More than 60% of all respondents 
had a normal BP, however, 20.3% of T1D, 39.3% of T2I and 31.7% of T2T had been told 
that they had high BP and took medication to control it. More than third 35.7% of T2I, 
41.7% of T2T and only 12.8% of T1D had high lipid profile (TC or TG) and were on lipid 
lowering medication. When respondents were questioned about other complications, 
35.8% of T1D, 30% of T2I and 21.7% of T2T had eyesight problems. None of T2I or T2T 
and only 1.4% of T1D had had a heart attack. Some of the respondents (14.3% of T2I, 
6.7% of T2T and 2% of T1D) had chest pain/pressure (angina). Stroke was suspected or 
experienced by 3.6% of T2I, 6.8% of T2T and 3.4% of T1D. A nationwide French survey 
by Charpentier et.al 2003, showed similar results from 4390 respondents with T2D, 
which showed that 15% of the patients had evidence of associated symptomatic 
coronary heart disease, 8% had a history of myocardial infarction, 8% had a history of 
angina, 4% had been hospitalised previously for cardiac insufficiency and 3% had a 




Table 8: Other medical conditions and complications. 
 
 T1D T2I T2T 
Has your eyesight suffered as a consequence of your 
diabetes? 
35.8% 30% 21.7% 
Do you have diabetic kidney disease? 1.4% 13.3% 3.3% 
Do you require dialysis? 2% 0% 0% 
Have you had a kidney transplant? 2.7% 6.7% 0% 
Is your usual blood pressure normal? 79.7% 60.7% 68.3% 
Do you take any medication to control blood pressure? 20.3% 39.3% 31.7% 
Are you on lipid lowering medication (for high 
cholesterol or triglycerides)? 
12.8% 35.7% 41.7% 
Have you ever had a heart attack? 1.4% 0% 0% 
Do you ever have chest pain or pressure (angina)? 2% 14.3% 6.7% 
Have you ever had heart bypass surgery (coronary 
artery bypass)? 
0% 0% 0% 
Have you ever had a balloon angioplasty or a coronary 
stent placed? 
0% 14.3% 1.7% 




4.4.4 Hypoglycaemia and Hyperglycaemia 
Not surprisingly the vast majority of T1D and T2I respondents had experienced 
hypoglycaemia at some time since diagnosis (95.1% T1D and 86.7% T2I) but this had 
affected less than half (42.4%) of T2T. Table 9 presents the symptoms the respondents 
had experienced with hypoglycaemia and most likely to be suffered by T1D and T2I. In 
contrast, as would be expected T2T respondents were least likely to have these 
symptoms compared with T1D and T2I, because they were using Sulphonylureas as the 
first line of treatment which can reduce BG level in the blood stream by higher 
pancreatic insulin output (Refer to Section 1.7.2). Most of these findings about 
hypoglycaemia from this study in agreement with previous study (Chapter 3) where 
98.9% of T1D and 86.1% of T2I reported that they had encountered hypoglycaemia at 
several times since diagnosis. 
About 62% of T1D, 54.1% of T2I 48% of T2 felt hypoglycaemic symptoms when their BG 
level was between 3 and 3.9 mmol/L. However, 18.7% of T1D and 16% of T2T felt 
similar symptoms between 4 and 5 mmol/L while 15.8% of T1D, 29.2% of T2I and 8% of 
T2T only felt symptoms below 3 mmol/L. A minority of T1D and T2T (15.5% and 4.2% 
respectively) and none of T2I stated that hypoglycaemia affected their day-to-day 
activities quite a lot or a great deal. Low BG is important as it has severe consequences 
such as seizure, coma, accidents and death. Clinically it is now appreciated that the 
greatest benefits on the complications of diabetes may be seen following minimisation 
of plasma BG and insulin excursion including low bold BG concentration providing 
better overall glycaemic control. However, 77.5% of T1D and 89% of T2I described little 
or no effect. Most of the respondents from all groups in this survey (more than 95%) 
responded to a low BG by taking a sugary food or drink immediately. 
When the respondents were asked about driving, none of T2I or T2T and only 5% of 
T1D said that the problems of hypoglycaemia stopped them permanently from being 
able to drive. When respondents were asked during the past 12 months did they have 
any “severe” hypoglycaemia episodes and how often, only 12.6% of T1D had it. The 
majority of them (81%) said that they had it 1-2 times, 14.3% 3-5times and 4.8% 6 or 
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more. Very few % of T1D and 3.8% of T2T reported they had to go to hospital because 
of their hypoglycaemic episode in the past 12 months. 
 
Table 9: Hypoglycaemia symptoms. 
 
Hypoglycaemia Symptoms  T1D T2I T2T 
Paleness 50.3% 10% 18% 
Trembling 74.5% 56.7% 24.6% 
Sweating 73.8% 53.3% 19.7% 
A feeling of weakness/fatigue 81.9% 50% 32.8% 
Rapid heartbeat 48.3 33.3% 9.8% 
Hunger 61.1% 16.7% 14.8% 
Agitation/irritability 51.7% 26.7% 21.3% 
Poor concentration 68.5% 40% 23% 
Blurred vision 35.6% 23.3% 13.1% 
Loss of coherence 41.6% 13.3% 9.8% 
Black out 10.7% 10% 8.2% 
Convulsion/fit 4% 0% 4.9% 
Coma 1.3% 3.3% 0% 
 
When respondents were asked if their BG had ever been above 20mmol/L, 84.2% of 
T1D, 57.5% of T2I and a third of T2T replied with yes. When they asked how many 
times per week their fasting BG was 10mmol/L (180 mg/dl) or above, 27.9% of T1D, 
25.9% of T2I and 20% of T2T had found their BG 10mmol/L or above once or twice a 
week. Forty one % of T1D and T2I, and only 12.7% had more than twice a week. About 
a third, (30.7%) of T1D, 33.3% of T2I and 67.3%T2T had never reported a BG as high as 
10mmol/L or above. More than 91% of all the groups had never been in a coma 
because of high BG. Some of these high BG readings may have been the results of the 
dawn phenomenon. This would be especially applicable to T1D who are often young as 
during their growth years the productions of hormones (primarily growth hormones 
and cortisol) stimulate the liver to release extra glucose into the blood stream.  
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Respondents in this survey were asked if they have ever been in (DKA), the condition 
where ketones in the blood due to catabolism. The vast majority of T2I and T2T, 96.4% 
and 86.4% respectively, and more than half (59%) of T1D said that they did not 
experienced DKA. However, minority of 3.6% of T2I, 13.6% of T2T and 41% of T1D had 
it before. 
4.4.5 Attitude to exercise and diet  
4.4.5.1  Diet and healthy lifestyle  
With regards to diet and healthy lifestyle, respondents were asked about drinking and 
smoking habits, more than 93.1% of all the groups did not smoke. However, 57.9% of 
T1D, 43.1% of T2T and 32.1% off T2I did drink alcohol. Respondents were asked how 
they would describe their current approach to diet, slightly more than half (55.3%) of 
all the groups mentioned that their eating habits were healthy. About third (29.6%) of 
T1D, quarter of T2T and 46.4% of T2I said that they sometimes try to eat healthy food. 
However, only few 5% of T1D and T2T had poor eating habits. Three quarter 74.1% of 
T1D, 37.9% of T2T and 42.9% of T2I reported that they counted carbohydrates 
regularly in order to help them to control their diabetes. In total, more than 85% of all 
the survey respondents had been given dietary advice to help control their diabetes 
with 30.9% describing their daily calories consumed in atypical day as between 1500 – 
2000. About quarter (24.8%) of T1D, 22.2% T2I, and 17.2% of T2T did not know what 
their daily calories consumption was. However, in a typical day 22% of respondents 
consumed >2000 – 2500 calorie which is recommended dietary allowance (RDA). 
These findings support what have been found from first survey (Chapter.3), 30.3% of 
T1D and 30.1% of T2I describing their daily calories consumed as between 1500 – 2000 





4.4.5.2  Attitude and barriers to exercise  
Over 67% of T1D and T2D respondents valued exercise and considered it important to 
them, with just a small minority (5% of T1D, 15% of T2T and 8% of T2I) stating that 
participation in sport and exercise not important. Most of the participants in this study 
(80.5% of T1D, 74% of T2T and T2I) undertook exercise regularly. A cross tabulation of 
the data found that 80% of T2D (T2T + T2I) who responded yes to regular exercise and 
who had a BMI which was overweight or obese (Refer to Section 1.9.1). For those who 
responded no to regular exercise 87.5% of T2D (T2T + T2I) were overweight or obese. 
These results suggest that T2D (T2T + T2I) struggle with their weight despite doing 
exercise. One possible reason for this may be that only 9.8% of T1D, 9.6% of T2T and 
5.9% of T2I were participating in at least 150 min of exercise per week which achieve 
the exercise recommendations. American college of Sport and Medicine (ACSM) and 
American Diabetes Association (ADA) recommended people with T2D diabetes to 
exercise at least 150 min per week of moderate to high intensity of AE spread out 
within at least 3 days per week, with no more than two consecutive days between 
bouts of AE. In addition to AE, ACSM and ADA recommended T2D to undertake RE at 
moderate to high intensity (3 sets × 10 repetitions) two or three days per week 
(American College of Sport and Medicine, American Diabetes Association. 2010) 
T2T and T2I were observed to exercise less compared with T1D group (73% and 80 .5% 
respectively). The results can be partly explained by these cohorts characteristics. T2T 
and T2I patients are usually older, have higher BMI, and lower education and often 
exercise for a short duration compared with the T1D group as shown previously in 
Section 4.4.1. Individuals with T1D are usually younger (Section 4.4.1) and, therefore, 
more likely to be active at work and during leisure time. About two thirds of T1D and 
T2T, 60% and 62%, respectively and 84% of T2I confirmed that exercise did have a 
positive impact on their diabetes and their life after becoming diabetic. The positive 
effects of exercise, included better general health (82% of T1D, 76.5% of T2I and 70.7% 
of T2T), low HbA1c (44.3% of T1D, 64.7% of T2I and 50% of T2T) and fewer 
hypoglycaemia events (44% of T1D, 50% of T2I and 16% of T2T). In contrast, only 
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12.1% of T1D and no T2D said that exercise had any negative impact. Less than a 
quarter 19.5% of T1D and 26% of T2T and T2I had some barriers preventing them from 
doing exercise in a regular basis. These barriers are summarised in Table 10 with lack 
of time being the most cited reason by 66.7% of T2T, and 50% of T1D and T2I. About 
half 48.6% of T1D, 27.8% of T2I and 56.5% of T2T said that lack of motivation was one 
of the main factors that discouraged them from doing exercise. A quarter of T1D and 
T2T, 24.3% and 25% respectively, and 20% of T2I did not do exercise due to health 
reasons, although these were not explicitly described.  
 
Table 10: Barriers preventing from exercise. 
 
Barriers preventing from exercise  T1D T2I T2T 
Health reasons 24.3% 20% 25% 
Lack of motivation 48.6% 27.8% 56.5% 
Embarrassment about how you look. EG overweight or 
lack of fitness 
17.3% 33.3% 20.5% 
You doubt it will lead to weight control 8.7% 0% 6.8% 
Lack of time  50% 50% 66.7% 
It does not interest me 21.9% 17.6% 27.7% 
It is too expensive 22.8% 27.8% 31.1% 
Lack of transport 9.7% 6.3% 15.9% 
Fear of injury 6.9% 5.9% 15.9% 




When respondents were asked about the factors that influenced their decision to 
participate in exercise and sport, more than 69% mentioned the following: to keep 
well with diabetes, better control of their BG, better HbA1c values and to improve 
health and fitness levels. Two thirds of T1D, 94.7% of T2I and 87.5% of T2T said that 
losing weight was one of the primary factors for participating in exercise. Table 11 
highlights more of these factors for all the groups.  
 
Table 11: Factors for participating in exercise. 
 
Factors for participating in exercise  T1D T2I T2T 
To keep well with diabetes 78% 100% 83.3% 
Better control of  BG 79.8% 100% 80.4% 
Better HbA1c value 69.8% 88.9% 79.5% 
Improvements health and fitness 93.2% 100% 83.3% 
Loss of weight 63% 94.7% 87.5% 
Family participates in sport 18.9% 28.9% 12.8% 
Because friends do it 40.6% 7.1% 13.2% 
Because I enjoy it 80.6% 84.2% 45.2% 
To relieve stress 69.6% 37.5% 58.1% 
 
When respondents were asked about the frustrating aspects about exercise, table 12 
shows that finding time for exercise and motivation were the most cited reasons for 




Table 12: Aspects of frustration about exercise. 
 
frustrating issues about exercise T1D T2I T2T 
Finding time to exercise every day 47.0% 40.0% 57.4% 
Motivating myself 34.2% 36.7% 55.7% 
Having to change my diet 10.1% 3.3% 6.6% 
Pain after exercise 10.7% 23.3% 18.0% 
 
4.4.5.3  Type and intensity of exercise performed by T1D and T2D 
About half 49% of T1D had membership with a Sports Centre or group, compared with 
37.2% of T2T and 44.4% of T2I. Figure 17 shows that walking was the most preferred 
form of exercise by 93.5% of T1D, 92.1% of T2T and 93.8% of T2I. The vast majority of 
the respondents performed exercise at moderate to high intensity exercise (86% of 
T1D, 70% of T2T and T2I). Only 14% of T1D undertook exercise every day in 
comparison with 29% of T2T and 35% of T2I. About half of T1D and T2T, 47% and 48% 
respectively, performed exercise 3 – 5 days per week compared with 29.4% of T2I. In a 
typical exercise day the majority (72.2%) of respondents performed exercise one time 
per day and 81.4% of T1D, 94.2% of T2I normally spend from 30 mins to 2 hours in 
sport or exercise compared with 66.7% of T2T. Figure 18 shows where the respondents 















Figure 18: Exercise places. 
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4.4.5.4  BG management and Insulin dose on normal and exercise days 
A greater proportion of T1D than T2T and T2I reported that they tested their BG more 
than four times on a non-exercise day (62%, 6% and 12.5% respectively). 
When the respondents were asked whether they changed this on an exercise day, 
57.4% of T1D said that they tested BG more often than usual on an exercise day 
compared with 13.9 of %T2T and no one of T2I. Furthermore, 77% of T2T and T2I did 
not change their testing BG habit on an exercise day in comparison with 42% of T1D. 
On an exercise day, respondents who inject insulin (T1D and T2I) did not change the 
number of insulin injections. Table 13 shows that 19% of T1D and 23.1% of T2I have 
taken their insulin dose before exercise and 35.9% of T1D and 23.1% of T2I 
administered their dose following exercise.  
About 49% of T1D, 12% of T2T and 35.3% of T2I had hypoglycaemia events up to three 
times in the past month with the major risk period up to 2 hours following the exertion 
of exercise. To mitigate this threat, carbohydrate boosts were used and were more 
common before exercise than after and few disturbed the session for this purpose. 
Respondents with T1D were more likely to test their BG more than those with T2I, 
before exercise (59.2% and 34.6% respectively), during exercise (23.3 % and 3.8% 
respectively) and after exercise as well (50% and 19.6% respectively). 
Respondents were asked what they would do if their BG were less than 4 mmol/L 
(72mg/dl), and the majority of all respondents (80%), said they would take some 
carbohydrate then exercise. More than 94% of T2T and T2I reported that they rarely or 
never had hypo during exercise compared to 68.6% of T1D. 29.4% of T1D said that they 
had it frequently. Moreover, when they asked about the previous month, a higher 
proportion of those with T1D (49%) had experienced hypoglycaemia events after 
exercise up to three times more than those with T2T and T2I, (11.5% and 35.3% 
respectively). In the event of hypoglycaemia after exercise, more than 96% of T1D and 
T2I would eat or drink some carbohydrate compared to 50% of T2T. These results 
indicate that T1D have more hypoglycaemic episodes and suggest that their current 
treatment with insulin is not optimal during exercise. It is also possible T2D patients 
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did not stress their body as much as T1D or perhaps exercise differently for example, 
short duration and lower intensity. It is well known that after exercise BG levels can 
drop several hours after exercise, the reason for this exercise makes muscle cells 
sensitive to insulin so following physical activity every unit of insulin covers a greater 
amount of carbohydrate producing a greater BG lowering effect. Extensive exercise 
depletes glycogen stores in the muscle and liver and when these stores replenish BG 
levels often drop. 
When the respondents were asked about how many times in the last month they 
suffered from hyperglycaemia and their BG had been above 10mmol/L (180mg/dl) 
after exercise, the majority of T2T (87%) and 65% of T2I said none. This compared with 
36.4% of T1D. However, T1D were most likely in the last month to have had up to 
three episodes of hyperglycaemia after exercise, with 41.4% compared with just 5.9% 
of T2I and 0% of T2T.  
Crosstab calculations with 2 layers were made to find the impact of regular exercise on 
HbA1c between the three groups. This study showed that those who did exercise 
regularly among all the groups had a better HbA1c than those who did not. HbA1c with 
desirable values between 5% - 7% (31 - 53 mmol/mol) were observed more among the 
patients who did exercise regularly (35.3% of T1D, 46.5% of T2T and 45.5% of T2I) 
compared with (27.6% of T1D, 31.3% of T2T and 37.5% of T2I) who did not. Moreover, 
patients from all the groups who did not exercise were most likely to have a high 
HbA1c over 8% (37.9% of T1D, 25.1% of T2T and 37.5% of T2I) in comparison with 
those who did it in a regular basis (23.4% of T1D, 18.6% of T2T and 26.9% of T2I).  
When the respondents were asked about the symptoms during or after exercise, Table 
14 shows a variety of answers from respondents for following symptoms: bleeding, 
chafing, flushing, hives, hyperthermia and colour or blood in the urine. Less than 
quarter of T2I had muscle cramps compared with 16.9% of T1D and 14.3% of T2T. 
About quarter of T1D and T2I had shortness of breath compared with 21.4% of T2T. 
Some of these can be real barriers and diabetes patient need better support and 
advice about some or all of these symptoms.  
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Table 13: BG, insulin and carbohydrate as related to exercise. 
 
  When do you test your blood glucose? 
  A. Before exercise B. During exercise C. After exercise 
T1D 59.2% 23.3 % 50% 
T2I 34.6% 3.8% 19.6% 
T2T 21.4% 3.6% 19.2% 











 When do you take carbohydrate? 
T1D 47.9% 20.4% 40.1% 
T2I 34.6% 19.2% 19.2% 






Table 14: Symptoms during and after exercise. 
 
Symptoms during and after exercise  T1D T2I T2T 
Bleeding 0% 0% 0% 
Chafing 4% 0% 7.1% 
Flushing 6.3% 3.8% 3.6% 
Hives 0.7% 0% 1.8% 
Hyperthermia 2.8% 0% 1.8% 
Muscle cramps 16.9% 23.1% 14.3% 
Red face 27.5% 7.7% 12.5% 
Shortness of breath 23.2% 23.1% 21.4% 
Urinary (colour, blood) 0% 0% 1.8% 
 
4.5 Conclusion 
This study showed that those who did exercise regularly among all the groups had a 
better HbA1c, than those who did not. HbA1c with desirable values between 5% – 7% 
(31 – 53 mmole/L) were observed more among the patients who did exercise regularly 
(35.3% of T1D, 46.5% of T2T and 45.5% of T2I) compared with (27.6% of T1D, 31.3% of 
T2T and 37.5% of T2I) who did not. Moreover, patients from all the groups who did not 
exercise were most likely to have a high HbA1c over 8% (37.9% of T1D, 25.1% of T2T 
and 37.5% of T2I) in comparison with those who did it in a regular basis (23.4% of T1D, 
18.6% of T2T and 26.9% of T2I).  
Patients with T2T and T2I were observed to exercise less (73%) compared with T1D 
group (80.5%). 
When physical exercise is considered, its type, duration, intensity, and target must be 
evaluated to be able to obtain the best benefits with the lowest rates of 
hypoglycaemia. Nevertheless it must be kept in mind that subjects with T1D or T2I and 
T2T have different requirements, which should be evaluated when exercise is 
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suggested as a part of diabetes management. BG testing self-monitoring should always 
be recommended, especially in patients exercising and using insulin. 
BG testing frequency has been investigated. A large minority (almost 20%) of T2I users 
tested only once a day. They would have to estimate their calorie intake on several 
occasions daily, but their BG management is not likely to be as good as it should be. 
This is reflected in their HbA1c values and suggests that even if they know their target 
HbA1c, they are either choosing to ignore or are not being supported adequate in 






Chapter 5: Effects of combined resistance and aerobic exercise 
on metabolic and glycaemic control in T1D and T2D  
5.1  Introduction 
Diabetes Mellitus is associated with a high risk of CVD, CHD and other heart disease 
mortality (Chen, Pei et al. 2015, Li, Xiao et al. 2014, Jaiswal, Schinske et al. 2014). It has 
been known for decades that exercise and physical activity are one of the main 
cornerstones along with medication and diet to treat and manage diabetes and high 
lipid profiles (Yavari, Najafipoor et al. 2012, Sigal, Kenny et al. 2006). Dietary 
intervention, and changes in sedentary lifestyle by increasing physical activity 
contribute to the prevention and management of T2D and lead to significant benefit in 
risk factors that are known to be associated with development of CVD in patients with 
T2D such as HbA1c, BMI, SBP, DBP and lipid profile (Chen, Pei et al. 2015, Li, Xiao et al. 
2014).  
In addition, in young people with T1D, CVD in later life is considered to be a major risk 
and is linked with mortality (McVeigh, Gibson et al. 2013). Presence of lipid disorders 
can be found in both T1D and T2D and it is associated with the development of T2D 
(Billimek, Malik et al. 2015, Jaiswal, Schinske et al. 2014, Verges 2009, Hjerrild, Gravholt 
2006). Therefore, it is crucial to investigate lipid abnormalities and to control lipids 
profile in people with T1D and T2D to reduce the risk of CVD and other diabetes 
complications such as hyperglycaemia, micro- and macrovascular complications 
(Jaiswal, Schinske et al. 2014, Maahs, Ogden et al. 2010). An improvement in glycaemia 
is suggested as an initial treatment for dyslipidaemia when caring for patients with T1D 
and T2D. Nevertheless, lipid-lowering medicine can also be administered if lipid goals 
are not achieved (Jaiswal, Schinske et al. 2014, Brunzell, Davidson et al. 2008, Buse, 
Ginsberg et al. 2007).  
T1D patients who have reduced or sub-optimal glycaemic control will eventually 
present with heightened LDL levels in comparison to ND people and T1D patients with 
optimum glycaemic control (Guy, Ogden et al. 2009). Elevated HbA1c level has been 
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considered as a risk factor for CHD and CVD in patients with diabetes (Haring, 
Baumeister et al. 2014, Selvin, Coresh et al. 2005, Selvin, Marinopoulos et al. 2004). 
Furthermore, it is also has been observed that there is a direct correlation between 
raised HbA1c concentration and the severity of CAD  and CVD in people with diabetes 
(Hong, Li et al. 2014, Jaiswal, Schinske et al. 2014). 
HBA1c is often linked with alterations in lipids in adults who have T1D but not taking 
dyslipidaemia medications (Maahs, Ogden et al. 2010). It is reported that most patients 
with T1D and T2D could have dyslipidaemia at varying degrees, characterised by 
increased levels of TG, LDL and decreased HDL. Significantly higher rates of 
hypercholesterolemia and hyperlipidaemia have been observed in T2D with CVD 
compared to their counterparts who do not have CVD (Giansanti, Rabini et al. 1999), 
which may elevate the mortality rate of these patients (Sultan, Thuan et al. 2006).  
It is a well-established fact that the long-term benefits of frequent aerobic physical 
activity for the general population can be applied to T1D patients and T2D (De Feo, Di 
Loreto et al. 2006). Exercise is linked with a heightened risk of hypoglycaemia during or 
after exercise because the increase of glucose uptake into the skeletal muscle during 
moderate exercise. In addition, exercise might lead to hyperglycaemic events if it is has 
been performed at high intensity exercise (anaerobic exercise) and this is due the 
hepatic glucose production which may reach 15 mg/kg body mass/min, an amount that 
exceeds muscular glucose disposal (Kapitza, Hovelmann et al. 2010, Riddell, Perkins 
2009).  
It has been suggested that the roles of intensive insulin as a treatment of T1D is not 
only to improve HbA1c and the prevention of premature cardiovascular events 
(Nathan, Cleary et al. 2005) but are also linked with lipid profile (Feitosa, A.,Feitosa-
Filho,G.S., Freitas et al. 2013). An absolute decrease of 1% in HbA1c levels has been 
associated with a 15% to 20% decrease in major CVD events and a 37% decrease in 
microvascular complications (Selvin, Marinopoulos et al. 2004, Stratton, Adler et al. 
2000). Thus, a significant reduction of 0.3 to 0.5% HbA1c levels achieved by 
combination exercise programme (AE + RE) might be expected to produce a 5% to 7% 
reduction in CVD risk and a 12% reduction in risk of microvascular complications 
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(Church 2011). The improvements of glycaemic control without weight gain has been 
associated with lipids control and this include TG, TC and LDL (Purnell, Hokanson et al. 
1998). AE, RE or combined exercise programme is recommended in the management 
of T1D and T2D, and has physiological benefits including improved physical work 
capacity, body composition, blood pressure, blood lipid profile (Chen, Pei et al. 2015) 
and HbA1c. It is associated with less risk of diabetes complications and mortality in 
individuals with diabetes (Hordern, Dunstan et al. 2012).  
5.2  Study aims 
The purpose of this study was to examine the effects of six weeks of combination 
exercise (RE and AE), twice a week, on lipid profile, metabolic and glycaemic control in 
T1D and T2D. The ethical approval for this study was obtained from De Montfort 
University (DMU) Ethics Committee, Faculty of Health and Life Science, Leicester, UK. 
5.3  Volunteers 
Four groups of volunteers (n = 25) were involved in this study: ND = 7, T1D = 7, T2T = 7 
and T2I = 4. The volunteers were 18-55 years old and not physically active or engaged 
in any regular exercise or formal training programmes, more details can be found on 
section 2.4. Volunteers were recruited and screened as detailed in Section 2.4.2 and 
2.5.1. 
5.4  Inclusion and exclusion criteria 
The volunteers who participated in the exercise programme had met specific inclusion 
criteria as they were defined in section 2.4.2. Further information detailing recruitment 
response and excluded volunteers can be found in Sections 2.4 and 2.4.2. 
5.5  Materials and methods  
A brief description of the methods is provided below. Please refer to the methods in 





5.5.1 Experimental design 
After the preliminary tests and familiarisation sessions (Refer to Section 2.5), 
volunteers participated in the main exercise trial which was a combined exercise 
session involving stretches, warm up on the bike for 10 min followed by 35 min of RE at 
50-60% of 1RM (determined in Section 2.5.1.2). After RE they had 5 min of rest 
followed by 20 min of AE (cycling) at 50-60% of HRR (Section 2.5.1.3) and finally 10 min 
cooling down involves stretches (Figure 19). The chronic exercise programme involved 
2 sessions (48 hours apart) for a total of 150 min each week for a 6-week period. 
Detailed description for the main exercise trial can be found in (Section 2.5.2). 
 
 
Figure 19: Schematic representation of the exercise session. 
 
5.5.2 Anthropometric assessment  
Measurements of body mass, height, BMI, %BF, % BW, waist and hip circumference 
were made as described in Section 2.3.19. Weight, %BF, %BW and BMI data were 
measured at three time points: before the exercise programme at the first session, 
after session 6 and at the end after session 12. Waist and hip measurements were 
101 
 
taken at two time points, before exercise at the first session and at the end after 
session 12. 
5.5.3 Lipids, blood gases and electrolytes measurements  
Lipids (HDL, LDL, TC, TG) were measured as previously described in Section 2.3.14 , 
blood gases (PCO2, PO2), electrolytes (Na
+, K+, Ca2+, Cl− ) were analysed as outlined in 
Section 2.3.17. These variables were measured three time points: before the exercise 
programme at the first session, after session 6 and at the end after session 12. 
5.5.4 HbA1c, BG, BP, HR and RPE 
HbA1c and BG levels were measured as previously described in Sections 2.3.11 and 
2.3.12, respectively. BG was measured 4 times in each exercise session: at rest before 
exercise, after RE exercise, after 10 min of AE and at the end of each session. HbA1c 
level was measured at session 1 and after session 12. BP (DBP and SBP) was measured 
(Section 2.3.13) and it was taken at different time points during exercise trials as 
outlined in Section 2.5.2. HR values were monitored (Section 2.3.8) at rest and 
continuously during the combined exercise trial as explained earlier in Section 2.5.2. 
RPE were obtained from the subjects using the Borg scale (Section 2.3.9) during RE and 
AE exercise as described in Section 2.5.2. RER values were calculated during the 20 min 
of AE using ADI system as described in Section 2.5.2.  
5.5.5 Blood collection, C-peptide and insulin analysis 
Venous blood samples were collected from the volunteers in EDTA tubes as described 
in (Section 2.3.15). It was of interest to investigate the effects of acute and chronic 
exercise on Insulin and C-peptide. Three blood samples were collected from the 
volunteer at the time points shown in (Figure 20). For the chronic effect, seven blood 
samples were collected as shown in (Figure 21). Insulin and C-peptide were determined 
using ELISA technique, full description of ELISA procedure and equipment can be found 







Figure 20: Venous blood samples from the first exercise session (acute effect). 
 
 





5.6  Results and discussion   
5.6.1 Volunteers characteristics, anthropometrics and clinical variables:  
Volunteers’ characteristics and some clinical variables are presented in Table 15 for ND, 
Table 16 for T1D, Table 17 for T2T and Table 18 for T2I. It should be noted that the 
comparison in this section is (1st Pre-Ex vs 12th Post-Ex), ie: between the first session 
before exercise and at the end after the last session of the six weeks exercise trial 
because this demonstrate the change in these parameters as result of the exercise 
intervention.  
Tables 15 - 18 demonstrate HR at rest values were significantly improved in all the 
study groups: ND from 72.3 ± 9.8 to 68.7 ± 9.0 (p < 0.01), T1D from 74.6 ± 7.4 to 70.7 ± 
6.8 (p < 0.01), T2T from 77.4 ± 7.8 to 73.0 ± 6.8 (p < 0.01), T2I 69.7 ± 6.8 to 66.0 ± 6.1 (p 
< 0.05). SBP at rest readings were significantly decreased in ND from 130 ± 7.1 to 125 ± 
5.8 (p < 0.05), T2T from 130 ± 11 to 121 ± 3.9 (p < 0.05) and in T2I from 126 ± 1.6 to 
121 ± 2.1 (p < 0.05), and was improved in T1D (p = 0.16). DBP at rest readings were 
slightly decreased in all the study groups ND (p = 94), T1D (p = 0.9), T2T (p = 0.12) and 
T2I (p = 0.16). 
Table 15 shows that ND volunteers at baseline were overweight with BMI = 26.2±3.3. 
Despite that ND weight and BMI did not change (1st Pre-Ex vs 12th Post-Ex), their BF% 
was reduced from 23.0 ± 7.3 to 21.5 ± 7.3, (p = 0.07) and their hip and waist were 
reduced, (p = 0.06, p = 0.17, respectively). As can be seen from tables 16, 17 and 18, 
T1D, T2T and T2I had smaller reductions in their weight and BMI. However, BF% in T2T 
was reduced significantly from 37.1 ± 8.6 to 34.8 ± 8.2 (p < 0.01), compared with a 
slight decrease in T1D (p = 0.1) and close to the level of significance in T2I from 28.1 ± 
4.6 to 25.3 ± 3.2 (p = 0.07). As can be seen from tables 16 -18, T1D, T2T and T2I tested 
their BG levels significantly more times after the whole exercise trial compared to 
before. This is beneficial and important for diabetes patients. It indicates that their 
knowledge and understanding gained from the exercise trial provoked them to increase 
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the frequency of BG testing, which shows that they manage their diabetes more 
intensively than previously. 
BW% was increased, but not at a significant level in ND (p = 0.39), T1D (p = 0.72), T2I (p 
0.53) and was significantly increased in T2T from 42.7 ± 5.4 to 45.5 ± 4.9 (p < 0.01). Hip 
and waist measurements were slightly decreased in T1D, T2I and were significantly 
decreased in T2T, hip at (p < 0.05) and waist at (p < 0.01). All the study groups were 
overweight with BMI values: T1D = 29.3±6.9, T2T = 29.2±3.5 and T2I = 29.2±1.5 and 
BMI was not significantly improved in all study groups.  
The above results from the present study can be supported by many previous studies 
such as a randomised trial by Sigal et al. 2007, which compared the effects of RE, AE or 
both in combination for 22 weeks on the glycaemic control in patients with T2T. They 
found that, none of the three different exercise regimens produced a significant change 
in BMI and body weight. BF% was improved from 36 ± 9.6 to 35 ± 9.6, and waist 
circumference was reduced from 112 ± 24 cm to 108 ± 24 (44 to 42 inch) as well as an 
improvement in SBP and no change in DBP with combined exercise group (Sigal, Kenny 
et al. 2007). There are some agreement between the results from the current study 
and those described by Sigal (2007).  
In addition, exercise interventions investigated by Yavari et al 2012 and his colleagues 
who had compared between AE and RE alone or the combination of AE and RE three 
times per week for 52 weeks in patients with T2D (Yavari, Najafipoor et al. 2012). They 
found that combined exercise programme had positive impact after the exercise 
intervention on the HR and reduce significantly BMI, BF%, visceral fat%, muscular 
percentage%, SBP and DBP (Yavari, Najafipoor et al. 2012). The effect of combined 
training programme AE and RE has been investigated for 8 weeks in T2T, showed that 
BF%, Hip:Waist ratio at rest was reduced significantly (p < 0.05) after the training 
programme (Maiorana, O'Driscoll et al. 2002). Moreover, a research conducted the 
effect of combined RE and AE intervention for 16 weeks on glycaemic control in T2D, 
demonstrated that body weight and BMI did not change after 4 weeks and 16 weeks of 
the combined programme (Tokmakidis, Zois et al. 2004). 
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Fenicchia et al (2004) reported that participating in 3 days per week for six weeks of RE 
did improve BMI, weight and fat mass in patients with T2D. A meta-analysis study by 
Harris et al (2009) concluded that BMI was not improved after 6 months of physical 
activity in ND primarily elementary school children; although they had other beneficial 
health effects (Harris, Kuramoto et al. 2009) and this shows that if there is no change in 
BMI does not mean that overall health has not improved. Other research on T1D 
supported the current study results and showed that BMI did not change after 3 times 
per week for 12 weeks of RE (8 – 12 repetition of 9 RE) or AE (40 min walk or run). 
However, there was a reduction in waist circumference (Ramalho, de Lourdes Lima et 
al. 2006).  
In contrast, ND overweight or obese volunteers who have done combined AE and RE at 
moderate intensity for 30 min, 5days/week for 12 weeks was reported to produce a 
significant improvement of BMI and body weight, compared to AE or RE alone which 
had no significant effects on BMI, weight, BF% and fat mass (Ho, Dhaliwal et al. 2012). 
Moreover, in this study BF%, waist, fat mass were significantly reduced with the 
combined model and some of these findings seem to be in agreement with the current 
study findings in ND group (Table 15). It was concluded that the combination of the RE 
and AE exercise was one of the optimal exercise strategy to reduce body weight, BMI, 
BF% and waist circumstances (Davidson, Hudson et al. 2009).  
Other researchers have investigated the effects of 8 weeks of a combined RE and AE 
programme in T2T supported the findings from this research study and they reported 
that, BMI and body weight did not change. However, BF%, resting HR and waist/hip %, 
had reduced significantly (p ˂ 0.05) after the combined training programme (Maiorana, 
O'Driscoll et al. 2002). 
Furthermore, a moderate to high intensity AE (60 min/day, 2 to 3 times/week) for 16 
weeks was observed to reduce BMI significantly in a ND moderate dyslipidemic 
volunteers (Yoshida, Ishikawa et al. 2010). A randomised controlled trial by Church et 
al. (2010) for 9 months of combination exercise showed a significant decrease in BMI 
compared to RE or AE alone in patients with T2D (Church, Blair et al. 2010). These 
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studies highlight that different exercise trials may produce conflicting result for the 
present study, however the general trend appear to be similar.  
5.6.2 Blood gases and electrolytes  
As can be seen from Tables 15 - 18, PCO2 and PO2 levels were in the normal ranges in 
ND and T2I and were slightly changed, but about normal in T1D and T2T and there was 
no severe reduction in PO2. Electrolytes (Na
+, K+, Ca2+, Cl− ), pH and lactate were always 
in or just about the normal ranges with no drastic changes. This indicates that all the 
volunteers who participated in the exercise trial showed basic signs of good health 
during the 12 sessions. So for example, there were no sodium, potassium, calcium or 
pH profiles that suggested cardiac, respiratory or renal problems. In addition to this, 
no-one suffered angina or any distress and although one or two experienced some 
hypoglycaemia, this was mild, quickly detected and corrected. The blood pressure 
readings and heart rates that were recorded within the exercise periods showed no 
sharp changes. This set of observations suggested that exercise trials exclusion criteria 




Table 15: Characteristics, changes in anthropometric, clinical and physiological variables for 
ND volunteers at the first session (1st Pre-Ex), after the sixth session (6th Post-Ex) and the 
end (12th Post-Ex). Data are presented as Mean ± SD. (*) P < 0.05, (**) P < 0.01 for (1st Pre-
Ex vs 12th Post-Ex) 
 
  1st Pre-Ex 6th  Post-Ex 12th Post-Ex P value 
Anthropometric and clinical variables 
Age (year)  31 ± 5.3 
- - - 
Height (cm) 175 ± 4.6 
- - - 
Weight (kg) 80.16 ± 9.9 80.46 ± 10 80.27 ± 10 0.86 
BMI (Kg/m2 ) 26.2 ± 3.3 26.2 ± 3.4 26.2 ± 3.3  1.0 
SBP (mmHg) 130 ± 7.1 125 ± 6.9 125 ± 5.8* ˂ 0.05 
DBP (mmHg) 79 ± 7.5 75 ± 8.2 78 ± 8.2 0.64 
Body Fat (%) 23.0 ± 7.3 22.3 ± 7.4 21.5 ± 7.3  0.07 
Body Water (%) 55.0 ± 9.4 54.6 ± 8.2 56.4 ± 8.2  0.39 
Resting HR (bpm) 72.3 ± 9.8 - 68.7 ± 9.0**  ˂0.01 
Hip (inch) 38.4 ± 5.0 - 37.8 ± 4.7  0.06 
Waist (inch) 36.0 ± 3.9 - 34.7 ± 3.1  0.17 
Hip/Waist Ratio 0.95 ± 0.1 - 0.92 ± 0.1  0.44 
Blood gases and Electrolytes  
PCO2 (mmHg)  33.7 ± 5.4 34.9 ± 4.7 34.3 ± 5.6  0.75 
PO2 (mmHg) 103.3 ± 8.9 105.1 ± 11.5 100.9 ± 13.4  0.67 
K+ (mmol/L) 4.5 ± 0.5 4.5 ± 0.3 4.2 ± 0.4  0.36 
Na+ (mmol/L) 128.0 ± 6.3 125.1 ± 10.4 126.6 ± 10.2  0.75 
Ca2+ (mmol/L) 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.2  0.18 
Cl− (mmol/L) 101.7 ± 3.8 100.4 ± 6.1 100.4± 4.4  0.39 
Lactate (mmol/L)  1.6 ± 0.6 1.6 ± 0.6 1.5 ± 0.6  0.28 




Table 16: Characteristics, changes in anthropometric, clinical and physiological variables for 
T1D volunteers at the first session (1st Pre-Ex), after the sixth session (6th Post-Ex) and the 
end (12th Post-Ex). Data are presented as Mean ± SD. (*) P < 0.05, (**) P < 0.01 for (1st Pre-
Ex vs 12th Post-Ex). 
 
  1st Pre-Ex 6th  Post-Ex 12th Post-Ex P value 
Anthropometric and clinical variables 
Age (year)  31 ± 12 
- - - 
Height (cm) 178.8 ± 6 
- - - 
Weight (kg) 91.3 ± 18.9 91.1 ± 19 90.6 ± 18.8 0.15 
BMI (Kg/m2 ) 29.3 ± 6.9 29.3 ± 6.9 29.1 ± 6.9  0.2 
BG tests (per day) 4.6 ± 0.3 
- 
5.4 ± 0.3** 
 ˂0.01 
SBP (mmHg) 129 ± 11 127 ± 11 124 ± 9.4  0.16 
DBP (mmHg)  82 ± 8.3 78 ± 6.5 81 ± 4.1  0.81 
Body Fat (%) 31.3 ± 10.9 30.8 ± 11.2 29.5 ± 11.0  0.1 
Body Water (%) 49.5 ± 11.3 48.4 ± 9.9 50.2 ± 9.8  0.72 
Resting HR (bpm) 74.6 ± 7.4 - 70.7 ± 6.8**  ˂0.01 
Hip (inch) 40.2 ± 2.7 - 39.0 ± 3.8  0.24 
Waist (inch) 38.1 ± 7.7 - 37.8 ± 7.7  0.11 
Hip/Waist Ratio 0.94 ± 0.1 - 0.96 ± 0.1  0.34 
Blood gases and Electrolytes  
PCO2 (mmHg)  32.3 ± 8.7 31.1 ± 6.7 31.8 ± 4.6  0.87 
PO2 (mmHg) 116.1 ± 24.1 110.2 ± 25.6 111.1 ± 23.7  0.07 
K+ (mmol/L) 4.8 ± 0.4 4.6 ± 0.4 4.6 ± 0.2  0.29 
Na+ (mmol/L) 131.1 ± 12.6 121.7 ± 10.0 124.4 ± 10.2*   ˂0.05 
Ca2+ (mmol/L) 0.8 ± 0.3 0.8 ± 0.3 0.8 ± 0.3  0.31 
Cl− (mmol/L) 106.9 ± 9.6 104.9 ± 7.6 104.9 ± 7.8  0.19 
Lactate (mmol/L)  1.1 ± 0.6 0.9 ± 0.6 1.0 ± 0.5  0.49 




Table 17: Characteristics, changes in anthropometric, clinical and physiological variables for 
T2T volunteers at the first session (1st Pre-Ex), after the sixth session (6th Post-Ex) and at the 
end (12th Post-Ex). Data are presented as Mean ± SD. (*) P < 0.05, (**) P < 0.01 for (1st Pre-
Ex vs 12th Post-Ex). 
 
  1st Pre-Ex 6th  Post-Ex 12th Post-Ex P value 
Anthropometric and clinical variables 
Age (year)  44 ± 8.3 
- - - 
Height (cm) 174.4 ±  11.7 
- - - 
Weight (kg) 89.9 ± 21.3 89.4 ± 20.7 89.4 ± 21.1 0.39 
BMI (Kg/m2 ) 29.2 ± 3.5 29.1 ± 3.4 29.1 ± 3.5 0.60 
BG tests (per day) 2.6 ± 1.0 
- 
3.4 ± 1.0**  ˂0.01 
SBP (mmHg) 130 ± 11 125 ± 10 121 ± 3.9  ˂0.05 
DBP (mmHg)  80 ± 5 72 ± 7.2 76 ± 6.7 0.11 
Body Fat (%) 37.1 ± 8.6 35.5 ± 8.7 34.8 ± 8.2**   ˂0.01 
Body Water (%) 42.7 ± 5.4 45.1 ± 3.7 45.5 ± 4.9**   ˂0.01 
Resting HR (bpm) 77.4 ± 7.8 - 73.0 ± 6.8**   ˂0.01 
Hip (inch) 41.4 ± 3.3 - 40.9 ± 3.1*   ˂0.05 
Waist (inch) 41.5 ± 3.3 - 40.4 ± 3.1**   ˂0.01 
Hip/Waist Ratio 1.0 ± 0.1 - 0.99 ± 0.1  0.06 
Blood gases and Electrolytes  
PCO2 (mmHg)  33.8 ± 6.3 32.4 ± 7.1 29.5 ± 8.5  0.9 
PO2 (mmHg) 111.7 ± 20.9 113.5 ± 22.3 123.8 ± 20.0  0.07 
K+ (mmol/L) 4.2 ± 0.6 4.7 ± 0.5 4.6 ± 0.5  0.07 
Na+ (mmol/L) 125.7 ± 1.3 123.0 ± 2.4 128.7 ± 2.6  0.05 
Ca2+ (mmol/L) 0.9 ± 0.2 1.0 ± 0.2 1.0 ± 0.1  0.26 
Cl− (mmol/L) 99.6 ± 5.2 105.6 ± 7.2 103.0 ± 4.0  0.14 
Lactate (mmol/L)  1.6 ± 0.8 1.5 ± 0.8 1.5 ± 0.7  0.5 
pH Value 7.42 ± 0.02 7.46 ± 0.07 7.47 ± 0.04  0.07 
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Table 18: Characteristics, changes in anthropometric, clinical and physiological variables for 
T2I volunteers at the first session (1st Pre-Ex), after the sixth session (6th Post-Ex) and at the 
end (12th Post-Ex). Data are presented as Mean ± SD. (*) P < 0.05, (**) P < 0.01 for (1st Pre-
Ex vs 12th Post-Ex). 
 
  1st Pre-Ex 6th  Post-Ex 12th Post-Ex P value 
Anthropometric and clinical variables 
Age (year)  45 ± 4.5 
- - - 
Height (cm) 175 ± 7.6 
- - - 
Weight (kg) 88.8 ± 4.8 88.4 ± 5.1 88.7 ± 5.0  0.8 
BMI (Kg/m2 ) 29.2 ± 1.5 29.0 ± 1.3 29.1 ± 1.7  0.4 
BG tests (per day) 3.8 ±  0.5 
- 4.5 ± 1.0* 
˂0.05 
SBP (mmHg) 126 ± 1.6 119 ± 6.1 121 ± 2.1* ˂0.05 
DBP (mmHg) 80 ± 5 72 ± 7.2 76 ± 6.7  0.16 
Body Fat (%) 28.1 ± 4.6 26.3 ± 4.2 25.3 ± 3.2  0.07 
Body Water (%) 48.9 ± 3.1 48.8 ± 3.0 49.7 ± 3.1  0.53 
Resting HR (bpm) 69.7 ± 6.8 - 66.0 ± 6.1*  ˂0.05 
Hip (inch) 40.0 ± 3.0 - 39.8 ± 3.3  0.42 
Waist (inch) 37.8 ± 2.1 - 37.3 ± 2.1  0.25 
Hip/Waist Ratio 0.95 ± 0.04 - 0.94 ± 0.03  0.06 
Blood gases and Electrolytes  
PCO2 (mmHg)  39.1 ± 3.8 39.9 ± 2.7 33.5 ± 3.4  0.28 
PO2 (mmHg) 103.3 ± 4.8 94.8 ± 7.0 109.3 ± 22.3  0.74 
K+ (mmol/L) 4.4 ± 0.7 4.3 ± 0.6 4.3 ± 0.3  0.76 
Na+ (mmol/L) 134.7 ± 2.1 131.3 ± 1.2 132.0 ± 2.6  0.09 
Ca2+ (mmol/L) 0.8 ± 0.3 0.8 ± 0.2 0.7 ± 0.2  0.79 
Cl− (mmol/L) 109.0 ± 5.3 105.0 ± 4.4 102.0 ± 8.2  0.39 
Lactate (mmol/L)  1.7 ± 0.4 1.4 ±0.6 1.6 ± 0.5  0.13 
pH value 7.39 ± 0.01 7.41 ± 0.02 7.42 ± 0.11  0.75 
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5.6.3 Changes in RER, 1RM and RPE across whole trial 
Figure 22 shows Mean RER values during the 20 min of AE across the whole exercise 
trial (12 sessions) for all the 4 study groups. RER is the ratio of the volume of carbon 
dioxide released to the volume of oxygen taken up into the lungs at the same time. RER 
normal ranges are between 0.7 and 1.2 and this factor is used as an indicator of 
substrate oxidation, where 1.0 indicates total carbohydrate oxidation, while 0.7 refers 
to total fat oxidation and 0.85 suggests a mix of fat and carbohydrates (Simonson DC 
1990, Ferrannini 1988). Data from Figure 22 shows that RER readings for all the groups 
were steady and most of the values were between 0.85 and 1.2 indicating that 
carbohydrates are being predominantly oxidised during the 20 min of AE in all the 
groups. These results correlate with and support the findings from the BG responses to 
AE exercise across the whole trial (12 sessions). BG levels fell during the AE which was 
evident by RER which shows CHO been oxidised as the predominate substrate.  
Figure 23 illustrates percentages (after the six weeks exercise trial vs before) of the 
1RM strength improvement for the five different RE exercises working upper and lower 
muscle group (Chest, Squat, Back, Biceps and Triceps) in all the study groups (ND, T1D, 
T2T and T2I). As can be seen from Table 19 and Figure 23, all the volunteers showed 
significant strength increases ranging from 16% to 75% in all exercises with p values of 
(˂0.01) or (˂0.05). T2T and T2I had a higher percentage of improvement than T1D and 
ND. As shown in Table 19, strength capability of all the volunteers has significantly 
improved and there was a strength gain in both upper and lower body muscle groups. 
This might be due increase in their lean body mass which lead to an improvement in 
the insulin sensitivity and fat oxidation (Lee, Boyko et al. 2011, Van Der Heijden, Wang 
et al. 2010). Some of these findings in line with results of past study examined the 
effects of RE on glucose control in patients with T2T by Fenicchia et al (2004) who 
reported that both T2T and ND volunteers had a significant percentage of 
improvement in their 1RM after six weeks of RE ranging from 19% to 57% in all RE 
exercises (p ˂0.01) and improvement in integrated glucose concentration after single 
bout of RE (Fenicchia, Kanaley et al. 2004). 
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Furthermore, another study investigated a combined training programme for 8 weeks 
in T2T which supported the current study about the improvement in the muscle 
strength. It has shown that muscle strength in upper and lower muscle groups has 
improved significantly (p < 0.001) after the training programme (Maiorana, O'Driscoll et 
al. 2002). Moreover, other researchers have conducted a combined AE and RE for 16 
weeks in T2T, and they reported results are consistent with this study. They found that 
muscular strength bench press, seated row, leg extension, pull-down, and leg curl was 
significantly improved after 4 weeks (˂0.01) as well as after 16 weeks (˂0.001) of 
exercise (Tokmakidis, Zois et al. 2004). 
In addition, a study has investigated the effects of RE or AE + RE on the muscular 
strength in T2D and they found that both groups had significant improvements in the 
lower and upper muscles at 3 and 6 months (Larose, Sigal et al. 2012). Furthermore, 
results from other study have been conducted on overweight/ obese ND volunteers 
who participated in 16 weeks of RE are in line with findings from the present study. 
This study showed that there were statistically significant improvement (p ˂ 0.05) in 
muscular strength of chest press and front lat pull-down (Tibana, Navalta et al. 2013). 
In addition, It was reported that the combination of the RE and AE exercise was one of 
the optimal exercise strategy to improve muscular strength for the lower and upper 






Figure 22: Mean RER values during the 20 of AE across the whole exercise trial (12 sessions) 
for all the study groups. 
 
 
Table 19: Percentages of 1RM improvement Post-Ex trial vs Pre-Ex trial for all the study 
groups (ND, T1D, T2T and T2I). 
 
% Change ND P. value T1D P. value T2T P. value T2I P. value 
SQUAT 36% ˂0.01 41% ˂0.01 75% ˂0.01 47% ˂0.05 
CHEST 19% ˂0.01 27% ˂0.01 27% ˂0.01 26% ˂0.05 
BACK 21% ˂0.01 17% ˂0.01 33% ˂0.05 21% ˂0.05 
TRICEP 17% ˂0.01 20% ˂0.01 48% ˂0.05 37% ˂0.05 





























Figure 24: RPE Post-1st set of RE across whole trial (12 sessions) for all the study groups (ND, 










































RPE is valid method for exercise prescription and determination intensity of exercise 
(Iellamo, Manzi et al. 2014, Scherr, Wolfarth et al. 2013). RPE was recorded 5 times in 
each exercise session; after 1st, 2nd and 3rd sets of RE and recorded twice after 10 and 
20 minutes of AE. RPE value over the 12 week exercise trial period in all the study 
groups reveals that there has been downward slope in RPE value which would indicate 
that over time across the whole exercise trial (12 sessions) the volunteers perceived 
exertion to RE became lower and showed an improvement in the final session when 
compared to the first session in the four study groups (ND, T1D, T2T and T2I). This 
suggests that they found RE become easier and their performance and strength had 
improved which is in agreement with significant improvement in all the volunteers 
strength as can be seen from 1RM results Post-Ex trial vs Pre-Ex trial in Table 19 and 
Figure 24 – 26. This is consistent with previous study reported that participating in 3 
days per week for six weeks of RE in T2T improved strength of upper and lower muscle 
groups (Fenicchia, Kanaley et al. 2004).  
Figures 24 - 28 indicate that all the volunteers performed the exercise (RE and AE) at 
the target intensity (moderate intensity) and these figures show that mean RPE values 
across the 12 sessions of the exercise trial were between (10.9 and 14.5). In addition, 
mean RPE values between the 1st and the 3rd set of RE became progressively higher and 
there has been gradual increase in 2nd and 3rd set for all the study groups. As would be 
expected this increase occurs because the volunteer would have exerted energy in the 
first two sets making the third more difficult. RPE plotted in Figure 27 and 28 clearly 
show that there has been a steady decline in mean RPE values at 10 and 20 min of AE 
throughout the whole exercise trial (12 sessions) and they found it become more easier 












Figure 25: RPE Post-2nd set of RE across whole trial (12 sessions) for all the study groups (ND, 





Figure 26: RPE Post-3rd set of RE across whole trial (12 sessions) for all the study groups (ND, 






































Figure 27: RPE at 10 min of AE across whole trial (12 sessions) for all the study groups (ND, 




Figure 28: RPE at 20 min of AE across whole trial (12 sessions) for all the study groups (ND, 



































5.6.4 Changes in cardiovascular fitness parameters across whole exercise 
trial 
Table 20 and 21 compares SBP and DBP, respectively across whole exercise trial (12 
sessions) between all the study groups (ND, T1D, T2T and T2I). Table 20, 21 and 
(Figures 29 – 34) show that there has been a general gradual decrease for SBP and DBP 
across the exercise trial in all the study groups. All the study groups had same BP 
reaction to the 1st , 2nd and 3rd set of RE across whole 12 sessions. Figure 30 shows that 
SBP readings Post RE were declined significantly (p < 0.05) in ND, but were more 
resistant in diabetic volunteers especially T2I where it was not responsive. Figure 31 
demonstrate that SBP Post AE decreased moderately in all the groups, except T2I 
where it was not responsive. As can be seen from Table 20 , SBP at rest readings were 
significantly decreased in 12th session compared to 1st session for ND from 130 ± 7.1 to 
125 ± 5.8 (p < 0.05). Similarly, for T2T from 130 ± 11 to 121 ± 3.9 (p < 0.05), T2I from 
126 ± 1.6 to 121 ± 2.1 (p < 0.05), however showed an improvement for T1D (p = 0.16). 
In addition, Table 21 shows that DBP at rest readings had a steady decrease in all the 
study groups ND (p = 64), T1D (p = 0.81), T2T (p = 0.11) and T2I (p = 0.16).  
HR at rest was measured before commencing and after finishing the 6 week exercise 
trial and a significant decrease in all the study groups was observed: ND from 72.3 ± 9.8 
to 68.7 ± 9.0 (p < 0.01), T1D from 74.6 ± 7.4 to 70.7 ± 6.8 (p < 0.01), T2T from 77.4 ± 7.8 
to 73.0 ± 6.8 (p < 0.01), T2I 69.7 ± 6.8 to 66.0 ± 6.1 (p < 0.05). Table 22 shows HR 
readings Pre-EX, Post 1st , 2nd and 3rd set of RE across whole 12 sessions for all the study 
groups (ND, T1D, T2T and T2I). It can be seen from Table 22 that HR Pre-Ex was always 
within the normal range of 68 and 83 for all groups.  
As would be expected, Figure 36 and 37 illustrates that during RE, HR became 
progressively higher and there was a gradual increase in the 2nd and 3rd set during each 
exercise session for all the study groups. This correlate with earlier data from RPE 
(Figures 24 – 26) where values of RPE multiply by ten give HR values similar those in 
(Figures 35 – 37) these findings are similar to those of Borge et al 1983. However, 
across the whole 12 sessions there has been a slight decrease in HR readings between 
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Pre-EX and the 3rd set of RE, suggesting that volunteers from all the study groups 
showed an improvement in their cardiovascular fitness level. HR results from the 
present study are in a partial agreement with (Goto, Ishii et al. 2007), who found that 
the mean value of HR during AE endurance exercise was significantly higher when it 
was preceded by RE with 20 min of rest compared to trial with only AE exercise. A 
study by Burleson et al. 1998 reported that mean values of HR and RER were 
significantly greater during RE than during treadmill AE (Burleson, O'Bryant et al. 1998). 
High BP (hypertension) is common comorbidity of diabetes, and it has been estimated 
to affect 20–60% of T1D and T2D (Arauz-Pacheco, Parrott et al. 2002). Hypertension is a 
major risk for the development of the macrovascular and microvascular complications 
in ND, T1D and T2D (North, Palmer 2015, Takao, Matsuyama et al. 2014, Frontoni, 
Solini et al. 2014, Pal, Radavelli-Bagatini et al. 2013, Arauz-Pacheco, Parrott et al. 2002). 
Additional blood pressure lowering was independently associated with reduced 
cardiovascular mortality and improved renal outcome (Lovshin, Zinman 2014, Poulter 
2009). The current study showed a significant reduction in HR and BP at rest which 
indicate an improvement of the cardiovascular fitness level and could lead to a 
decrease in risk factors of CVD and heart diseases mortality (Lovshin, Zinman 2014, 
Poulter 2009). Improvements in BP like what the present study showed, have been 
reported in previous studies after different modes of exercise such as AE (Montero, 
Roche et al. 2014, Collier, Kanaley et al. 2008), RE (Drenowatz, Sui et al. 2014, Collier, 
Kanaley et al. 2008) and a combination of AE and RE (Laoutaris, Adamopoulos et al. 
2013, Sigal, Kenny et al. 2007). 
As mentioned above, the present study showed that HR at rest was reduced 
significantly in all the study groups. SBP values were also reduced significantly in ND, 
T2T and T2I as well as showed an improvement for T1D. DBP at rest readings showed a 
steady decrease in all the study groups, however not at a significant level. Some of the 
above findings in the current study in agreement with a previous research showed that 
a combination of AE and RE exercise programme three times per week for 52 weeks in 
patients with T2D had a positive impact after the exercise programme on the HR and 
reduced significantly SBP and DBP (Yavari, Najafipoor et al. 2012).  
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Improvement was reported in SBP and no change in DBP with combined exercise group 
3 times weekly for 22 weeks in T2D (Sigal, Kenny et al. 2007). In addition, the effect of 
combined training programme AE and RE has been investigated for 8 weeks in T2T, 
showed that HR at rest was reduced significantly (p < 0.05) after the training 
programme (Maiorana, O'Driscoll et al. 2002). Moreover, another study on T2T 
investigated the effect of different modalities of exercise (AE, RE or combined both AE 
+ RE) showed that combined exercise had reduced significantly SBP and DBP, these 
results in partially agreement with the findings from the current work with regard T2T 
(Jorge, de Oliveira et al. 2011). 
A study on sedentary ND volunteers with normal BP (<140/90 mm Hg), showed that 12 
weeks of moderate AE (30 minutes, 5 days per week) had significantly decreased 
resting BP (Maeda, Tanabe et al. 2004). Moderate AE compared with baseline 
significantly reduced SBP (124±13 vs. 112±9 mm Hg; P < 0.05) and DBP (73±11 vs. 66±6 
mm Hg; P < 0.05) (Maeda, Tanabe et al. 2004). In contrast, a study with ND, sedentary 
subjects without high BP, found that 60 minutes of walking (either single bouts of 20 
minutes on 3 days per week, or accumulated bouts of two 10 minutes walks on 3 days 
per week) for 12 weeks was not sufficient to cause changes in BP post-intervention or 
compared with control (Murtagh, Boreham et al. 2005). It was concluded that the 
combination of the RE and AE exercise was the optimal exercise strategy for 











Table 20: SBP Pre-EX , Post-RE and Post-AE across whole trial (12 sessions) for all the study groups (ND, T1D, T2T and T2I). Data expressed as Mean±SEM. 
 
  

























ND Pre-EX  1303 1282 1272 1263 1252 1253 1263 1263 1253 1243 1253 1252 
  Post-RE  1404 1385 1313 1454 1314 1417 1257 1345 1289 1333 1354 1315 
  Post-AE  1296 1294 1313 1315 1277 1265 1286 1285 1275 1285 1235 1285 
T1D Pre-EX  1294 1265 1264 1275 1325 1274 1265 1245 1244 1264 1253 1244 
  Post-RE  1347 1364 1292 1377 1323 1356 1286 1346 1328 1314 1344 1324 
  Post-AE  1265 1284 1285 1244 1253 1274 1243 1263 1213 1235 1252 1233 
T2T Pre-EX  1304 1263 1314 1263 1294 1254 1285 1255 1234 1233 1234 1214 
  Post-RE  13411 1317 1387 1333 1303 1368 1316 1275 1305 1345 1346 1295 
  Post-AE  1345 1293 1265 1256 1264 1266 1274 1295 1276 1265 1225 1295 
T2I Pre-EX  1261 1276 1183 1175 1203 1192 1192 1184 1187 1212 1224 1211 
  Post-RE  1281 1263 1295 1304 1286 1303 1269 1333 1282 1262 1301 1261 
  Post-AE  1184 1213 1191 1273 1201 1194 1194 1224 1213 1223 1182 1211 
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ND Pre-EX  793 792 783 773 724 753 805 804 784 742 733 783 
  Post-RE  772 843 741 742 762 751 723 751 722 762 752 773 
  Post-AE  745 735 744 694 725 764 775 753 724 763 733 754 
T1D Pre-EX  824 803 784 803 794 782 794 802 774 813 852 812 
  Post-RE  807 824 692 732 762 752 723 753 712 732 742 742 
  Post-AE  792 833 814 763 793 833 825 812 774 813 822 774 
T2T Pre-EX  802 793 763 773 773 723 773 735 802 742 802 763 
  Post-RE  723 673 772 692 712 712 723 703 722 743 763 733 
  Post-AE  783 743 764 752 732 722 753 743 763 732 752 773 
T2I Pre-EX  761 733 785 732 784 782 752 745 794 764 730 721 
  Post-RE  792 732 762 722 772 721 721 741 713 722 726 695 





Table 22: HR Pre-EX , Post 1st , 2nd and 3rd set of RE across whole trial (12 sessions) for all the study groups (ND, T1D, T2T and T2I). Data are expressed 
as Mean±SEM. 

























ND  Pre EX  762 764 763 752 744 753 733 725 722 723 712 683 
   Post 1st set  1205 1224 1153 1216 1192 1245 1225 1284 1263 1193 1204 1233 
   Post 2nd set  1308 1279 1218 1279 1268 1288 1289 1319 1288 1267 1238 1237 
   Post 3rd set  1446 1402 1417 1447 1343 1417 1427 1404 1434 1375 1355 1426 
T1D  Pre EX  816 803 735 775 715 773 795 774 824 825 805 814 
   Post 1st set  1264 1234 1246 1266 1214 1294 1275 1213 1215 1235 1223 1195 
   Post 2nd set  1336 1324 1326 1336 1286 1354 1335 1305 1326 1316 1316 1286 
   Post 3rd set  1396 1386 1366 1387 1336 1415 1397 1345 1367 1346 1345 1326 
T2T  Pre EX  773 782 752 752 761 732 782 783 743 733 762 734 
   Post 1st set  1264 1273 1323 1282 1242 1273 1282 1253 1224 1235 1224 1193 












   Post 3rd set  1425 1444 1435 1403 1404 1374 1364 1324 1314 1326 1345 1305 
T2I  Pre EX  771 814 825 774 807 743 744 7610 834 766 766 755 
   Post 1st set  1208 1195 1250 1144 1185 1122 1184 1122 1182 1222 1134 1091 
   Post 2nd set  1325 1314 1283 1253 1245 1235 1303 1174 1243 1235 1203 1184 










































































































































Figure 35: HR Post-1st set of RE across whole trial (12 sessions) for all the study groups (ND, 
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Figure 36: HR Post-2nd set of RE across whole trial (12 sessions) for all the study groups (ND, 




Figure 37: HR Post-3rd set of RE across whole trial (12 sessions) for all the study groups (ND, 
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5.6.5 Metabolic responses to exercise 
5.6.5.1  Glucose control and HbA1c 
BG levels during every single exercise session (Pre-Ex, Post-RE and Post-AE) and over 
the whole exercise trial (12 sessions) have been demonstrated in Figure 39 for ND, 
Figure 40 for T1D, Figure 41 for T2T and Figure 42 for T2I. Figure 39 shows that all ND 
volunteers were on the normoglycaemic range (4 – 8 mmol/L), for every session 
throughout the exercise trial (12 sessions).  
There was a slight increase in BG level after RE and this may be due to hepatic 
production of BG during RE exercise which is fuelled mainly by creatine phosphate (CP), 
adenosine triphosphate ATP and glycogen, due to a reliance on anaerobic glycolysis. 
However, it can be seen that after AE at the end of each exercise session BG levels 
tended to decrease because during moderate to high intensity exercise the source of 
energy is a mixture of both carbohydrate and fat.  
Figure 40 demonstrated that T1D volunteers in every session started in the 
hyperglycaemic range (8.5 – 10.5 mmol/L) which would indicate poor BG control. 
Therefore, after the (RE + AE) exercise session most of their BG values had returned to 
within the normoglycaemic range. These volunteers had deviated from the normal 
range prior the exercise session using their current insulin regimen. The benefits of 
exercise showed better glucose management, however T1D have to deal with diabetes 
on a daily basis, therefore, it is not surprising they would intensively managed their BG, 
but their insulin regimen was not ideal.  
Figure 42 shows that T2I exhibited hyperglycaemic BG (10.5 – 13.5 mmol/L) Pre Ex in 
almost every session which was higher than T1D. Some of these volunteers must have 
been exhibiting DKA symptoms on arrival prior to exercise sessions. This group of 
volunteers have more difficulties with BG management and with their current insulin 
regimen than T1D. This is not surprising as T2D who inject insulin are usually the most 
insulin resistant (Lovre, Fonseca 2015). After each exercise session BG value fell in a 
similar way to the other groups. In most session BG value returned to the 
normoglycaemic range, highlighting the benefits of the current combined exercise trial. 
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Figure 41 shows that T2T were above or near the upper high for normoglycaemic range 
Pre EX, these BG values suggest that they are not as insulin resistant as T2I who 
displayed much higher BG values at the beginning of each exercise session. This 
indicate that their insulin resistance is not as prevalence as T2I, and their residual 
pancreatic activity is still be able to maintain their BG value close to normoglycaemic 
range. This group T2T would benefit most from the exercise trial as a decrease in 
insulin resistant could prevent excursion into hyperglycaemia. Therefore, preventing 
diabetes complications and introducing insulin injections later in their lives. 
The present study show that  BG level was generally reduced after AE more than RE but 
not at hypoglycaemia level and this result in consistent with other study by Yardley, 
Iscoe et al. (2013) who studied the effect of performing RE pre- vs post AE on glucose 
control in T1D. They had similar reductions in glucose levels during moderate AE when 
performed after RE, they concluded that performing RE before AE improves glycaemic 
control (Yardley, Kenny et al. 2013).  
Moreover, Guelfi et al 2009, compared the effect of 30 min of moderate AE to 30 min 
of intermittent high-intensity exercise concluded that the decrease in BG levels was 
higher with moderate AE compared with intermittent high-intensity exercise in T1D 
(Guelfi, Jones et al. 2005). As shown in this study the AE is more likely to result in a 
reduction of BG level than RE. Yardley, Kenny et al. (2012) in agreement with this and 
they recommend performing AE after RE as in the present study protocol. BG levels are 
expected to drop steadily by this exercise protocol more than when exercise is 
performed in the opposite order (Yardley, Kenny et al. 2012). 
Figure 38 compares HbA1c values Pre-Ex in the first session with Post-Ex in the last 
session of the exercise trial (session 12) and this is one of the main findings in the 
present work. As shown in figure 38, HbA1c values decreased significantly in Post-Ex of 
12th session compared to the base line reading before exercise trial (Pre-Ex 1st session) 
in all the study groups: ND from 5.4-5.2% or 36-33mmol/mol (p ˂ 0.01), T1D 7.0 to 
6.7% or 53-50mmol/mol (p ˂ 0.01), T2T 7.6 to 7.2% or 60-55mmol/mol (p ˂ 0.05), T2I 
7.3 to 6.8 or 56-51mmol/mol (p ˂ 0.05). 
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A decrease in HbA1c level was associated with a 15% - 20% reduction in major CVD 
episodes and a 37% fall in microvascular complications (Selvin, Marinopoulos et al. 
2004, Stratton, Adler et al. 2000). Hence, in this work HbA1c levels showed a significant 
reduction of 0.3 to 0.5% which could produce a 5% to 7% reduction in CVD risk as well 
as a 18% reduction in microvascular risks. In contrast, other research has shown that 12 
weeks of either RE (8 – 12 repetition of 9 RE) or AE (40 min walk or run) performed 3 
times a week by T1D showed no improvement in HbA1c (Ramalho, de Lourdes Lima et 
al. 2006). In addition, healthy overweight or obese volunteers who have done 
combined AE and RE at moderate intensity for 30 min, 5 days/week for 12 weeks was 
reported to produce a no significant changes in BG and insulin after week 8 as well as 
at week 12 of the combined exercise intervention (Ho, Dhaliwal et al. 2012).  
 
Other study has been conducted on overweight/ obese ND volunteers who 
participated in 16 weeks of resistance training, showed that there were no statistically 
significant alterations on BG, HbA1c and insulin (Tibana, Navalta et al. 2013). However, 
other researchers have investigated the effects of 8 weeks of a combined RE and AE 
programme in T2T supported the findings from this research study and they reported 
that, fasting BG and HbA1c reduced significantly (p ˂ 0.05) after the combined training 
programme (Maiorana, O'Driscoll et al. 2002). Moreover, research conducted on the 
effect of combined RE and AE intervention for 16 weeks on glycaemic control in T2D, 
demonstrated that HbA1c, BG and insulin were improved significantly after 4 weeks 
and these variables were further significantly improved after 16 weeks (Tokmakidis, 
Zois et al. 2004). 
 
Salem, Aboelasrar et al. (2010) reported that 6 months of structured AE and RE 
exercise improved glycaemic control among children with T1D (Salem, Aboelasrar et al. 
2010). Regular physical activity has been recommended to control glycaemia without 
increasing the risk for severe hypoglycaemia (Herbst, Bachran et al. 2006). Physical 
activity has provided clear evidence of improved glycaemic control in T1D and T2D 
patients (Chimen, Kennedy 2012). In 2007 the Diabetes AE and RE (DARE) study, which 
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compared AE, RE, or both with changes in HbA1c in individuals with T2D. They found a 
reduction in HbA1c for all exercise groups compared with the control group, with the 
combination group producing a larger reduction (−1.0%) compared with the RE (−0.4%) 
and aerobic (−0.5%) groups, so they concluded that AE and RE alone each could result 
in reduction of glycaemic control. However a combined of AE and RE would be more 
effective than those of either programme alone (Sigal, Kenny et al. 2007). However, in 
this study the combination exercise (AE and RE) was performed for a total of 270 
minutes (135 minutes for each of AE and RE) per week of exercise, so it is unclear 
whether the additional benefit observed was due to the combination of AE and RE or 
to the duration of exercise time. In the present work it could be attributed that the 
reduction in HbA1c was from the effects of the six week exercise trial, because all the 
different study groups (ND, T1D, T2T and T2I) had the same intensity and duration of 
the combined RE and AE exercise regimen.  
 
  
Figure 38: HbA1c levels Pre-Ex (1st session) and Post-Ex (12th session) for all the study 
groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. (*) P < 0.05, (**) P < 0.01 





















































































































































5.6.5.2  Mean plasma TC responses 
Figure 43 shows that mean TC concentrations in all the study groups (ND, T1D, T2T and 
T2I) were gradually decreased after the 6th session as well as at the end after the 12th 
session. However, the reduction was not at significant level in ND, T1D and T2I. On the 
other hand, mean TC levels in T2T were significantly decreased as follows: 1st Pre-Ex = 
4.04±0.44 mmol/L, 6th Post-Ex = 3.9±0.36 mmol/L and 12th Post-Ex = 3.7±0.49 mmol/L. 
Significant levels were 12th Post-Ex vs. 1st Pre-Ex (p ˂ 0.05) and 12th Post-Ex vs. 6th Post-




Figure 43: Mean TC levels at three time points (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for 
all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. (*) P < 0.05 




























5.6.5.3  Mean plasma LDL responses 
Figure 44 presents the mean LDL concentrations at 3 different time points throughout 
the exercise trial (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for all the study groups (ND, 
T1D, T2T and T2I). Mean LDL concentrations were slightly increased after 6th Post-Ex in 
T1D, T2T and T2I and no change was observed in ND compared to 1st Pre-Ex. However, 
mean LDL concentrations were decreased at 12th Post-Ex compared to 1st Pre-Ex and 
6th Post-Ex but did not reach significant level in ND, T2T and T2I. A significant reduction 
was observed in T1D from 6th Post-Ex = 1.76±0.77 mmol/L to 12th Post-Ex = 1.59±0.74 




Figure 44: LDL levels at three time points (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for all the 
study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. (**) P < 0.01 for 

























5.6.5.4  Mean plasma HDL responses  
Figure 45 compares the mean HDL concentrations at 3 different time points throughout 
the exercise trial (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for all the study groups (ND, 
T1D, T2T and T2I). Mean HDL concentrations were gradually improved in all the study 
groups at 6th Post-Ex and 12th Post-Ex compared to 1st Pre-Ex, but not at a significant 
level in T2T and T2I. However, mean HDL concentrations were increased significantly in 
ND from 1st Pre-Ex =1.30±0.56 mmol/ to 12th Post-Ex = 1.62±0.51 mmol/L, with (p ˂ 
0.05), and in T1D from 1st Pre-Ex =1.27±0.50 mmol/ to 12th Post-Ex = 1.52±0.55 




Figure 45: HDL levels at three time points (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for all 
the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. (*) P < 0.05 for 























5.6.5.5  Mean plasma TG responses  
Figure 46 shows the mean of TG concentrations at 3 different time points throughout 
the exercise trial (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for all the study groups (ND, 
T1D, T2T and T2I). Mean TG concentrations were reduced in 12th Post-Ex compared to 
1st Pre-Ex, but did not reach the significant level in all the study groups: ND (p = 0.30), 
T1D (p = 0.34), T2T (p = 0. 26) and T2I (p = 0.96). 
 
 
Figure 46: TG levels at three time points (1st Pre-Ex, 6th Post-Ex and 12th Post-Ex) for all the 
study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. 
 
All the volunteers from the different study groups (ND, T1D, T2T and T2I) started the 
exercise trial with well controlled lipid profile, most likely because of the restricted 
exclusion criteria and high percentage of T2T and T2I volunteers taking medication.  
It should be note that during the last few years efforts have been made to simplify 
blood sampling by replacing fasting lipid profile with non-fasting lipid profile as it has 
been found that lipids and lipoproteins were not much different in fasting and non-
fasting state with the exception of TG which were higher in non-fasting state and all 
these were associated with cardiovascular risk prediction (Nordestgaard, Langsted et 




















cardiovascular risk as compared to fasting TG (Bansal, Buring et al. 2007, Nordestgaard, 
Benn et al. 2007). 
Mean TC, LDL, HDL and TG concentrations were gradually improved at 6th Post-Ex and 
12th Post-Ex and were within the normal range for most of the volunteers. As would be 
expected ND volunteers had normal lipids profile because they were healthy, T1D were 
younger, and most T2T and T2I were on lipid lowering medication such as statin. Most 
common lipid abnormalities in T2D are increased plasma TG and low levels of HDL. 
Controlling lipid profile is very important In ND and even more crucial in T1D and T2D 
because high lipid profile would lead CVD and diabetes complications. It has been 
known for decades that exercise and physical activity one of the main cornerstone with 
medication and diet to treat and manage diabetes and high lipid profiles (Yavari, 
Najafipoor et al. 2012, Sigal, Kenny et al. 2006).  
The findings from the present study in relation to lipid profile (TC, HDL, LDL and TG) are 
consistent with previous studies such as an exercise study investigated by Yavari et al 
2012 and his colleagues who had compared between AE and RE alone or the 
combination of AE and RE three times per week for 52 weeks in patients with T2D. This 
study showed that a combination of RE and AE led to reduction in TC, TG, no change in 
HDL and decreased LDL level close to significant level (P = 0.07), (Yavari, Najafipoor et 
al. 2012). 
Other researchers have investigated the effects of 8 weeks of a combined RE and AE 
programme in T2T supported parts of the findings from this research study and they 
reported that there was a significant reduction in HbA1c, HR at rest, no significant 
changes in TC, LDL, and a slight decrease in HDL and TG after the combined training 
programme (Maiorana, O'Driscoll et al. 2002). It is not surprising that there was a slight 
change detected in this study as the lipid profile for the volunteers was within the 
normal range in the untrained state. Similarly, the results in the present work also 
showed lipid profile prior to exercise well within the normal range, however showed 
significant improvement in some of the lipids over a shorter time period of six weeks.   
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In addition, a research study consisted of AE or a combined of AE and RE in obese T2D 
on diet treatment for 3 weeks, was partially consistent with the present study. Lucotti 
et al 2011 showed that TC and TG had a significant reduction and slight improvement in 
HDL after the combined Ex programme compared with no significant changes for the 
lipid profile with AE only (Lucotti, Monti et al. 2011). In addition, healthy overweight or 
obese volunteers who have participated in a combined AE and RE at moderate 
intensity for 30 min, 5 days/week for 12 weeks was reported to produce a no 
significant improvement of TG, TC, HDL and LDL after week 8 as well as week 12 (Ho, 
Dhaliwal et al. 2012). Another study has been conducted on overweight/ obese ND 
volunteers who participated in 16 weeks of resistance training, showed that there were 
no statistically significant alterations on BG, HbA1c, insulin, TG, and HDL (Tibana, 
Navalta et al. 2013). In contrast, the present study findings show significant increase in 
HDL level and decrease in HbA1c for ND; however it is in agreement with no significant 
change in TG, TC and LDL for ND volunteers. 
Sigal et al 2007 investigated the effects of AE, RT and combined (AE + RT) training on 
cardiovascular risk factors in T2T individuals. Similar to the results of the present study, 
there was a significant fall in TC, LDL and TG after the combination exercise 
programme. Changes in body modification were only significantly produced with AE 
and combined training. After 22 weeks of RE associated with dietetic reduction, there 
was a decrease of HbA1c while combined training induced a superior decrease on 
HbA1c compared to only AE or RT (Sigal, Kenny et al. 2007).  
Moreover, research on T2T investigated the effect of different modalities of exercise 
(AE, RE or combined both AE + RE) showed that combined exercise had reduced 
significantly TC and TG level and did change HDL level. These results in agreement with 
the findings from the current work with regard T2T (Jorge, de Oliveira et al. 2011). A 
randomised control trial also examined the effect of different exercise interventions 
(AE, RE or combined both AE + RE) for 6 months in ND older obese adults. In a study by 
Davidson et al. 2009, where nutritional intake was strictly controlled and the results 
obtained could be attributed to the exercise performed and the reduction in nutritional 
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intake. Improvements were obtained in total abdominal and visceral fat and 
cardiovascular fitness in both groups studied (Davidson, Hudson et al. 2009).  
5.6.5.6  Mean plasma Insulin and C-peptide responses  
Figure 47, 48 and 49 shows the acute response of the mean of insulin, BG and C-
peptide concentrations, respectively at 3 different time points in the first exercise 
session (Pre-Ex, Post-RE and Post-AE) for all the study groups (ND, T1D, T2T and T2I). As 
can be seen from Figure 47 and 48, mean insulin and BG levels were decreased 
similarly, and no significant changes were observed in ND, T1D and T2I. However, in 
T2T mean BG level had significantly declined Post-AE compared to Pre-Ex (from 8.2±1.5 
mmol/L to 5.6±0.5 mmol/L), (P < 0.05). Likewise, in T2T the mean insulin level was 
significantly decreased Post-AE compared to Pre-Ex (from 42.03±24.8 ulU/ml to 
19.29±11.5 ulU/ml), (P < 0.05) and Post-RE compared to Pre-Ex (from 42.03±24.8 
ulU/ml to 26.9±13.7 ulU/ml), (P < 0.05). Figure 49 shows that mean C-peptide levels 
were reduced Post-RE and Post-AE, which indicate that it had similar responses to 
exercise as Insulin in ND, T2T and T2I. C-peptide levels were reduced at a significant 
level Pre-Ex vs. Post-AE, in ND from 2.53±1.2 to 1.61±0.4 ng/ml, (P < 0.05) and in T2T 
from 7.01±3.3 to 4.33±1.9 ng/ml. As would be expected there were very low or almost 
no C-peptide in T1D. In T2I, mean C-peptide levels were reduced Post-RE and Post-AE, 
but no significant changes were observed.  
Figure 50 and 51 show mean insulin and C-peptide levels, respectively across the whole 
exercise trial for all the study groups (ND, T1D, T2T and T2I). Insulin and C-peptide 
levels were decreased after the 2nd session then had similar trend. In general, Insulin 
and C-peptide levels were decreased in 12th Post-Ex compared to 1st Pre-Ex. BG control 
depends on neuroendocrine system activities, at rest cellular BG uptake rely on insulin, 
where the glucose transporter 4 (GLUT-4) is translocated to the cell membrane, 
allowing glucose to ingress the cell cytoplasm. The presence of GLUT-4 in the cell 
membrane is magnified with exercise, leading to elevated glucose uptake, even in low 
insulin concentrations (Krook, Wallberg-Henriksson et al. 2004). Exercise stimulates a 
fall in BG, which is related to the duration and intensity of the exercise, BG control 
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before the exercise and state of physical training (Asano, Sales et al. 2014). Higher C-
peptide levels are associated with elevated lipid profile and complications such as 
nephropathy vascular disease in T2D (Mavrakanas, Frachebois et al. 2009). During 
moderate intensity exercise in ND individual, the rise in peripheral glucose uptake is 
matched by an equal rise in hepatic glucose production, the result being that BG does 
not change except during prolonged, glycogen-depleting exercise (Borghouts, 
Wagenmakers et al. 2002, Burke, Hawley 1999) and this in agreement with the findings 
from the current study, (Refer to Figure 39).  
In individuals with T2D performing moderate exercise, BG utilisation by muscles usually 
rises more than hepatic glucose production, and BG levels tend to decline (Minuk, 
Vranic et al. 1981), this support the results from the present study (Refer to Figure 41). 
The effects of one AE session on insulin sensitivity would be dependent on factors such 
as duration, intensity, and subsequent diet; a single session would promote insulin 
sensitivity and glucose tolerance for more than 24 h but usually less than 72 h (Boule, 
Weisnagel et al. 2005, Cartee, Young et al. 1989). A single bout of exercise increase 
skeletal muscle BG uptake by enhance insulin clearance in T2D, although the resultant, 
insulin action after exercise is generally short-lived and disappears after about 48 hours 
(Hawley, Lessard 2008, King, Baldus et al. 1995). Directly after exercise, glycogen 
depletion increase BG uptake, which might last for several hours after an acute exercise 
session with little insulin required (Halse, Bonavaud et al. 2001). Musi et al, 2001 has 
shown that decline of the insulin concentration was also observed in T2D during a 
moderate exercise (Musi, Fujii et al. 2001), but not during intense exercise (Kjaer, 
Hollenbeck et al. 1990).  
After exercise a fall in BG when performing AE accompanied by a decrease of insulin 
and C-peptide level in T2D was reported and in line with the findings from the current 
study. A reduction in insulin concentration directly after exercise is a desirable 
phenomenon as it assures better glucose supply (Zajadacz, Skarpańska-Stejnborn et al. 
2009). 
Insulin and C-peptide are released by β cells in the pancreas in similar amounts; 
however, a significant proportion of insulin is removed by the liver. Healthy overweight 
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or obese volunteers who have done combined AE and RE at moderate intensity for 30 
min, 5 days/week for 12 weeks were reported to produce a no significant changes in 
BG and insulin after week 8 as well as at week 12 of the combined exercise 
intervention (Ho, Dhaliwal et al. 2012). A study has been conducted on overweight/ 
obese ND volunteers who participated in 16 weeks of resistance training, showed that 
there were no statistically significant alterations on BG, HbA1c and insulin (Tibana, 
Navalta et al. 2013). It was concluded that the combination of the RE and AE exercise 
was the optimal exercise strategy for improvements to insulin resistance and functional 
limitations (Davidson, Hudson et al. 2009). Moreover, a research conducted the effect 
of combined RE and AE intervention for 16 weeks on glycaemic control in T2D, 
demonstrated that HbA1c, BG and insulin were improved significantly after 4 weeks 
and these variables were further significantly improved after 16 weeks (Tokmakidis, 
Zois et al. 2004). A combination of AE and RE may be more effective for BG 
management than either type of exercise alone (Jorge, de Oliveira et al. 2011, Sigal, 
Kenny et al. 2007).  
An increase in muscle mass resulting from RE would promote BG uptake without 
altering the muscle’s ability to respond to insulin. AE enhances this uptake by a greater 
insulin, despite any changes in muscle mass or aerobic capacity. AE and RE in 
combination can improve BG control than either form of exercise alone; however, more 
studies are needed to determine if total caloric expenditure, exercise, duration, or 








Figure 47: Acute response of Insulin levels to exercise on the first session (Pre-Ex, Post-RE 
and Post-AE) for all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± 




Figure 48: Acute response of BG levels to exercise on the first session (Pre-Ex, Post-RE and 
Post-AE) for all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. 















































Figure 49: Acute response of C-peptide levels to exercise on the first session (Pre-Ex, Post-RE 
and Post-AE) for all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± 






























Figure 50: Mean insulin levels across the whole exercise trial for all the study groups (ND, 




Figure 51: Mean C-peptide levels across the whole exercise trial for all the study groups (ND, 
















































5.7  Conclusion 
This work examined the effects of a combination exercise protocol of RE and AE 
modalities on cardiovascular parameters, objective and subjective assessment of 
strength, metabolic metrics, as well as glucose and lipid profile in T1D and T2D 
compared with ND.  It is the first study to report significant improvements in aerobic 
capacity, as well as strength, in T1D and T2D subjects following same combined 
exercise programme of RE and AE for six weeks.  
Resting HR was significantly improved in all the study groups: eg ND from 72.3 to 68.7, 
T1D from 74.6 to 70.7, T2T from 77.4 to 73.0, T2I 69.7 to 66.0. Similarly both resting 
blood pressures (SBP and DBP) were reduced. 
The protocol minimised local muscle fatigue but the 1RM strength improvement was 
clear for the five different RE exercises working upper and lower muscle group ( Chest, 
Squat, Back, Biceps and Triceps) in all the study groups (ND, T1D, T2T and T2I). All the 
volunteers showed significant strength increases ranging from 16% to 75% in all 
exercises. T2T and T2I had the highest percentage of improvement than T1D and ND.  
The RPE data over the 12 week exercise trial period in all the study groups reveals that 
there has been downward slope in the volunteer’s perceived exertion to RE, agreeing 
with others (Fenicchia, Kanaley et al. 2004). 
In addition, HbA1c decreased and can be linked to Increases in muscle mass as skeletal 
muscle represents the largest mass of insulin sensitive tissue. Glucose was measured 
by HbA1c while BG was also linked to insulin levels. As shown in Figure 38, HbA1c 
values were decreased significantly in Post-Ex of 12th session compared to the base line 
reading before exercise trial (Pre-Ex 1st session) in all the study groups. 
Mean Insulin and BG levels were decreased similarly in all groups for the acute phase 
of both exercise types, significantly in the case of T2T. This was also true for mean C-
peptide levels which were reduced Post-RE and Post-AE, indicating similar responses to 
exercise as Insulin in all groups. Not surprisingly, there were very low C-peptide in T1D 
while in T2I, mean C-peptide levels were reduced Post-RE and Post-AE as receptors 
were made more effective when exercised.  
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The RER readings for all the groups were steady and most of the values were between 
0.85 and 1 which indicates that carbohydrates are being predominantly used during 
the 20 min of AE in all the groups. These results correlate and support the findings 
from the BG responses to exercise across the whole trial (12 sessions).  
The mean TC concentrations in all the study groups were gradually decreased after the 
6th session as well as at the end after the 12th session. However, the reduction was not 
at significant level in ND, T1D and T2I. Mean LDL concentrations were decreased at 12th 
Post-Ex compared to 1st Pre-Ex and 6th Post-Ex but did not reach significant level in ND, 
T2T and T2I. A significant reduction was observed in T1D. Mean HDL concentrations 
were gradually improved in all the study groups at 6th Post-Ex and 12th Post-Ex 
compared to 1st Pre-Ex, but not at a significant level in T2T and T2I. However, mean 
HDL concentrations were increased significantly in ND and T1D. Mean TG 
concentrations were reduced in 12th Post-Ex compared to 1st Pre-Ex. Blood lipids 
probably relate to body size. In the present study, %BF and waist:hip ratio decreased, 
body weight did not change and upper and lower muscle strength improved 
significantly, suggesting that lean body mass increased. 
Although the exercise programme here was tightly regimented and supervised for the 
purpose of documenting its effects, the principles of such a programme should be 







Chapter 6: Effects of acute and chronic combined exercise 
programme on immune-inflammatory markers in 
T1D and T2D  
6.1 Introduction 
A complex interaction between innate and adaptive immune system cells and 
pancreatic β-cells is considered to be behind the development of T1D (Lehuen, Diana 
et al. 2010). Insulin resistance and β-cells destruction suggest have a primarily role in 
the development of T2D. Variation in blood circulation adipokines levels along with 
other elements produced by adipose cells, develop a significant link between extra 
adiposity in obesity and both of those factors earlier mentioned (Dunmore, Brown 
2013). Obesity and abnormal (visceral) fat distribution increase the risk for metabolic 
(T2D and dyslipidaemia), cardiovascular (hypertension, CAD, stroke) diseases (Blüher, 
Mantzoros 2015, Van Gaal, Mertens et al. 2006).  
Inflammatory markers released from adipose tissues and other tissues contribute to 
alteration in the body composition and endocrine gland dysfunction in obesity 
(Labouesse, Gertz et al. 2014, Prestes, Shiguemoto et al. 2009, Forsythe, Wallace et al. 
2008). Some studies have mentioned that there is association between obesity and 
increases in the levels of TNF-α, IL-6 and CRP inflammatory markers and high risk of 
CHD (Akbarpour 2013, Bouassida, Chamari et al. 2010, Beavers, Hsu et al. 2010). 
Cytokines IL-6 and TNFα each play a significant role in the pathogenesis of T2D 
(Hossain, Faruque et al. 2010, Rodriguez-Caballero, Garcia-Montero et al. 2004). Pro-
inflammatory cytokines TNFα and IL-6 might results in deteriorate of the pancreatic β-
cells (Donath, Storling et al. 2003). However, chronic effect of exercise induced insulin 
sensitivity as a result of hypertrophy and replication of the pancreatic β-cells. In 
addition, GLUT-2 and protein kinase B were significantly increased after regular 
exercise (Giovanni Vinetti, Chiara Mozzini et al. 2015). Interestingly , IL6 released from 
skeletal muscle during exercise seems to promote Glucagon-like-peptide 1 (GLP-1) 
secretion which in turn elicit insulin release (more precisely glucose-induced insulin 
release) and regeneration of β cells, so In this particular circumstance interleukin acts 
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as an anti-inflammatory agent. Interestingly is GLP-1 released from α pancreatic cells 
and not from ileal cells (Ellingsgaard, Hauselmann et al. 2011). 
Initially, the function of adipose tissue was thought to be as largest source of energy 
storage in the body; however, it has become clear that adipose tissue is in fact the 
largest endocrine organ in the body, secreting hormones and many bioactive 
substances (adipocytokines) such as IL-6, TNFα , resistin and leptin that are required for 
normal body function and are found at altered levels in metabolic disease (Poulos, 
Hausman et al. 2010, Galic, Oakhill et al. 2010). Adipocytokines appear to contribute to 
inflammation and atherosclerosis and may be involved in the development of T2D, 
possibly constituting the missing link between obesity and insulin resistance (Havel 
2002). Obesity-related insulin resistance is strongly associated with a relative increase 
in inflammation in adipose tissue. It is suggested that adipocytokines secreted by 
adipose tissue play a role in the development of obesity-related complications and 
diabetes. TNFα is one of the major inflammatory mediators secreted by macrophages 
upon stimulation with pro-inflammatory molecules. Leptin is identified as an adipokine 
related to the body fat mass and the loss of weight and fat percentage is often 
accompanied by a decrease in the leptin levels (Koerner, Kratzsch et al. 2005, Sinha, 
Ohannesian et al. 1996). An increase in the level of leptin is observed in heart diseases 
and diabetes. Leptin could have impact on glucose metabolism via different actions, 
such as muscle glucose uptake, liver glucose production and glucagon release by 
pancreatic α-cells. Leptin suppresses insulin secretion, as well as induces fatty acid 
oxidation, while insulin promotes leptin release (Park, Ahima 2015).  
Resistin is a hormone identified as one of the markers of atherosclerosis and is one of 
the important predicting factors of CVD (Kadoglou, Perrea et al. 2007). The increase in 
the level of resistin mostly happens in inflammatory conditions and it is shown that 
resistin stimulates the synthesis and the release of pre-inflammatory cytokines such as 
TNFα (Silswal, Singh et al. 2005). The inflammatory cytokines, TNFα and interleukin IL-6 
have been associated with insulin resistance, obesity, T1D and T2D. Any improvement 
in these inflammatory cytokines would improve and decrease the risk factors for some 
chronic diseases and conditions such as diabetes, obesity and heart diseases (Blüher, 
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Mantzoros 2015). AE and RE (acute and chronic) have different impacts on 
inflammatory adipocytokines (Cullen, Thomas et al. 2015, Moran, Barwell et al. 2011, 
Goldhammer, Tanchilevitch et al. 2005).  
It is well-known that a single bout of strenuous or moderate exercise acutely increases 
systemic IL-6 levels, as well as concentrations of other cytokines such as TNFα 
(Christiansen, Bruun J. et al. 2013, Pedersen, Steensberg et al. 2001). In acute exercise, 
IL-6 is released by muscles and the level of IL-6 may increase significantly (Christiansen, 
Bruun J. et al. 2013, Petersen, Pedersen 2005). Chronic exercise for different duration 
and intensities reduce the basal level of TNFα, IL-6 , resistin and leptin (Reihmane, Dela 
2014, Rashidlamir, Saadatnia 2012, Moran, Barwell et al. 2011).  
Exercise has been shown to lower levels of inflammatory markers. However, results are 
inconsistent, indicating different modes, durations and intensities of exercise may have 
different effects on inflammatory cytokines. Exercise may lower the risk for coronary 
heart disease (CHD) by mitigating inflammation. 
6.2 Study aims 
The purpose of the present study is to examine the effects of one exercise session 
(acute effect) and 12 sessions (chronic effect) of combination RE and AE exercise on 
selected immune-inflammatory parameters such as IL-6, TNFα, leptin and resistin in 
ND, T1D and T2D. 
6.3 Volunteers 
Four groups of volunteers (n = 25) were involved in this study: ND = 7, T1D = 7, T2T = 7 
and T2I = 4. The volunteers were 18-55 years old and not physically active or engaged 
in any regular exercise or training programmes. Volunteers were recruited and 
screened as detailed in Section 2.4.2 and 2.5.1.  
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6.4 Inclusion and exclusion criteria 
Subjects who volunteered in this study had to meet specific inclusion criteria as they 
were defined in section 2.4.1. Further information detailing recruitment response and 
excluded volunteers can be found in 2.4 and 2.4.2. 
6.5 Materials and methods  
A brief description of the methods is provided below. Please refer to the methods in 
Chapter 2 for more detailed description of procedures associated with this chapter. 
6.5.1 Experimental design 
After the preliminary tests and familiarisation sessions (Section 2.5.1), volunteers 
participated in the main exercise trial which was a combined exercise session involving 
stretches, warm up on the bike for 10 min followed by 35 min of RE at 50-60% of 1RM 
(determined in Section 2.5.1.2). After RE they had 5 min of rest followed by 20 min of 
AE (cycling) at 50-60% of HRR (Section 2.5.1.3) and finally 10 min cooling down involves 
stretches (Figure ). The chronic exercise programme involved 2 sessions (48 hours 
apart) for a total of 150 min each week for a 6-week period. Detailed description for 
the main exercise trial can be found in (see Section 2.5.2).  
6.5.2 Blood collection, IL-6, TNFα, leptin and resistin 
Venous blood samples were collected from the volunteers in EDTA tubes as described 
in (Section 2.3.15). It was of interest to investigate the effects of acute and chronic 
exercise on immune-inflammatry markers IL-6, TNFα, leptin and resistin. Three blood 
samples were collected from the volunteer at the time points shown in (Figure 52). For 
the chronic effect, seven blood samples were collected as shown in (Figure 53). IL-6, 
TNFα, leptin and resistin were determined using ELISA technique by Randox machine 

















6.6 Results and discussion 
6.6.1 Mean plasma IL-6 responses to exercise 
Figure 54 shows the acute response of IL-6 concentrations to a single bout of RE and AE 
exercises, there was gradual elevation of IL-6 concentrations after RE then after AE as 
well in all the study groups (ND, T1D, T2T and T2I). There were no significant 
differences between the baseline concentrations Pre EX and Post RE or Post AE, as well 
as no significant changes detected Post-RE vs. Post-AE in ND, T1D and T2I. However, in 
T2T a significant increase in IL-6 concentration was detected Post-AE vs Pre-EX (3.67 vs. 
1.66 pg/ml) with p < 0.05. Table 23 presents the chronic response of IL-6 
concentrations across the exercise trial for six weeks (12 sessions) for all the study 
groups. There were reductions in IL-6 concentrations after the last session (12th Post-
Ex) compared to the concentrations at the first session (1st Pre-AE) in all the study 
groups, but it did not reach the significant levels and can be summarised as follows: ND 
(from 3.97±4.3 to 2.7±3.0 pg/ml, p = 0.25), T1D (from 2.15±1.2 to 1.02±0.2 pg/ml, p = 
0.22), T2T (from 3.67±0.3 to 2.72±1.4 pg/ml, p = 0.30) and T2I (from 3.66±2.7 to 
















Figure 54: Acute response of IL-6 levels to exercise on the first session (Pre-Ex, Post-RE and 
Post-AE) for all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. 
(*) P < 0.05 for (Pre-Ex vs. Post-RE). 
 
 
Table 23: Mean IL-6 concentrations across the whole exercise trial for all the study groups 
(ND, T1D, T2T and T2I). Data are presented as Mean±SD. P value is for 1st Post-AE vs. 12th 
Post-EX. 
 
IL-6 1st Post AE 2nd 4th 6th 10th 12th P value 
ND 3.97±4.3 3.65±3.7 3.59±4.2 4.06±4.8 3.74±3.3 2.7±3.0 0.25 
T1D 2.15±1.2 1.50±1.0 1.97±1.0 1.64±0.9 1.56±1.3 1.02±0.2 0.22 
T2T 3.67±0.3 4.44±4.3 4.81±4.6 2.19±0.8 2.43±0.7 2.72±1.4 0.30 

























6.6.2 Mean plasma TNFα responses to exercise 
Figure 55 shows the acute response of TNFα concentrations to a single bout of RE and 
AE exercises. There was slight reduction of TNFα concentrations Post RE 3.79±1 pg/ml 
then Post AE 3.63±0.4 pg/ml as well, in ND compared to the baseline reading Pre Ex 
4.15±1 pg/ml. There was a slight decrease in T1D and small increase in T2I after both 
types of exercise RE and AE. A minor increase Post RE 4.19±1.0 pg/ml has been 
detected in T2T, however, TNFα level was back close the baseline reading Pre EX 
3.74±0.8 pg/ml at the end of the session Post AE 3.93±1.1 pg/ml. None of the above 
differences were statistically significant. Table 24 presents the chronic response of 
TNFα concentrations across the exercise trial for six weeks (12 sessions) for all the 
study groups. There were reductions in TNFα concentrations after the last session (12th 
Post-Ex) compared to the concentrations at the first session (1st Post-AE) in all the 
study groups (ND, T1D, T2T and T2I), but it did not reach the significant levels and can 
be summarised as follows: ND (from 3.63±0.4 to 3.42±0.3 pg/ml, p = 0.5), T1D (from 
3.11±2.0 to 2.89±1.6 pg/ml, p = 0.4), T2T (from 3.93±1.1 to 3.56±0.6 pg/ml, p = 0.4) 






Figure 55: Acute response of TNFα levels to exercise on the first session (Pre-Ex, Post-RE and 
Post-AE) for all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± SEM. 
 
Table 24: Mean TNFα concentrations across the whole exercise trial (12 sessions) for all the 
study groups (ND, T1D, T2T and T2I). Data are presented as Mean±SD. P value is for 1st Post-
AE vs. 12th Post-EX. 
TNFα 1st Post AE 2nd 4th 6th 10th 12th P value 
ND 3.63 ±0.4 3.26±0.6 3.52±0.6 3.89±0.8 4.18±0.8 3.42±0.3 0.5 
T1D 3.11±2.0 3.45±2.2 3.42±2.1 3.81±2.5 3.14±1.8 2.89±1.6 0.4 
T2T 3.93±1.1 4.12±1.0 4.35±0.8 4.09±0.6 4.09±1.0 3.56±0.6 0.4 
T2I 5.10±1.6 5.98±2.4 4.35±0.8 4.15±0.8 4.19±0.8 4.20±0.5 0.3 
 
6.6.3 Mean plasma leptin responses to exercise 
Figure 56 shows the acute response of leptin concentrations to a single bout of RE and 
AE exercises. There was slight reduction of leptin concentrations which were non-
significant after exercise as follows: ND (Pre Ex = 1.19±0.6 pg/ml, Post RE = 0.92±0.2 
pg/ml and Post AE = 0.93±0.3 pg/ml), T1D (Pre Ex = 1.45±0.5 pg/ml, Post RE = 1.19±0.6 
pg/ml and Post AE = 1.01±0.6 pg/ml), and T2I (Pre Ex = 1.67±1.0 pg/ml, Post RE = 






















no change between the two types of exercise Post RE and Post AE as well as the 
baseline Pre Ex concentrations. No significant differences were found in between the 
exercises (Post RE and Post AE) and versus the baseline Pre EX in all the study groups 
(ND, T1D, T2T and T2I). Table 25 demonstrates the chronic response of leptin 
concentrations across the exercise trial for six weeks (12 sessions) for all the study 
groups. There were reductions in leptin concentrations after the last session (12th Post-
Ex) compared to the concentrations at the first session (1st Post-AE) in all the study 
groups except in T2T, where leptin level had slightly increased. None of these 
differences were statistically significant and can be summarised as follows: ND (from 
0.93±0.3 to 0.89±0.1 pg/ml, p = 0.9), T1D (from 1.01±0.6 to 0.95±0.4 pg/ml, p = 0.6), 
T2T (from 1.24±0.5 to 1.33±0.6 pg/ml, p = 0.6) and T2I (from 1.50±0.8 to 1.43±1.0 
pg/ml, p = 0.2).  
 
 
Figure 56: Acute response of Leptin levels to exercise on the first session (Pre-Ex, Post-RE and 























Table 25: Mean Leptin concentrations across the whole exercise trial (12 sessions) for all the 
study groups (ND, T1D, T2T and T2I). Data are presented as Mean±SD. P value is for 1st Post-
AE vs. 12th Post-EX. 
 
Leptin 1st Post AE 2nd 4th 6th 10th 12th P value 
ND 0.93±0.3 0.99±0.1 1.15±0.5 1.44±0.9 1.19±0.2 0.89±0.1 0.9 
T1D 1.01±0.6 0.92±0.4 0.95±0.6 0.98±0.5 0.99±0.6 0.95±0.4 0.6 
T2T 1.24±0.5 1.36±0.2 1.62±0.6 1.46±0.7 1.53±0.6 1.33±0.6 0.6 
T2I 1.50±0.8 1.87±0.8 1.35±0.5 1.49±0.4 1.72±0.9 1.43±1.0  0.2 
 
6.6.4 Mean plasma Resistin responses to exercise 
Figure 57 shows the acute response of resistin concentrations to a single bout of RE 
and AE exercises. There was slight reduction of resistin concentrations have been 
observed after exercise in ND with no significant differences between the three time 
points (Pre Ex = 3.11±1.1 ng/ml, Post RE = 2.89±0.9 ng/ml and Post AE = 2.71±0.9 
ng/ml). In contrast, as can be seen from Figure 57, with T2I there was a clear trend of 
increasing in resistin concentrations from Pre Ex = 1.92±0.2 ng/ml to Post RE = 2.06±0.4 
ng/ml and Post AE = 2.21±0.4 ng/ml with P < 0.05 for Post-RE vs. Post-AE. In T1D, 
resistin concentrations have increased Post RE = 2.63±1.6 ng/ml compared to Pre Ex = 
2.5±1.7 ng/ml and back to the Pre EX level in Post AE = 2.5±1.5 ng/ml. T2T had the 
same trend of resistin concentrations, it had increased Post RE and decreased Post AE 
although it was higher than the baseline reading: (Pre Ex = 2.79±0.4 ng/ml, Post RE = 
3.42±0.8 ng/ml and Post AE = 3.01±0.8 ng/ml). There were no significant differences in 
these results for T1D and T2T.  
Table 26 compares the chronic response of resistin concentrations across the exercise 
trial for six weeks (12 sessions) for all the study groups. There were reductions in 
resistin concentrations after the last session (12th Post-Ex) compared to the 
concentrations at the first session (1st Post-AE) in all the study groups (ND, T1D, T2T 
and T2I), but none of these differences were statistically significant and the results can 
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be summarised as follows: ND (from 2.71±0.9 to 2.56±0.9 ng/ml, p = 0.4), T1D (from 
2.50±1.5 to 2.36±1.7 ng/ml, p = 0.5), T2T (from 3.02±0.8 to 2.73±0.6 ng/ml, p = 0.4) 
and T2I (from 2.21±0.4 to 1.84±0.5 ng/ml, p = 0.1).  
 
 
Figure 57: Acute response of resistin levels to exercise on the first session (Pre-Ex, Post-RE 
and Post-AE) for all the study groups (ND, T1D, T2T and T2I). Data are presented as Mean ± 
SEM. (*) P < 0.05 for Post-RE vs. Post-AE). 
 
 
Table 26: Mean resistin concentrations across the whole exercise trial (12 sessions) for all the 
study groups (ND, T1D, T2T and T2I). Data are presented as Mean±SD. P value is for 1st Post-
AE vs. 12th Post-EX. 
 
Resistin 1st Post AE 2nd 4th 6th 10th 12th P value 
ND 2.71±0.9 2.85±0.9 2.50±0.7 2.72±0.8 3.42±2.2 2.56±0.9 0.4 
T1D 2.50±1.5 2.90±1.8 2.97±2.0 3.34±2.4 2.53±1.6 2.36±1.7 0.5 
T2T 3.02±0.8 2.98±1.0 2.59±1.0 2.88±1.0 3.21±1.2 2.73±0.6 0.4 
T2I 2.21±0.4 2.10±0.8 2.18±1.1 1.93±0.8 1.74±0.9 1.84±0.5 0.1 
 
The above results can be favourably compared with the work of others for the 
























there have been relatively very few studies where a single exercise regime of AE and RE 
components has been applied to ND, T1D and T2D volunteers.  
The current research has investigated the effects of acute and chronic combined 
exercise programme (AE and RE) on immune-inflammatory markers in ND, T1D and 
T2D. Specifically it has tested the hypothesis that exercise (AE and RE) would induce 
reduction and improvement in resistin, leptin, IL-6 and TNFα. 
Exercise suppresses the production of proinflammatory cytokines and enhances anti-
inflammatory cytokines. Because proinflammatory cytokines IL-6 and TNFα have 
cytotoxic actions, it can be proposed that regular exercise prevents further damage to 
insulin-producing β-cells by attenuating the production of these proinflammatory 
cytokines (Akbarpour 2013, Jorge, de Oliveira et al. 2011). However, the effects of IL-6 
can be complex, as, despite its known proinflammatory effects, it can also promote 
insulin release and possibly pancreatic beta cell regeneration via activation GLP-1 
peptide release from pancreatic α-cells (Ellingsgaard, Hauselmann et al. 2011). 
It has been determined that regular physical activity and exercise decrease the levels of 
inflammatory markers and decrease the risk of CHD (Beavers, Hsu et al. 2010). The 
results of different researches investigated the effects of regular exercise in diabetes 
TD1, T2D as well as ND have reported significantly decreases in the levels of TNF-α, IL-
6, IL-1β and CRP (Rosa, Heydari et al. 2011, Christiansen, Paulsen et al. 2010, Nicklas, 
Hsu et al. 2008, Kadoglou, Perrea et al. 2007, Kohut, McCann et al. 2006). There is a 
relationship between higher levels of physical activity/physical fitness and lower levels 
of these inflammatory markers (Akbarpour 2013). It has been established that IL-6 can 
be released locally from contracting skeletal muscle tissue and that the net release 
from the muscle can account for the exercise-induced rise in arterial concentration of 
IL-6 (Cullen, Thomas et al. 2015).  
Typically, IL-6 is the first cytokine present in the circulation during exercise. The level of 
circulating IL-6 increases in an exponential fashion (up to 100-fold) in response to 
exercise and declines in the recovery stage after exercise (Petersen, Pedersen 2005, 
Suzuki, Nakaji et al. 2002, Pedersen, Hoffman-Goetz 2000, Pedersen, Steensberg et al. 
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2001). In addition, it has been demonstrated that the IL-6 protein is expressed in 
contracting muscle fibres (Hiscock, Chan et al. 2004, Penkowa, Keller et al. 2003) and 
that IL-6 is released (Steensberg, Keller et al. 2002) from skeletal muscle during 
exercise whereas TNF-α is not released by skeletal muscle during exercise (Febbraio, 
Steensberg et al. 2003, Steensberg, Keller et al. 2002, Steensberg, Van Hall et al. 2000). 
The current study found that in both ND and diabetics volunteers, levels of IL-6 
consistently increased after moderate RE and AE compared to the baseline levels.  
Moderate exercise has major effects on muscle-derived IL-6. In young healthy 
individuals, 3 hours of dynamic two-legged knee-extensor exercise at 50% of individual 
maximal power output only moderately increased HR (113 to 122 beats/min), but 
induced a 16-fold increase in IL-6 mRNA, a 20-fold increase in plasma-IL-6, likely due to 
marked IL-6 release from working muscle (Fischer, Hiscock et al. 2004).  
When the same model was applied in elderly healthy untrained subjects, even higher 
amounts of IL-6 were released from working muscle during exercise at the same 
relative intensity (Pedersen, Steensberg et al. 2004). Higher levels of IL-6 are produced 
in response to acute exercise compared to any other cytokine, IL-6 is released locally in 
the skeletal muscle as a result of physical exercise, and IL-6 is known to stimulate 
hepatic glucose production and to provoke lipolysis (Gleeson 2007). Also paradoxically, 
as mentioned earlier, IL-6 can improve insulin release by stimulating GLP-1 secretion 
from α-cells (rather than solely from intestinal cells) which in turn have insulinotropic 
effect and which in diabetes improve β-cells function and regeneration (Ellingsgaard, 
Hauselmann et al. 2011). These facts suggest that IL-6 could possibly indicate an 
important link between contracting skeletal muscles and exercise-related metabolic 
alterations (Pedersen, Steensberg et al. 2001).  
Moderate exercise can improve immune function; however, high or extreme exercise 
might disturb the immune system (Fitzgerald 1988, Liesen, Baum 1997). Evidence 
suggests that exercise intensity and duration as well as the form of contraction (e.g. 
eccentric or concentric) and muscle damage all influence IL-6 response to acute 
exercise (Reihmane, Dela 2014). The current study observation of a reduction in IL-6 
with chronic exercise training is consistent with some previously published data from a 
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longer duration (12 weeks of AE) (Goldhammer, Tanchilevitch et al. 2005) and the 
current study results mostly not significant due, probably, to small sample size. 
Furthermore, in accordance with the present results, previous study has demonstrated 
that resistin and IL-6 concentrations have reduced significantly after 12 weeks of AE in 
T2T (Kadoglou, Perrea et al. 2007).  
TNFα is one of the primary and most basic mediators of inflammatory processes that is 
highly produced by fat tissues (especially visceral fat) and its levels in the circulation 
indicates the production of this factor in fat tissues (Beavers, Hsu et al. 2010). There are 
different findings on the effect of exercise on the level of TNFα; some studies have 
reported a decrease (Bruun, Helge et al. 2006), and others have shown no change in 
response to exercise (Marques, Mota et al. 2013). Other research has determined that 
the serum level of TNFα did not change in response to 12 weeks of AE because the 
half-life of TNFα was low in the blood (Bruunsgaard 2005). The current study results in 
partially agreement with Bruunsgaard findings, however with shorter time for six 
weeks of combined RE and AE showing no significant changes in ND and diabetic 
volunteers after the exercise trial. Therefore, based on these findings, TNFα cannot be 
considered a stable marker for inflammation.  
A recent study by Ho et al., 2013 investigated the effects of 12-week of RE, AE, or 
combination exercise programme at moderate intensity and showed a reduction in 
TNFα and IL-6 in healthy volunteers with obesity or overweight. They found that TNF-α 
levels were significantly decreased at week 12 compared to baseline by 20.8 % in AE 
group, 26.9 % in RE group, and 32.6 % in the combination group. Thus, combination 
exercise may help to reduce the risk of common chronic diseases such as diabetes, CHD 
and CVD (Ho, Dhaliwal et al. 2013). Furthermore, another study on patients with CAD, 
reported that a 12 weeks of AE at 70–80% of individual maximal HR has reduced 
significantly baseline levels of inflammatory cytokines such as CRP, and IL-6 from 2.50
±1.50 to 1.44±0.57 pg/ml (Goldhammer, Tanchilevitch et al. 2005). 
Moreover, an investigation into the effect of 12 weeks of AE on inflammatory markers 
of CHD in obese men found decreases in the levels of CRP, IL-6, leptin and BF% and an 
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increase in the level of adiponectin in the experimental group relative to the control 
group. In addition, the level of TNFα in the experimental group decreased by 2.86% 
and 23.76% after 6 and 12-week AE, respectively, although this change was not 
statistically significant (Akbarpour 2013). These results were in line with the findings of 
the current study where a combined exercise trial (RE and AE) for six weeks led to a 
reduction by 19.3% in the level of TNFα in overweight ND, 10.2% in T1D, 4.9% in T2T 
and 15.4% in T2I and did not reach significant level. It might be that longer period more 
than (six weeks), for example (12 weeks) or larger sample size would detect significant 
results. For example, a research group has similarly investigated the effects of AE, RE or 
a combined of both exercise on inflammatory markers and metabolic control in T2T. 
They found that 12 weeks of the combined programme was more effective than AE or 
RE alone and had decreased HbA1c, TC, TG, resistin by 8.11%, TNFα by 11.3% and IL-6 
by 3.4% (Jorge, de Oliveira et al. 2011). This result was In agreement with the current 
study findings with regards T2D which reported that resistin and TNFα had reduced by 
2.2%, 4.9%, respectively.  
A 12-week exercise intervention resulted in a significant decrease in circulating IL-6, 
alongside a decrease in visceral adipose tissue and waist circumference, in lean 
subjects, obese subjects and subjects with T2D who underwent an exercise programme 
without weight loss (Dekker, Lee et al. 2007). Furthermore, another study compared 
the effects of 12 weeks of AE to RE in T2T, reported that both AE and RE had decreased 
TNFα and IL-6. They mentioned that AE was preferable in T2D for controlling insulin 
resistance, adipocytokines and inflammatory cytokine levels than RE (Abd El-Kader 
2011). 
Many studies have investigated the relationship between body composition and 
plasma levels of leptin and adiponectin, and most of the findings have demonstrated a 
positive relationship between weight, body mass index, waist size, fat distribution 
(waist/hip ratio) and fat mass on one hand and leptin on the other hand, and a 
negative relationship between these factors and adiponectin (Bouassida, Chamari et al. 
2010, Fu, Luo et al. 2005). 
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The results from studies investigating single exercise bouts including in T2D, suggest 
that serum leptin values tend to be unaltered short duration (41 minutes or less), low 
to moderate intensity exercise, but may be affected by short duration of high intensity 
exercise (Elias, Pandian et al. 2000, Kraemer, Chu et al. 2002). More convincingly, 
studies investigating long duration exercise bouts indicate that serum leptin 
concentrations are reduced with exercise durations ranging from one to multiple hours 
(Hulver, Houmard 2003). Exercise training protocols that result in reduced fat mass will 
lower leptin concentrations, thus, most investigators have reported lower leptin 
concentrations after accounting for fat loss.  
Exercise training-induced reductions in leptin levels have been attributed to alterations 
in energy balance, improvements in insulin sensitivity, alterations in lipid metabolism, 
and unknown factors (Kraemer, Chu et al. 2002) and similar effects have been noted in 
diabetic subjects (Blüher, Mantzoros 2015, Hayashino, Jackson et al. 2014, Moran, 
Barwell et al. 2011, Sandoval, Galassetti et al. 2003). A common concept regarding the 
pathophysiological mechanisms of inflammation associated with atherosclerosis is the 
production of cytokines with inflammation in response to oxidised LDL stimulation and 
macrophages along with atherosclerotic plaques (Nicklas, Beavers 2010). It was 
determined in laboratory experiments that different combinations of cytokines 
stimulate the production of CRP and leukocytes (Akbarpour 2013). The anti-
inflammatory effect of regular exercise may prolong the life of islet cells and empower 
them to produce insulin for a much longer period (Akbarpour 2013, Ellingsgaard, 
Hauselmann et al. 2011). 
Research has shown that participation in regular sport activity decreases the level of 
oxidised LDL and the serum levels of IL-6 and CRP (Nicklas, Beavers 2010). Therefore, 
the effect of regular exercise on the levels of IL-6 may be responsible for the decrease 
in CRP in the experimental groups. In contrast, the relationship between physical 
activity and lower levels of inflammation can be created through the relationship 
between endurance training and lower degrees of general and abdominal obesity. It 
has been found that obese people produce higher levels of leptin and mediators of 
inflammation including , IL-8 and IL-6, compared with volunteers who have normal 
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weight  in the control group, whereas obese volunteers have lower levels of 
adiponectin compared with ideal BMI volunteers (Jorge, de Oliveira et al. 2011, Fu, Luo 
et al. 2005, Jacobi, Ajuwon et al. 2004). In addition, TNFα is one of the primary and 
most basic mediators of inflammatory processes that is related to the high level in fat 
tissues (especially visceral fat) and its levels in the circulation indicates the production 
of this factor in fat tissues (Beavers, Hsu et al. 2010). There are different findings on the 
effect of exercise on the level of TNFα; some studies have reported a decrease (Bruun, 
Helge et al. 2006), and others have shown no change in response to physical training. 
Clearly this reflects the parabolic profiles as shown for several inflammatory markers 
after exercise (Petersen, Pedersen 2005).   
Exercise decreases inflammatory cytokine (and IL-6) in patients with T1D and T2D. 
Exercise could be a therapeutic option for improving abnormalities in inflammation 
levels in patients with diabetes. 
Combined RE and AE exercise training in patients with diabetes is an effective means of 
inducing reduction in IL-6, TNFα levels, thus, possibly improving coronary risk profile. 
According to the results of this study, regular combined (RE and AE) exercise trial may 
be physiologically relevant in decreasing the potential risk of CVD, diabetes 
complications by improving the plasma levels of IL-6, TNFα, resistin and leptin. 
Additionally, combined RE and AE exercise trial can be used as effective non-







Chapter 7: Conclusion  
 
Aside from the serious personal consequences, the cost of diabetes and its 
complications equates to about £1m/h, but the effects of exercise are so beneficial that 
as a prescribed treatment, it could reduce both risk and cost.  
The results from the first survey showed that current treatment and management of 
diabetes care poses difficulty for T1D and T2I diabetes patients and further 
improvement is required in their health provision. The second survey showed that 
patients from all the groups who did not exercise were most likely to have a HbA1c 
over 8% (64mmol/mol) in comparison with those who performed exercise on a regular 
basis. Type 2 respondents are more at risk because those with T2T and T2I exercised 
less compared with T1D group.  
T2I users who test only once a day, as found in survey 2, form a large minority who are 
at risk because they are unlikely to be managing their daily calorie intake without more 
frequent information. This would have an impact on their HbA1c values and suggests 
poor attitude and/or support but hypoglycaemia and diabetic complications are dual 
hazards for these people. T2D people need the same intensive intervention and 
encouragement as T1D and also early diagnosis to counteract the insidious but 
dangerous course of their condition. In the exercise practical study, the HbA1c values 
decreased significantly in Post-Ex of 12th session compared to the base line reading 
before exercise trial (Pre-Ex 1st session) in all the study groups, indicating how diabetic 
people respond to exercise to reduce their overall risk. Mean BG, insulin and C peptide 
levels decreased similarly after RE and AE, for all the study groups indicating the 
increased efficiency of tissue responses.  
Data from RER readings for all the groups were steady and most of the values indicated 
that carbohydrates was the predominant substrate during the 20 min of AE in all the 
groups. All the volunteers showed significant muscular strength improvement for the 
five different RE exercises working upper and lower muscle group (Chest, Squat, Back, 
Biceps and Triceps) as represented by 1RM. T2T and T2I had a higher percentage 
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improvement than T1D and ND. RPE data correlated well with the objective 
assessment. Increase in muscle mass correlates well with strength and also with 
glucose transfer into cells and thus with increasing sensitivity in both types of diabetes. 
Exercise that includes RE is therefore important and supports the idea of combined 
protocols.  
Risk reduction is also clear from the mean TC, LDL and TG concentrations in all the 
study groups were gradually decreased after the 6th session as well as at the end after 
the 12th session. Mean HDL concentrations were gradually improved in all the study 
groups after the exercise programme. All study groups demonstrated that resting HR 
and blood pressure were significantly improved after six weeks of the exercise 
programme, so that lipids and cardiovascular efficiency are both positive outcomes 
delivered in exercise for diabetes.  
Regular combined (RE and AE) exercise trial is physiologically relevant for improving the 
plasma levels of IL-6, TNFα, resistin and leptin and for improving abnormalities in 
inflammation levels in patients with diabetes.  
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Chapter 8: Limitations and Future work  
Limitations 
The main limitation was sample size. The target number of volunteer was to recruit 60 
subjects: 20 T1D, 20 ND, 20 T2T and 20 T2I. However, fewer were recruited in all 
groups and because T2I were rarer who fulfilled the exclusion criteria. 
Several were rejected in this process. Greater volunteer numbers and even sized 
groups would have improved the confidence in the comparison of the study groups 
(ND, T1D, T2T and T2I). On reflection, NHS ethical approval would have increased the 
pool of possible recruits and although NHS ethical approval can take more than a year, 
it would have been worth doing.  
Future work 
This project has opened the door to the objective assessment of combined exercise as 
a prescribable programme to treat diabetes without necessitating extra 
pharmacological input. Several variables were studied but others have become 
attractive targets that can improve and extend the study area. For example, the period 
of exercise was short (6 weeks with 12 sessions) but could be extended to 12 weeks so 
that meaningful HbA1c changes could be monitored. In addition, the changes in the 
resting, fasted metabolic rate (the resting energy expenditure, REE) were not assessed 
in this study as a baseline where the reading is taken for 20 minutes in the recumbent 
position at the start and finish of the study. Measurement of insulin sensitivity by Oral 
Glucose tolerance test OGTT would be useful to drill down on calorie use, with 
calculations using suitable indices such as the Matsuda Index.  
The team is interested in performing the exercise programme with AE prior to RE to 
assess any differences within the study groups and could also look at the variation in 
the intensity of exercise performed. In this connection, as the study is expanded, the 
more extended screening of cytokines and other inflammatory and metabolic markers 
could be undertaken economically (in terms of cost and time), using suitable multi-
array immunoassay equipment as at the latter part of this PhD project. Many projects 
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could be built on the basis of this one, but the re assessment of volunteers throughout 
a three year period to study physiological and immunological over the long term is 
particularly important as it is known that continuing support is needed for diabetic 
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Our research group in the School of Pharmacy are working to produce a medical device 
that might help people with diabetes maintain the right level of glucose in their blood.  
We would like to invite you to take part in this survey because you have either Type 1 
or Type 2 diabetes. It is an opportunity for you to discuss your experience with various 
aspects of your diabetes and your attitudes with exercise. The information we get from 
this survey will be combined with a practical study we will also be conducting which 
may lead to recommendations to improve the lifestyle of people with diabetes in the 
future. The information could also help research toward a suitable exercise regime for 
people with diabetes. 
 
All information collected about you during the course of the survey will be strictly 
confidential and we will not ask for any personal details. 
 
If you have any questions then please contact us. 
 
















Section A: About you 
 
Q1. Are you? 
1.  Female 
2.  Male 
 
Q2. How would you best describe your occupation? 
1.  Professional 
2.  Skilled 
3.  Semi-skilled 
4.  Manual labour 
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6.  Retired 
7.  Other, please state………………. 
 
Q3. How old are you? 
1.  Between 1 - 10 years 
2.  Between 11 - 20 years 
3.  Between 21 - 30 years 
4.  Between 31 - 40 years 
5.  Between 41 - 50 years 
6.  Between 51 - 60 years 
7.  Between 61 - 80 years 
8.  Over 80 years 
 
Q4. How old were you when your diabetes was first diagnosed? 
1.  Between 1 - 10 years 
2.  Between 11 - 20 years 
3.  Between 21 - 30 years 
4.  Between 31 - 40 years 
5.  Between 41 - 50 years 
6.  Between 51 - 60 years 
7.  Between 61 - 80 years 
8.  Over 80 years 
 
Q5. What is your highest level of education?  
1.  I am still in full time education 
2.  I underwent some form of educational training (e.g. vocational or college) 
3.  I am in or have had a higher education (e.g. university) 
4.  I am still in full time education as a mature student 
5.  I have not had any further education after leaving school 
 
Q6. What is your ethnic group? (Please tick one box from section A to E) 
A. WHITE 
1.  British 
2.   Irish 
3.   Any other White background (Please write in___________________) 
B. MIXED 
4.   White and Black Caribbean 
5.   White and Black African 
6.   White and Asian 
7.   Any other mixed background (Please write in___________________) 
B. ASIAN OR ASIAN BRITISH 
8.    Indian 
9.    Pakistani 
10.  Bangladeshi 
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11.   Any other Asian background (Please write here _______________) 
B.   BLACK OR BLACK BRITISH 
12.   Caribbean 
13.   African 
14.   Any other Black background (Please write in_________________) 
 B.   CHINESE OR OTHER ETHNIC GROUP 
15.   Chinese 
16.   Any other ethnic group (Please write in_____________________) 
Q7. Which country do you live in? 
………………………………………… 
 
Section B: Your diabetes 
 
Q8. How was your diabetes diagnosed?  
1.    By your GP (General Practitioner) 
2.   By hospital clinic 
3.   By friend/ family  
4.   By ambulance/Accident and Emergency  
5.   By yourself 
6.   By medical check-up (eg. work, insurance) 
7.   Other, please state……………………. 
 
Q9. What type of diabetes do you have? 
1.   Type 1 
2.  Type 2 
3.  I don’t know 
4.  Other, please state…………………. 
 
Q10. Please state your height, weight 
1. Height…………. (cm or feet and inches) 
2. Weight…………. (kg or stones and pounds) 
 
Q11. Is there a history of diabetes in your immediate family? 
1.  No  
2.  Yes, please state who……………….. 
 
Q12. What do you find most difficult about your diabetes? 
1.  Healthy diet 
2.  Exercising 
3.  Testing blood glucose levels 
4.  Other, please state……………………………………  
 
Q13. Do you use insulin? 
1.  Yes 
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2.  No. Please go to Q19 
 
Q14. What type of insulin(s) do you use? 
1.  Humalog® (Lispro) 
2.  Novorapid® or Novolog® (Aspart) 
3.  Actrapid® (regular or soluble insulin) 
4.  Humulin S® (regular or soluble insulin) 
5.  Humulin I® (Isophane) 
6.  Insulatard® (Isophane) 
7.  Mixtard® 
8.  Humulin M3® 
9.  Levemir® (detemir)  
10.  Lantus® (Glargine) 
11.  Other (list) _____________ 
 
Q15. How many insulin injections do you give yourself in a normal day? 
1.  1 - 2 
2.  2 - 4 
3.  4 or more  
 
Q16. How long have you been injecting this number of injections each day? 
1.  Ever since I started taking insulin 
2.  Less than one year 
3.  1 – less than 2 years 
4.  2 – less than 5 years 
5.  longer than 5 years 
 
Q17. What was the total amount of insulin you used yesterday (over 24 hours)? 
1.  Between 20 - 39 Units 
2.  Between 40 - 79 Units 
3.  Between 80 - 100 Units 
4.  Other, please state…………………………………… 
 
Q18. What is the typical total amount of insulin you use each day?    
1.  Between 20 - 39 Units 
2.  Between 40 - 79 Units 
3.  Between 80 - 100 Units 
4.  Other, please state…………………………………… 
 
Q19. What was your HbA1c when you were diagnosed with diabetes? (if known) 
1.  Don’t know 
2.  Below 5 % (31) 
3.  Between 5  and 6 % (31 and 42 ) 
4.  Between 6.1 and 7 % (43 and 53 ) 
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5.  Between 7.1 and 8 % (54 and 64 ) 
6.  Between 8.1 and 9 % (65 and 75 ) 
7.  Between 9.1 and 10 % (76 and 86) 
8.  Over 10% (86). Please state…………… 
 
Q20. How often is your HbA1c measured? 
1.   Every 3 months 
2.   Every 6 months 
3.   Every year 
4.   Other, please state…………………………………… 
 
Q21. What is your recent measured HbA1c result? 
1.   Don’t know  
2.   Below 5 % (31) 
3.   Between 5  and 6 % (31 and 42 ) 
4.   Between 6.1 and 7 % (43 and 53 ) 
5.   Between 7.1 and 8 % (54 and 64 ) 
6.   Between 8.1 and 9 % (65 and 75 ) 
7.   Between 9.1 and 10 % (76 and 86) 
8.   Over 10% (86). Please state…………… 
 
Q22. Was your HbA1c taken in the last 3 months? 
1.  Yes 
2.   No. Please state when…………… 
 
Q23. What do you think your HbA1c should be? 
1.   Don’t know 
2.   Below 5 % (31) 
3.   Between 5  and 6 % (31 and 42 ) 
4.   Between 6.1 and 7 % (43 and 53 ) 
5.   Between 7.1 and 8 % (54 and 64 ) 
6.   Between 8.1 and 9 % (65 and 75 ) 
7.   Between 9.1 and 10 % (76 and 86) 
8.   Over 10% (86). Please state…………… 
Q24. In the last 12 months, have you had any of the following tests?  
 Yes No Don’t 
know 
1. Your blood pressure taken by a doctor or nurse    
2. A cholesterol test by a doctor or nurse    
3. An eye test where a photograph of the back of your eyes was 
taken 
   
4. Your bare feet were examined    




Q25. For each question please tick yes, no or don’t know 
 Yes No Don’t 
know 
1. Has your eyesight suffered as a consequence of your 
diabetes? 
   
2. Do you have diabetic kidney disease?    
3. Do you require dialysis?    
4. Have you had a kidney transplant?    
5. Is your usual blood pressure normal?    
6. Do you take any medication to control your blood 
pressure? 
   
7. Are you on lipid lowering medication (for high cholesterol 
or triglycerides)? 
   
8. Have you ever had a heart attack?    
9. Do you ever have chest pain due to angina?    
10. Have you ever had heart bypass surgery (coronary artery 
bypass)? 
   
11. Have you ever had a balloon angioplasty or a coronary 
stent placed? 
   
12. Have you ever had, or suspected that you had a stroke?    
 
Q26. Please tell us what your cholesterol levels are, if known? 
1. Total cholesterol level………………… 
2. High-density lipoprotein (HDL)…………………. 
3. Low-density lipoprotein (LDL)…………………… 
 
Q27. Have you ever had a low blood glucose ‘hypoglycaemia’? 
1.   Yes  
2.   No. Please go to Q37 
 
Q28. What symptoms do you experience when you have a ‘hypoglycaemia’?  Tick all 
that apply to you 
1.  Pale skin 
2.  Trembling 
3.  Sweating 
4.   A feeling of weakness/fatigue 
5.   Rapid heartbeat 
6.   Hunger 
7.   Agitation/irritability 
8.   Poor concentration 
9.   Blurred vision 
10.    Loss of coherence  
11.    Black out 
12.    Convulsions/Fit 
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13.    Coma 
14.    Other, please state…………………… 
 
Q29. How low does your blood sugar get before you feel these symptoms? 
1.   Don’t know 
2.   Between 4 and 5 mmol/L (72 and  90 mg/dl) 
3.   Between 3.5 and 3.9 mmol/L (63 and 70 mg/dl) 
4.   Between 3 and 3.4 mmol/L (54 and 61 mg/dl) 
5.   Below 3 mmol/L (54 mg/dl), please give a value ___________mmol/L 
 
Q30. What time(s) of day do you have hypoglycaemia? (Tick all that apply) 
1.   Morning 
2.   Afternoon 
3.   Evening 
4.   During night 
5.   Any additional comments………………………………………….. 
 
Q31. Does hypoglycaemia affect your day-to-day activities?  
1.   A great deal 
2.   Quite a lot 
3.   A little 
4.   Not at all 
 
Q32. Do you respond to a low blood sugar by taking a sugary food or drink 
immediately? 
1.   Yes 
2.   No, please state what you do……………………………… 
 
 
Q33. Has problems with hypoglycaemia stopped you permanently from being able to 
drive?  
1.   Yes  
2.   No 
 
Q34. During the past 12 months have you had “severe” hypoglycaemia where you 
passed out or had a seizure that required help from others? 
1.  No, please go to Q36 
2.  Yes, Please state what happened…………………………………….. 
 
Q35. If yes, how many times has this occurred? 
1.   1 - 2 
2.   3 - 5 




Q36. How many times have you had to go to hospital because of hypoglycaemia in 
the past 12 months?  
1.  None 
2.  1 – 2 
3.  3 – 5 
4.  More than 5 
 
Q37. How many times per week is your measured fasting blood glucose 10 mmol/L 
(180 mg/dl) or above? 
1.   Once  
2.   Twice 
3.   More than twice 
4.   Never 
 
Q38. Has your blood sugar ever been above 20 mmol/L (360 mg/dl)? 
1.   Yes 
2.   No 
 
Q39. Have you ever been in diabetic ketoacidosis (DKA)?  
1.   Yes 
2.   No. Please go to Q41 
 
Q40. Do you know what caused your diabetic ketoacidosis (DKA)?  
1.   Because you were unwell 
2.   Missed taking insulin 
3.   Because you were stressed  
4.   Diet 
5.   Other, please state……………….  
 
Q41. Have you ever been in a coma because of “high” blood glucose?  
1.   Yes 
2.   No 
 
Section C: Your diet 
 
Q42. How would you describe your diet approach?   
1.  You are eating healthily. 
2.  You too busy to find healthy foods or meals. 
3.  You don't know enough about good nutrition or how to eat healthily. 
4.   Sometimes, you try to eat healthy food  
5.  You can’t resist junk food. 





Q43. Have you been given any dietary advice to help control your diabetes? 
1.  Yes 
2.  No 
 
Q44. Do you follow a medically approved dietary programme to help control your 
diabetes? 
1.  No 
2.  Yes, please state……………………… 
 
Q45. Do you count carbohydrates regularly in order to help you to control your 
diabetes? 
1.  Yes 
2.  No 
 
Q46. How many calories do you think you eat and drink in a typical day? 
1.  1500 or fewer 
2.  Over 1500 up to 2000 
3.  Over 2000 up to 2500 
4.  Over 2500 up to 3000 
5.  Over 3000 up to 3500 
6.  3500 or more 
7.  I don’t know 
 
Q47. Do you eat special diabetic food/drink? 
1.  No  
2.  Yes, please list and state why……………………………….. 
 
Q48.Do you drink alcohol? 
1.   No  
2.   Yes. How many units per week…………… 
Q49. Do you smoke? 
1.  No 
2.  Yes, please state how many per day……………………. 
 
 Section D: Your attitude to exercise 
 
Q50. How important is doing exercise to you? 
1.   Important 
2.   No view   
3.   Not important  
 
Q51. Do you exercise regularly? 
1.  Yes 
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2.  No, you do not exercise at all. For the rest of the survey answer only 
questions 52, 53 and 54. Thank you for your participation in this survey 
 
Q52. Are there any barriers preventing you from taking part in more exercise and 
sport? (Please tick all that apply) 
1.  Health reasons    
2.  Lack of motivation    
3.  Embarrassment about how you look. 
eg overweight or lack of fitness  
4.  You doubt it will lead to weight 
control 
5.  Lack of time    
6.  It does not interest me    
7.  It is too expensive 
8.  Lack of transport 
9.  Fear of Injury 
10.  Don't know 
11.  Other, please state…………… 
 
 
Q53. Which of the following factors influenced your decision to participate in 
exercise and sport? (Please tick all that apply) 
1.   To keep well with your diabetes 
2.  Better control of your blood glucose 
3.  Better for HbA1c value 
4.  To improve health and fitness 
5.   Loss weight 
6.  Family participate in sport 
7.  Because friends do it 
8.  Because you enjoy it 
9.  To relieve stress 
 
Q54. What frustrates you MOST about exercise? Tick all that apply 
1.  Finding time to exercise every day 
2.  Having to change your diet 
3.   Motivating yourself 
4.  Pain after exercise 
5.   Other, please state…………… 
 
Q55. What effect did exercise have on your life after you became diabetic?  
1.   No effect on your diabetes 
2.   Positive effect on your diabetes 
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3.   Negative effect on your diabetes 
 
Q56. How effective has exercise been on each of the following 
 Effective  No change Detrimental Comments 
1. Better general Health     
2. Low HbA1c     
3. Poor blood glucose 
control 
    
4. Fewer Hypoglycaemia 
events 
    
5. Fewer Hyperglycaemia 
events 
    
Q57. Where do you typically exercise?   
1.   At school/college/ work/ university 
2.   In a sports team (e.g. football, netball) 
3.   In a class or club (e.g. aerobics, dance, etc) 
4.   At a gym  
5.   On your journey home (eg. walking or cycling) 
6.   Elsewhere, please state………………………… 
 
Q58. Do you have a membership in any sport centre or physical activity group? 
1.   Yes 
2.   No 
 
Q59. What type of exercise do you do? (Please tick all that apply) 
1.  Walking 
2.  Cycling  
3.  Weight training (resistance 
exercise) 
4.  Swimming 
5.  Team sports 
basketball/football 
6.  Running  
7.  Other, please state…………… 
Q60. Typically what is your blood glucose value pre-exercise? 
1.   Below 5 mmol/l (90 mg/dl) 
2.   Between 5  and 6 mmol/l (91 and 108 mg/dl  ) 
3.   Between 6.1 and 7 mmol/l (109 and 126 mg/dl) 
4.   Between 7.1 and 8 mmol/l ( 127 and 144 mg/dl) 
5.   Between 8.1 and 9 mmol/l (145 and 162 mg/dl) 
6.   Between 9.1 and 10 mmol/l (163 and 180 mg/dl) 




Q61. At what level of intensity do you exercise? 
1.  Low (Easy, does not induce sweating unless it's a hot, humid day, no 
noticeable change in breathing patterns) 
2.  Moderate (Somewhat hard, sweat after about 10 minutes of exercise. 
Breathing becomes deeper and more frequent) 
3.  High (Hard, sweat after 3-5 minutes. Breathing is deep and rapid) 
4.  Combination between low and moderate 
5.  Combination between low and high 
6.  Combination between high and moderate 
 
Q62. Typically, how many days of the week do you undertake physical activity and 
exercise? 
1.   Every day 
2.   1 - 2 days 
3.   3 - 5 days 
4.   6 days 
 
Q63. How many times do you exercise per day? 
1.   Once 
2.   Twice 
3.   Three times 
4.   More than 3 times 
 
Q64. When do you do your exercise? Tick all that apply 
1.   Morning 
2.   Afternoon 
3.   Evening 
4.   After a meal 
5.   Before a meal 
 
 
Q65. In a typical exercise day how long do you spend participating in sport or 
exercise?   
1.  Less than 30 minutes 
2.  From 30 minutes to less than 1 hour 
3.  From 1 to less than 2 hours 
4.  From 2 to less than 3 hours 
5.  From 3 to less than 4 hours 
6.  More than 4 hours 
 
Q66. How many times do you test your blood glucose in normal day (24 hr)? 
1.  Once 
2.  Two – four  times 




Q67. Does this change on an exercise day? 
1.   Test more 
2.   Test less 
3.   No change 
 
Q68. Do you change the number of insulin injections on exercise day? 
1.   More 
2.   Less 
3.   No change 
 
Q69. Does your insulin dose change in exercise day? 
1.  More, how much………. 
2.  Less, how much……….. 
3.     No change 
4.  Dependent on type of exercise. Please state……………. 
 
Q70. Do you inject insulin pre-exercise? 
1.  No 
2.  Yes, please state how much…………… 







1. When do you test your 
blood glucose? 
   
2. When do you take your 
insulin dose? 
   
3. When do you take 
carbohydrate? 
   
 
Q72. If your blood sugar was less than 4mmol/L (72mg/dl) pre-exercises, what would 
you do? 
1.  Miss out your pre- exercise bolus 
2.  Reduce your pre- exercise bolus 
3.  Leave the exercises today 
4.  Take some carbohydrate then exercise 
5.  Nothing 
6.  Other, please state…………………………………………… 
 
Q73. Do you experience hypoglycaemia while exercising? 
1.  Always 
2.  Frequently 
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3.  Rarely 
4.  Never 
 
Q74. How many times in the last month has your blood glucose been below 4mmol/L 
(72mg/dl) after exercise? 
1.  Once  
2.  Between 1 - 3 times  
3.  More than 3 times 
4.  None, go to Q77 
 
Q75. If you experience a hypoglycaemia after exercise what action do you take? 
1.  Re-check your blood glucose 
2.  Eat or drink carbohydrate 
3.  Other, please state…………………………………………… 
 
Q76. If you have hypoglycaemia associated after exercise, when would be your major 
risk period? 
1.  0 - 1 hour 
2.  1 - 2 hours 
3.  3 - 6 hours 
4.  More than 6 hours 
 
Q77. How many times in the last month has your blood sugar been above 10mmol/L 
(180mg/dl) after exercises? 
1.  Once  
2.  Between 1 - 3 times  
3.  More than 3 times 
4.  None, go to Q79 
 
 
Q78. If you experienced hyperglycaemia (high blood glucose) after exercise what 
action do you take? 
1.   Inject insulin dose 
2.   Re-check your blood glucose  
3.   Drink water or any drink with no calories 
4.   Seek medical help 
5.   Eat some thing (eg.carbohydrate) 
 
Q79. Have you experienced any of the following symptoms during or after exercise?  
(Please tick all that apply)        
1.  Bleeding 
2.  Chafing 
3.  Flushing  
4.  Hives 
212 
 
5.  Hyperthermia 
6.  Muscle cramps 
7.  Red face 
8.  Shortness of breath 
9.  Urinary (colour, blood, pain) 
10.  Other 
11.  None 
 
























Leicester School of Pharmacy        
Faculty of Health & Life Sciences 
 
Volunteer Information Sheet 
Title of Project: The effects of aerobic and resistance exercise on 
diabetes 
 
Name of Principal Investigators: Prof MJ Taylor, Mr.Ahmed Alsabih and Mr.Mohamd Alblihed  
     
We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for you. 
Please take time to read the following information carefully. Talk to others about the 
study if you wish.  
 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. If you do wish to take part please 
complete the slip at the end of this sheet.  
 
What is the purpose of the study? 
As part of the growing research work into diabetes, School of Pharmacy, De Montfort 
University (DMU) are working to investigate the effects of  combined exercise 
programme (aerobic and resistance) on blood glucose, metabolic parameters that 




This research involves a combination of two types of exercises and this is where we 
need your help. We would like to invite you to take part in this study which will help us 
to understand the role of exercise and how it can help people with diabetes to 
maintain a healthy body weight and to possibly manage better their blood glucose 
level. 
We will keep your information strictly confidential and nobody other than the research 
team will have access to your personal information.  
Before any research goes ahead it has to be checked by De Montfort University 
Research Ethics Committee. They make sure that the research is fair.  
Why have I been invited? 
You have been invited to take part in this study because you are a healthy male, or 
have either Type 1 or Type 2 diabetes and your age is between (18 – 55). 
Do I have to take part? 
It is up to you to decide. We will answer any questions you have about the study and 
go through this information sheet. We will then ask you to sign a consent form to show 
you have agreed to take part. You are free to withdraw at any time, without giving a 
reason. This would not affect the standard of care you receive from your doctor or 
hospital. 
What will happen to me if I take part? 
Preliminary procedures 
Before enrolling in the study you will be asked to attend a screening visit where we 
will: 
 discuss and complete confidential questionnaires regarding your health, 
family history and physical activity level. 
 measure your blood pressure and heart rate. 
 measure your height and weight  
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 provide an opportunity for you to ask questions. 
 familiarise you with equipment to be used in the study and  teach you how  
to use the recumbent ergometer bike and how to lift the weights safely in 
the multigym machine. 
 This session will also be used to determine the intensity of exercise during 
cycling on the recumbent ergometer bike using Heart Rate Reserve (HRR). 
Also, in this orientation session we will use predicted one repetition 
maximum (1RM) to determine how much weight for different muscles you 
should lift in the resistance exercise session later. 
 
These preliminary procedures will enable us to determine whether you are suitable to 
safely participate in the study or not. 
Main experimental trials  
The main experimental trials will involve 2 x 2 hour exercise sessions a week for a 6- 
week period, (exercise session includes rest + final observation of volunteer for hypos 
etc…). 
Blood glucose levels will be monitored before, during and after each session, using a 
standard finger prick test.  By using the Radiometer, Blood gases, Albumin, Lactate, 
and Electrolytes will be tested before, and after exercise programme. In addition, 
Cholesterol, High density lipoprotein, low density lipoprotein and Triglyceride will be 
monitored before, and after exercise programme using a finger prick test. 
Each exercise session will consist of a combined  exercise protocol of 35 min of 
resistance exercise (3 sets of 8 -10 repetitions at 50 – 60% of  predicted one-repetition 
maximum strength 1-RM ) using upper and lower muscle groups followed by 20 min 
moderate cycling at 50 – 60% of  predetermined heart  rate reserve (HRR).  Heart rate 
(HR) and rate of perceived exertion (RPE) will be taken in a different time points 




Expenses and payments  
We would like to pay expenses and to offer an incentive of £120 each on completion of 
100% of the dates agreed to. 
What are the possible benefits of taking part? 
There may be no benefits to you but as a result of being involved in this study may will 
receive health and fitness information about yourself including fitness tests and body 
measurement. The findings of this study will be published in scientific journals so that 
understanding about how exercise can help people with diabetes to improve their 
health and control their weight and blood glucose levels. This information may 
contribute towards improved exercise guidelines for the diabetic patients. 
We will provide you with feedback about the main study findings and also about your 
own results and would be delighted to explain our findings and discuss possible 
implications with you. 
What if there is a problem?  
The chance of something going wrong is small. All of the procedures involved in this 
study are low risk and our screening tests are designed to ensure that you will only 
participate if it is safe for you to do so. However, if you have any concerns at any time 
about any aspect of the way you have been approached or treated during the course 
of this study, you should ask to speak to the researchers who will do their best to 
answer your questions (contact details below), and the normal De Montfort University 
complaints mechanisms will be available to you. 
Will my taking part in the study be kept confidential? 
All information that is collected about you during the course of the research will be 
kept strictly confidential. Any information about you, which leaves the University, will 






What will happen if I don’t want to carry on with the study? 
While we do not expect the programme to cause you to become upset if this does 
happen then you will have the option to pause or stop your participation immediately, 
you may continue only if you wanted to. If you withdraw from the study, we will 
destroy all your identifiable data, but may use the data collected up to your 
withdrawal  
Who has reviewed the study? 
This study has been reviewed and approved by the Faculty of Health and Life Sciences 
Ethics Committee at De Montfort University. Approval does not guarantee that you 
will not come to any harm if you take part. However, approval means that the 
Committee is satisfied that your rights will be respected, that any risks have been 
reduced to a minimum and balanced against possible benefits and that you have been 
given sufficient information on which to make an informed decision. 
You will be given a copy of this information sheet and a signed consent form to keep 
for your records. 
 
Contact for Further Information 
Any questions about the procedures used in this study are encouraged. If you 
have any doubts or questions, please ask for further explanations by 
contacting Ahmed Alsabih on p09053155@myemail.dmu.ac.uk or Mohamd 
Alblihed on p06004947@myemail.dmu.ac.uk or Prof.Taylor on 01162506317 
or mjt@dmu.ac.uk  
 










Leicester School of Pharmacy   Faculty of Health & Life Sciences 
 
Standard Operation Procedure (SOP) 
Title of Project: The effects of aerobic and resistance exercise on diabetes 
Name of Principal Investigators: Prof MJ Taylor, Mr.Ahmed Alsabih and Mr.Mohamd 
Alblihed  
Preliminary procedures 
Before enrolling in the study the volunteer will be asked to attend a screening visit 
where we will: 
 discuss and complete confidential questionnaires regarding his health, family 
history and physical activity level. 
 measure his blood pressure. 
 measure his height and weight  
 provide an opportunity for him to ask questions 
 familiarise him with equipment to be used in the study and teach him how  to use 




 This session will also be used to determine the intensity of exercise (moderate 
intensity) on the recumbent ergometer bike and how much weight he should lift in 
the resistance exercise session later.  
These preliminary procedures will enable us to determine whether the volunteer 
suitable to safely participate in the study or not. 
Main experimental trials  
The main experimental trials will involve 2 x 2 hour exercise sessions a week for a 6- 
week period,( exercise session includes rest + final observation of volunteer for hypos 
etc…). 
Blood glucose levels will be monitored before, during and after each session, using a 
standard finger prick test. Total Cholesterol, High density lipoprotein, Low density 
lipoprotein and Triglyceride will be monitored before, during and after exercise 
programme and after the second session in each week of 6 weeks of exercise 
programme using a finger prick test. There may be occasions when the volunteer may 
not be allowed to participate if that or another health issue is deemed to threaten 
wellbeing. 
Each exercise session will consist of a combined  exercise protocol of 35 min of 
resistance exercise (3 sets of 8 -10 repetitions at 50 – 60% of one-repetition maximum 
strength 1-RM ) using upper and lower muscle groups followed by 20 min moderate 
cycling at 50 – 60% of  predetermined heart  rate reserve (HRR)or ratings of perceived 
exertion (RPE). 
The exercise session will include the following 6 phases: 
1. Stretching: stretch lower and upper muscle groups for 5 min  
2. Warm-up: start with cycling for 10min on the recumbent ergometer bike at low 
to moderate intensity (30 to 40% of HRR). Warm-up is an essential part of the 
exercise session and designed to prepare the body for exercise, increase body 
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temperature and to reduce the potential post-exercise injury or pain (muscle 
stiffness). 
3. Resistance exercise: this phase will include 35 min of five different exercises 
working upper and lower muscle groups (3 sets of 8 -10 repetitions at 50 – 60% 
of one-repetition maximum strength 1-RM )  and using the Multigym machine 
Working muscle groups as follows: (3 sets of 8 -10 repetitions each exercise) 
a. Squat b. Incline bench 
press 
c. lat curl pull 
down 
d. Triceps e. Biceps  
 
4. Cycling 
The volunteer will do moderate cycling at 50 – 60% of predetermined heart rate 
reserve (HRR) or ratings of perceived exertion (RPE) for 20 min. The volunteer and the 
bike will be attached to monitoring equipment that can produce instant graphical 
representation of performance linked to work done and produce different metabolic 
parameters such as Oxygen consumption (VO2), Carbon Dioxide Production (VCO2), 
Respiratory Exchange Ratio (RER), Heart rate (HR) etc. The volunteer attachment will 




5. Cool-down: cycling for 5 - 10min on the recumbent ergometer bike at low to 
moderate intensity (30 to 40% of HRR). The purpose of the cool-down phase is 
reducing the risk of injury and brings the body physiological responses back to 
normal such as heart rate and blood pressure. 
6. Stretching: stretch lower and upper muscle groups for 5 min. 
     
I ………………………………(NAME AND ADDRESS OF PARTICIPANT)    would like to 
participate in a focus group/interview in the DMU research study ‘Investigating views 
on acceptable methods for controlling blood sugar’. 
___________________________    
 ___________________ 
Signed by Participant       date 
Name …………………………………..Address…………………………………………….. 






Leicester School of Pharmacy 
Faculty of Health & Life Sciences 
Study Number: 
Patient Identification Number for this trial: 
Consent Form 
Title of Project: The effects of aerobic and resistance exercise on diabetes 
Name of Principal Investigator: Prof MJ Taylor, Mr.Ahmed Alsabih and Mr.Mohamd 
Alblihed  
Please initial at the end of each point 
1. I confirm that I have read and understand the Participant Information Sheet dated. 
(05/10/2011) (Version 2) for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily. I 
understand that agreeing to take part means that I am willing to undertake some 
exercise and giving samples in the above study. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my legal rights being affected. 
3. I understand that any information I provide is confidential, and that no information 
that could lead to the identification of any individual will be disclosed in any reports on 
the project, or to any other party. No identifiable personal data will be published. The 
identifiable data will not be shared with any other organisation.   
4. I understand that confidentiality can be guaranteed for information which I might 
disclose in any session or visit I attend. I understand that this information will be used 
only for the purpose(s) set out in this statement and my consent is conditional on the 
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University complying with its duties and obligations under the Data Protection Act 
1998.  
5. I agree to take part in the above study. 
Participant Name…………………….. Signature…………………….Date…………………. 
Person Taking consent………………...Signature……………………Date………………….. 








Leicester School of Pharmacy 
Faculty of Health & Life Sciences 
Volunteers Health Screen for Study Volunteers 
Name: ……………………………… Volunteer Identification Number……………………. 
It is important that volunteers participating in research studies are currently in good 
health and have had no significant medical problems in the past.  This is to ensure (i) 
their own continuing well-being and (ii) to avoid the possibility of individual health 
issues confounding study outcomes. 
Please complete this brief questionnaire to confirm fitness to participate: 
At present, do you have any health problem for which you are: 
(a) On diabetes medication, prescribed or otherwise    yes [    ]         no [ ] 
(b) Other medication                                                    yes [    ]          no [ ] 
(c)  Attending your general practitioner                 yes [    ]           no [ ] 
(d) On a hospital waiting list                             yes [     ]          no [ ] 
In the past two years, have you had any illness which required you to: 
(a) consult your GP yes [ ] no [ ] 
(b) was this related to diabetes    yes [ ] no [ ] 
(c) attend a hospital outpatient department  yes [ ] no [ ] 
(d) be admitted to hospital     yes [ ] no [ ] 
Have you ever had any of the following: 
(a) Convulsions/epilepsy     yes [ ] no [ ] 
(b) Asthma      yes [ ] no [ ] 
(c)  Eczema      yes [ ] no [ ] 
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(d)  Heart problems     yes [ ] no [ ] 
(e) A blood disorder     yes [ ] no [ ] 
(f) Head injury      yes [ ] no [ ] 
(g)  Digestive problems     yes [ ] no [ ] 
(h) Hearing problems     yes [ ] no [ ] 
(i) Problems with bones or joints   yes [ ]  no [ ] 
(j) Disturbance of balance/co-ordination  yes [ ]  no [ ] 
(k) Numbness in hands or feet    yes [ ] no [ ] 
(l) Disturbance of vision     yes [ ] no [ ] 
(m) Thyroid problems     yes [ ] no [ ] 
(n) Kidney or liver problems    yes [ ] no [ ] 
(o) Chest pain                               yes [ ] no [ ] 
(p) Any other health problems    yes [ ] no [ ] 
Do you currently smoke     yes [ ] no [ ] 
 Have you ever smoked     yes [ ] no [ ] 
 
 If so, for how long did you smoke and when did you stop? …………………… 
How many units of alcohol do you typically drink in a week? …………………. 
 
If YES to any question, please describe briefly if you wish (e.g. to confirm whether 
problem was short-lived, insignificant or well controlled.) (Use a separate sheet if 
necessary) 
………………………………………………………………. 
Name and address of your GP ………………………………………………………………………………… 








Private and confidential  
Volunteer Record Sheet 
 
Volunteer Identification Number: 
 
TITLE…….… FIRST NAME………………………..… SURNAME…………………………….… 
DATE OF BIRTH…………………………………..…. AGE………………MALE / FEMALE … 
CORRESPONDENCE ADDRESS…………………………………………………………….... 
………………………………………………………… POSTCODE: …………………….………. 
HOME TELEPHONE: ……………………………….. MOBILE: ………………………….……….. 
WORK TELEPHONE ……………………………… 
EMAIL ADDRESS: …………………………………………………………………………………. 
Please tick    I am happy for De Montfort University Diabetes and Exercise Group to contact me 
by email  
(We may will be sending key information via emails, so please include an up to date email 
address that you will check on a regular basis)  
PERSON TO CONTACT IN CASE OF EMERGNCY………………….……………………… 
RELATION TO YOU…………….……………………………………………………..………. 
HOME TELEPHONE: ……………………………….. MOBILE: ………………………….…. 
EMAIL ADDRESS: …………………………………………………………………………….. 
Type of diabetes?               Healthy        Type 1                   Type 2                    Other 
Number of years with DM duration………………..… 
Do you have any other medical conditions?   Yes/ No 
If yes, please state: ……………………………………………………….…… 
Do you have any specific dietary requirements?      Yes/ No 
If yes, please state: …………………………………………………………………. 
Name of your GP…………………………………….  Tel…………………………… 
Address …………………………………………………………….Post Code…………………. 
Do you have any existing medical conditions    Yes / No 
If yes, please state.………………..…………………………………………………………………..…  
Any infectious diseases                                       Yes / No 
 If yes, please state ……………………………………………………………………….……….. 
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Have you been in hospitalised the past year        Yes / No  
If yes, why …………………………………………………………………………………………… 
History of acute diabetic complications  
Number of Hypoglycaemia (low blood sugar) event in last month………………………………….. 
Number of Hyperglycaemia (high blood sugar) event in last month ………..……………………….  
Number of Diabetic ketoacidosis event in last month……………………………………………… 
Are you taking any medications, pills or drugs…………….....  If yes, please list and state dose 
………………………………………………………………………………………………….. 
Do you have any of the following?  
 Yes No   Yes  No  
Heart Disease   Liver Disease   
High Blood Pressure   Kidney Disease   
Rheumatic arthritis    Hepatitis   
Heart Murmur   Asthma   
HIV Positive /Aids    Tuberculosis (TB)   
Any allergy    Stroke   
Tumour (Cancer) History   Epilepsy   
Terminally or mentally ill   Any recent surgery   
Restriction in physical activity 
because of disease 
  Had an active infection   
Participation in exercise (aerobic or resistance) 2 times or more weekly for 20 
minutes or longer per session during the previous 6 months  
  
Diabetes mellitus DM 
Type of insulin…………………………………………..…………………. 
Units / day…………………………………………………….……………. 
Injections / day……………………………………………………..………. 
Blood glucose testes / day …………………………………………………. 
PLEASE RETURN THIS FORM TO: De Montfort University Diabetes and Exercise Group 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
(October 2002) 
 
LONG LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 questionnaires. 
Long (5 activity domains asked independently) and short (4 generic items) versions for use by 
either telephone or self-administered methods are available. The purpose of the 
questionnaires is to provide common instruments that can be used to obtain internationally 
comparable data on health–related physical activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in Geneva in 
1998 and was followed by extensive reliability and validity testing undertaken across 12 
countries (14 sites) during 2000. The final results suggest that these measures have acceptable 
measurement properties for use in many settings and in different languages, and are suitable 
for national population-based prevalence studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It is 
recommended that no changes be made to the order or wording of the questions as this will 
affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is encouraged to facilitate worldwide use of IPAQ. Information on the 
availability of IPAQ in different languages can be obtained at www.ipaq.ki.se. If a new 
translation is undertaken we highly recommend using the prescribed back translation methods 
available on the IPAQ website. If possible please consider making your translated version of 
IPAQ available to others by contributing it to the IPAQ website. Further details on translation 
and cultural adaptation can be downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical Activity 





More detailed information on the IPAQ process and the research methods used in the 
development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. (2000). 
Assessment of Physical Activity: An International Perspective. Research Quarterly for Exercise 
and Sport, 71 (2): s114-20. Other scientific publications and presentations on the use of IPAQ 
are summarized on the website 
 
INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as part of 
their everyday lives. The questions will ask you about the time you spent being physically 
active in the last 7 days. Please answer each question even if you do not consider yourself to 
be an active person. Please think about the activities you do at work, as part of your house and 
yard work, to get from place to place, and in your spare time for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. Vigorous 
physical activities refer to activities that take hard physical effort and make you breathe much 
harder than normal. Moderate activities refer to activities that take moderate physical effort 
and make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
The first section is about your work. This includes paid jobs, farming, volunteer work, course 
work, and any other unpaid work that you did outside your home. Do not include unpaid work 
you might do around your home, like housework, yard work, general maintenance, and caring 
for your family. These are asked in Part 3. 




 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as part of your 
paid or unpaid work. This does not include traveling to and from work. 
 
2.  During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, heavy construction, or climbing up stairs as part of your work? 
Think about only those physical activities that you did for at least 10 minutes at a time. 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous physical 
activities as part of your work? 
 
_____ hours per day 







4. Again, think about only those physical activities that you did for at least 10 minutes at 
a time. During the last 7 days, on how many days did you do moderate physical 
activities like carrying light loads as part of your work? Please do not include walking. 
_____ days per week 
 
 No moderate job-related physical activity Skip to question 6 
 
5. How much time did you usually spend on one of those days doing moderate physical 
activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time as part of your work? Please do not count any walking you did to travel to or 
from work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part of your 
work? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
These questions are about how you traveled from place to place, including to places like work, 
stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle like a train, 
bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days traveling in a train, bus, 
car, tram, or other kind of motor vehicle? 
 
_____ hours per day 
_____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to and from 







10. During the last 7 days, on how many days did you bicycle for at least 10 minutes at a 
time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
11. How much time did you usually spend on one of those days to bicycle from 
place to place? 
 
_____ hours per day 
_____ minutes per day 
12. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE 
MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from place to 
place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 7 days in 
and around your home, like housework, gardening, yard work, general maintenance work, and 
caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes at a time. 
During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
 
 
15. How much time did you usually spend on one of those days doing vigorous physical 
activities in the garden or yard? 
 
_____ hours per day 







16. Again, think about only those physical activities that you did for at least 10 minutes at 
a time. During the last 7 days, on how many days did you do moderate activities like 
carrying light loads, sweeping, washing windows, and raking in the garden or yard? 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
17. How much time did you usually spend on one of those days doing moderate physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
activities like carrying light loads, washing windows, scrubbing floors and sweeping 
inside your home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: 




19. How much time did you usually spend on one of those days doing moderate physical 
activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have already 
mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, on how 
many days did you walk for at least 10 minutes at a time in your leisure time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in your leisure 
time? 
 
_____ hours per day 







22. Think about only those physical activities that you did for at least 10 minutes at a time. 
During the last 7 days, on how many days did you do vigorous physical activities like 
aerobics, running, fast bicycling, or fast swimming in your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time did you usually spend on one of those days doing vigorous physical 
activities in your leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 minutes at 
a time. During the last 7 days, on how many days did you do moderate physical 
activities like bicycling at a regular pace, swimming at a regular pace, and doubles 
tennis in your leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time Skip to PART 5: TIME SPENT 
SITTING 
 
25. How much time did you usually spend on one of those days doing moderate physical 
activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, while doing 
course work and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading or sitting or lying down to watch television. Do not include any time spent 
sitting in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a weekend 
day? 
_____ hours per day 
_____ minutes per day 
 







Visit Measurements sheet 
 
 
TRIAL 1 TRIAL 2 
Sessions number  1 3 5 7 9 11 2 4 6 8 10 12 
1. Subject name/Ref Name  Ref: 
2. Date                  /         /                 /         / 




4. Temperature of 
the lab   
 
5. ADI calibration    
6. Zero all input 
 
 
7. Chest polar 
Attached   
 
8. RER at rest 5 min 
on (ADI)   
 
9. BP & HR   at rest   /          mm Hg           bpm  /       mm Hg            bpm 
10. BG  before 
exercise 
mmol/L mmol/L 
11. Stretching for 5 
min    
 
12. Warm up on the 
bike for 5 min (at 
50-55 % HRR) 
 
 
Resistance Sets 1st 2nd 3rd 1st 2nd 3rd 
13. Exercise 1 Squat       
14. Exercise 2 Chest       
15. Exercise 3 Back       
16. Exercise 4 Triceps       
17. Exercise 5 Bicep       
 
RPE HR RPE HR 
18. After 1st  set of 
Resistance     
  
19. After 2nd  set of 
Resistance    
  
20. After 3rd  set of 
Resistance    
  
21. BG after 
Resistance 
                             mmol/L                       mmol/L 




23. 5 minute break 
(attach the 3 leads 
ECG, pulse rate 
and mouth piece)   
 
24. Start cardio 




RPE HR BG RPE HR BG 




   
26. At 20 min of 
Cycling   
 
 
   




28. BP & HR after 
Cycling   
           /            mm Hg bpm         /          mm Hg bpm 
29. BG after Cycling   
                                            mmol/L                                               mmol/L 
 
 Visits  
1st 6
th 12th 
1.  Height    
2. Weight     
3. Body water %    
4. Body Fat %    
5. BMI    
6. Blood  Gases  
A. Blood pH 
   
B. pCO2 mmHg    
C. pO2 mmHg    
7. Electrolytes   
A. K+  mmol/L    
B. Na+ mmol/L    
C. Ca+ mmol/L    
D. Cl- mmol/L    
E. Lactate mmol/L     
8.  Lipids profile  
 
A. LDL mmol/L    
237 
 
B. HDL mmol/L    
C. Total cholesterol 
mmol/L 
   
D. Triglyceride 
mmol/L 
   
9. HbA1c 1
st  12th  
10. Waist (cm):   1
st  12th  
11. Hip (cm):   1
st  12th  
12. Waist/HIP Ratio:   1
st  12th  
13. Blood samples for 
Immuno assay, 
Insulin, C-peptide 
Acute exercise  Chronic exercise 












Assessment of caloric intake 
FOOD INVENTORY INSTRUCTIONS 
It is important that you weigh and record everything that you eat and drink except 
water for the day prior to each main experimental trial. Please do not take any alcohol 
on these days.  
Please     
 start a separate page for each day.  
 start a separate line for each item 
 for the day before exercise, try to eat  same food as similar as you can.        
Column 1  
Record meal and time and place of eating. 
Column 2  
Describe each item as accurately as possible, stating where relevant: 
(i) Type and brand 
(ii) Whether food is fresh, dried, canned, frozen, salted, smoked, etc. 
(iii) Whether food is cooked, if so give method of cooking e.g. fried, baked, 
etc. 
Column 3  
Record the weight of each item after cooking: 
(i) Place scales on a level surface 
(ii) place plate or container on top of scales 
(iii) press 'ON/Reset' button to turn on scales 
(iv) once zero appears, add first item of food 
(v) record weight displayed 
(vi) press reset button before weighing next item 
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Wherever possible, record weights in grams. If this is not possible, record weights in 
household measures (e.g. sugar or jam in teaspoons, stating whether level, rounded, 
or heaped). 
Column 4  
Record the weight of any leftovers, such as food remaining on plate, weight of 
container in which food has been weighed, apple cores, etc. 
If food consists of several items, please list each on a separate line i.e. instead of 
writing 'one cheese sandwich', record separately the weights of bread margarine, 
cheese, etc. 
Please remember to record all drinks, as well as food, giving weights where possible, or 
volumes if these are known. Record separately the weight of added milk and sugar. 
































Breakfast Cornflakes (Kelloggs) 28  
8:30am Milk (Sainsbury's virtually fat-free) 48  
Home Bread (Mothers Pride, large white 76  
 sliced, toasted)   
 Flora margarine 7  
 Robinsons lemon marmalade 12  
 Coffee (instant) 2  
 Milk (whole pasteurised) 10  
    
Lunch Cheese (Cheddar) 55  
1:00pm Bread (white, crusty) 76  
Pub Butter 4  
 Chutney (2 teaspoons)   
    
Snack Coffee (instant) 2  
3:30pm Coffee-mate 6  
Office Mars Bar 35  
 Apple 76 8 (core) 
    
Dinner Turkey Fillet (frozen, grilled) 102  
6:30pm Potatoes, old, boiled 320 74 
Home   (leftover) 
 Peas (Birds Eye, frozen, boiled) 50  
 Heinz tomato ketchup 14  
 Yoghurt (Ski strawberry thick and 162 10 
 creamy)  (carton) 
 Coffee, filter 148  
 Milk (Sainsbury's virtually fat-free) 8  
 
 
